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RESUMEN 
 
Las enfermedades mentales tales como la esquizofrenia, el trastorno bipolar y la 
depresión son dolencias graves que afectan a un elevado porcentaje de la población 
mundial. En este sentido, se estima que aproximadamente un 7.4% de las causas de 
discapacidad global en adultos es debido a trastornos mentales y del 
comportamiento. Además, a parte de los efectos devastadores que estas 
enfermedades tienen tanto en los afectados como en su entorno más próximo, 
suponen un alto coste para toda la sociedad siendo la tercera condición médica más 
costosa del mundo. Un problema importante de estos trastornos es que a pesar de la 
gran cantidad de fármacos existentes, su tratamiento sigue teniendo importantes 
limitaciones. De hecho se calcula que un 30% de los pacientes no responden a estas 
drogas y además estas conllevan elevados efectos secundarios. La dificultad a la 
hora de desarrollar tratamientos más eficaces para este tipo de trastornos es en 
parte debida a su compleja etiología. Gracias a los estudios familiares, hoy en día, 
está claro que los factores heredables tienen un gran peso a la hora de medir el 
riesgo de padecer alguna enfermedad mental. Sin embargo, aunque pueden ser el 
resultado de la alteración de un gen concreto, en la mayoría de los casos estos 
trastornos se piensa que tienen un origen poligénico. A esto además, hay que 
sumarle un claro componente ambiental. Otra limitación son los sistemas de 
diagnóstico que se han estado utilizando hasta ahora. Estos tienden a crear límites 
estáticos entre las distintas enfermedades; sin embargo, las evidencias sugieren que 
las enfermedades mentales, aún tratándose de trastornos con una clínica muy 
distinta si comparten alteraciones en ciertos procesos clave para el buen 
funcionamiento del cerebro. Todos estos motivos hacen necesario una ampliación  
del conocimiento sobre la etiología de las enfermedades mentales y la identificación 
de desencadenantes comunes.  
 
En 1990 en una familia escocesa se descubrió una translocación ente los 
cromosomas 1 y 11 que cosegregaba con varios casos de esquizofrenia, depresión 
mayor, trastorno bipolar y otras enfermedades mentales menores. Posteriormente se 
 8 
 
demostró que dicha mutación es causal y su presencia incrementa de forma 
considerable el riesgo de padecer alguna de estas alteraciones. La translocación 
afecta a un gen presente en el cromosoma 1 que recibió el nombre de Disrupted in 
schizophrenia (DISC1). A día de hoy DISC1 es uno de los pocos genes considerados 
como de riesgo para el padecimiento de distintas enfermedades mentales en un 
elevado número de estudios independientes. En este sentido, desde su 
descubrimiento DISC1 demostró tener una relación causal con casos de 
esquizofrenia, trastornos esquizoafectivos, depresión mayor, trastorno bipolar o 
trastornos de espectro autista.  
 
La expresión de DISC1 es elevada en el cerebro durante el desarrollo embrionario y, 
aunque se reduce de forma considerable tras el nacimiento, en el cerebro adulto se 
puede encontrar también una elevada expresión del gen en el hipocampo y, más 
concretamente, en el giro dentado. La proteína codificada, la cual recibe el mismo 
nombre, también se puede encontrar en abundancia en áreas del córtex cerebral, 
bulbo olfatorio y cerebelo. DISC1 no tiene ninguna función enzimática conocida; sin 
embargo, las evidencias apuntan a que funciona como un andamio molecular que 
por interacción directa es capaz de regular en el tiempo y en el espacio la actividad 
de más de 100 proteínas distintas. Gracias a esta capacidad de unión, se ha 
demostrado que DISC1 tiene un papel importante en gran variedad de procesos 
esenciales para el correcto funcionamiento del cerebro incluyendo la proliferación y 
diferenciación neuronal, la migración celular o la formación y mantenimiento de las 
sinapsis. 
 
El objetivo principal de este estudio es profundizar en las funciones que DISC1 tiene 
en la célula para un mayor entendimiento de su implicación en las enfermedades 
mentales. Con este fin, se realizaron experimentos de silenciamiento o “knock-down” 
de DISC1 mediante RNA de interferencia. Para esto, lentivirus que contenían 
shRNAs (small hairpin RNAs) dirigidos contra la secuencia de DISC1, se usaron para 
infectar la línea celular de neuroblastoma humano SH-SY5Y y cultivos de neuronas 
de córtex e hipocampo de ratón. Como era de esperar dicha infección produjo en 
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ambos modelos celulares el silenciamiento del gen y por tanto un marcado descenso 
en los niveles totales de proteína.  
 
En un estudio proteómico previo, el silenciamiento de DISC1 produjo un claro 
descenso de la cantidad de distintas isoformas del neuropéptido VGF (nombre no 
acronímico) en células SH-SY5Y. El gen Vgf se expresa en neuronas en el cerebro, 
la médula espinal y órganos neuroendocrinos. Una vez sintetizada, la proteína se 
procesa en las mismas neuronas dando lugar hasta a 10 péptidos con distintas 
actividades que son secretados de forma selectiva en respuesta a diferentes 
estímulos. Los péptidos derivados de VGF tienen un amplio abanico de funciones 
abarcando, por ejemplo, desde el control de la homeostasis energética hasta la 
regulación de procesos relacionados con la reproducción. Otro aspecto de VGF, que 
hace que sea importante su regulación por parte de DISC1, es que algunos de sus 
péptidos derivados actúan en el sistema nervioso como agentes neuroprotectores, 
estimuladores de la neurogénesis y potenciadores de la actividad sináptica. Gracias 
a estas características, VGF presenta probadas propiedades antidepresivas. 
Además, varios estudios apuntan a que alteraciones en VGF se encuentran 
presentes en los tejidos de algunos pacientes con depresión mayor, trastorno bipolar 
o esquizofrenia. De este modo, teniendo en cuenta que DISC1 y VGF presentan un 
patrón de expresión parecido, participan en procesos similares en neuronas y están 
relacionadas con las mismas enfermedades, el esclarecimiento de la ruta molecular 
que conecta ambas proteínas podría ser de gran importancia para la creación de 
nuevas terapias más efectivas para tratar los trastornos mentales. En el presente 
estudio se confirmó el descenso observado de VGF producido por el silenciamiento 
de DISC1 en células de neuroblastoma en neuronas primarias de ratón, un modelo 
más representativo de lo que sucede in vivo. Además se demostró cómo, de forma 
contraria, la inducción de la expresión de DISC1 también produce un incremento de 
los niveles de VGF.  
 
Para profundizar en el tema y tratar de identificar la ruta molecular que conecta a 
DISC1 con VGF, se comenzó por medir los niveles de diferentes moléculas 
inductoras de la expresión de VGF por "western blot" y se compararon dichas 
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cantidades entre células control y células con DISC1 silenciado.  Entre los principales 
estimuladores de la expresión de VGF se encuentra la neurotrofina BDNF (de sus 
siglas en inglés Brain Derived Neurotrophic Factor). En este estudio, la ausencia de 
DISC1 no produjo ningún cambio en los niveles de BDNF tanto en células SH-SY5Y 
como en neuronas indicando que, en este caso, BDNF no está implicado en el 
descenso de VGF observado en ambos modelos celulares.  Al contrario, el “knock-
down” de DISC1 resultó en los dos modelos en un claro descenso de los niveles de 
la forma activa (fosforilada) de CREB; un factor de transcripción necesario para la 
activación de la expresión de Vgf. Por lo tanto dicha disminución de la forma activa 
de CREB en la ausencia de DISC1 explica el marcado descenso de  los niveles 
proteicos de VGF. Teniendo esto en cuenta se procedió al estudio por western blot 
de moléculas que regulan la actividad de CREB. AKT y ERK1/2 son dos quinasas 
que fosforilan directamente a CREB activándolo. El silenciamiento de DISC1 en 
neuronas de ratón no produjo ningún cambio en la cantidad total de ambas proteínas. 
Sin embargo, si se observó un descenso en la forma activa (fosforilada) de AKT en 
neuronas que fue confirmado en SH-SY5Y. Al contrario, la fosforilación activadora de 
ERK1/2 no experimentó ningún cambio en sus niveles.  
 
GSK3β es otra conocida diana de AKT que a su vez también puede fosforilar a 
CREB participando en el control de su actividad. Por otro lado, DISC1 se une a 
GSK3β inhibiéndola.  Teniendo estos dos datos en cuenta, se investigó una posible 
implicación de GSK3β en los efectos producidos por el “knock-down” de DISC1. En 
neuronas en las que DISC1 había sido previamente silenciado, se observó un 
inesperado descenso de la cantidad total de la proteína. También la fosforilación 
inhibidora de GSK3β producida por AKT experimentó un descenso en concordancia 
con la observada caída de la activación de dicha quinasa. Sin embargo, la auto-
fosforilación activadora de GSK3β no sufrió ningún cambio significativo. De los 
resultados aquí presentados se puede extraer información sobre una nueva forma de 
regulación de GSK3β por parte de DISC1 por medio de la regulación de sus niveles 
y/o su grado de fosforilación. Para comprobar si la disminución de VGF en las células 
en las que DISC1 fue suprimido se debe al aumento de la actividad de GSK3β, se  
procedió a la inhibición de esta quinasa en neuronas primarias con el inhibidor 
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selectivo CHIR-99021. Por western blot se comprobó que este tratamiento no tiene 
ningún efecto sobre la cantidad de VGF indicando que en este modelo GSK3β no 
modula los niveles de expresión del neuropéptido.  
 
Otra molécula que regula la actividad de CREB es el segundo mensajero AMP cíclico 
(cAMP) que  promueve la fosforilación de CREB por parte de la Proteína Quinasa A 
(PKA). Cuándo en la célula aumentan los niveles de cAMP la fosfodiesterasa 4 
(PDE4) se activa e hidroliza dicho segundo mensajero. Curiosamente, DISC1 se une 
a distintas isoformas de esta familia de proteínas, secuestrándolas y manteniéndolas 
en un estado de baja actividad. Por tanto, la ausencia de DISC1 podría resultar en 
una activación excesiva de PDE4 provocando niveles de cAMP anormalmente bajos 
y por lo tanto produciendo un defecto en la activación de CREB. Para comprobar si el 
descenso en VGF se debe a una activación anormal de PDE4 las neuronas primarias 
se trataron con el inhibidor de PDE4 rolipram. Apoyando esta hipótesis, el 
tratamiento con rolipram produjo un aumento de los niveles de VGF aunque este no 
llegó a ser estadísticamente significativo. Con estos datos no se puede descartar la 
posibilidad de que bajo otras condiciones de tiempo y concentración del tratamiento, 
este podría producir un cambio significativo.  
 
Para seguir profundizando en la ruta que conecta DISC1 con VGF y sabiendo que 
CREB y AKT son dos eslabones implicados, se procedió a la inhibición de PI3K. Esta 
es una quinasa que cuando es activada provoca la fosforilación y activación de AKT. 
La inhibición de PI3K con el compuesto LY294002 resultó efectivamente en un 
descenso de los niveles de VGF en cultivos primarios neuronales. Esto podría indicar 
que DISC1 regula la cantidad de VGF en la célula a través de la ruta de señalización 
PI3K/AKT/CREB. Curiosamente, la ausencia de DISC1 resultó en un descenso de 
los niveles de Grb2 en SH-SY5Y, una proteína importante para la ruta de 
señalización de los receptores de neurotrofinas Trk. En este sentido, cuando dichos 
receptores son activados, reclutan a un grupo de proteínas, entre ellas Grb2 que es 
esencial para la activación de PI3K. Al contrario, el silenciamiento de DISC1 no llevó 
a ningún cambio en la cantidad total de Grb2 en neuronas primarias. Este resultado 
concuerda con los datos obtenidos previamente en otro estudio realizado en 
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neuronas, en el que se demostró que aunque DISC1 no regula la cantidad de Grb2, 
si regula su distribución en la célula promoviendo el crecimiento de los axones. En el 
presente trabajo  se propone un modelo según el cual o bien por la regulación de la 
localización de Grb2 en neuronas o de sus niveles en SH-SY5Y, DISC1 podría 
controlar la activación de PI3K regulando así la actividad de AKT y CREB y en 
consecuencia modulando la cantidad de VGF.  
 
En este trabajo también se incluyen los resultados obtenidos por el análisis 
proteómico de neuronas con DISC1 silenciado comparándolas con neuronas control. 
Para esto, los extractos celulares de cada una de estas condiciones fueron 
sometidas a electroforesis bidimensional en geles de poliacrilamida para la 
separación de las proteínas en función de su punto isoeléctrico y su peso molecular. 
Posteriormente las proteínas se tiñeron y los geles se analizaron por medio del 
software Ludesi REDFIN 3. Gracias a este programa se detectaron 68 “spots” con 
distinta intensidad entre los geles de las dos muestras (control y silenciado). Tras ser 
analizados por espectroscopía de masas estos “spots” resultaron corresponder a 48 
proteínas diferentes. La validación por western blot mono y dimensional de alguna de 
estas proteínas permitió identificar modificaciones post-traduccionales 
diferencialmente reguladas dependiendo de la presencia o la ausencia de DISC1.  
 
Entre las proteínas identificadas, doce participan en distintos aspectos del 
neurodesarrollo. Este proceso comprende distintos eventos como la proliferación, la 
diferenciación o la migración neuronal que requieren una dinámica apropiada del 
citoesqueleto. Apoyando un papel para DISC1 en estos procesos, su silenciamiento 
causó diferencias notables en la expresión de un alto número de proteínas 
relacionadas con la organización y dinámica del citoesqueleto, el crecimiento de las 
neuritas y los axones o la migración neuronal. En concreto, los niveles de los 
principales componentes de los microtúbulos y los filamentos de actina, la tubulina y 
la actina respectivamente, sufrieron una clara disminución en aquellas células en las 
que DISC1 había sido silenciado. Por otro lado, varias proteínas de unión al 
citoesqueleto que regulan su dinámica también resultaron alteradas por la falta de 
DISC1 como por ejemplo MAP1B, LIS-1, distintas proteínas de la familia 14-3-3, 
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CRMP-1 o la tropomiosina. Cabe señalar que la alteración de alguna de estas 
proteínas ya había sido previamente identificada como la causa de ciertas dolencias 
como por ejemplo LIS-1 cuya mutación causa lisencefalia.  
 
Por otro lado, en este estudio proteómico también se encontró otro grupo de doce 
proteínas cuya expresión se ve modificada por la ausencia de DISC1 que participan 
en la formación, la maduración y el mantenimiento de las sinapsis. En este grupo se 
encuentran entre otras la cadherina, la calreticulina o NCS. Junto a estas proteínas, 
también se identificaron otras importantes para el transporte de endosomas y de 
vesículas sinápticas como la sintaxina-7, MUNC-18 o diferentes proteínas Rab. Estos 
resultados indican un claro papel de DISC1 en la dinámica de estas vesículas 
esenciales para la comunicación entre neuronas.  
 
Es de destacar que siete de las proteínas que fueron identificadas por ser reguladas 
diferencialmente en ausencia de DISC1 en este estudio, comparten función tanto 
durante la el neurodesarrollo como en la sinapsis. Este es el caso de CRMP-2, 
CRMP-5, MAP1B, estatmina, cadherina-13, calreticulina y dinamina-1. Esto indica 
que ambos procesos no son completamente independientes y sugiere que DISC1 
cuenta con un papel central en las neuronas desde el inicio de la neurogénesis hasta 
que estas ya son totalmente funcionales.  
 
Otro aspecto importante, es que algunas de las proteínas encontradas en este 
estudio pertenecen al “interactoma” de DISC1. Este es el caso de CRMP-2, MAP1B, 
14-3-3γ y LIS-1 cuya actividad puede ser modulada por su unión con DISC1. Sin 
embargo, esta es la primera vez que se describe que DISC1 también puede regular 
sus cantidades. Además cabe señalar que algunas de estas moléculas son 
conocidas por ser substratos de GSK3β como CRMP-2, MAP1B y LIS-1. Como ya se 
comentó previamente, DISC1 se une a GSK3β inhibiéndola, pero cuando esta unión 
se rompe, la quinasa queda liberada y tiene la capacidad de fosforilar a un amplio 
número de sustratos. De acuerdo con los resultados apuntados con anterioridad, el 
silenciamiento de DISC1 aparentemente produce la desregulación de la actividad de 
GSK3β y por lo tanto a través de dicha quinasa, DISC1 podría también estar 
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regulando la actividad de sus sustratos. En resumen, los resultados obtenidos en 
este estudio proteómico aportan una nueva vía de acción de DISC1 regulando los 
niveles de ciertas proteínas en neuronas que participan en el neurodesenvolvemento 
y la sinapsis. Por otro lado, los datos aquí presentados también apoyan las 
numerosas evidencias que sugieren que las enfermedades neuropsiquiátricas  están 
causadas por alteraciones durante el neurodesarollo y en la sinapsis.  
 
Por último, se realizó un trabajo de medición del efecto de la ausencia de DISC1 en 
el crecimiento de neuritas. Para este propósito, células SH-SY5Y con un 
silenciamiento estable de DISC1 y células control fueron tratadas con ácido retinoico 
durante 7 y 14 días con la intención de inducir su diferenciación en células post-
mitóticas de tipo neuronal. Esta transformación se debe a la expresión de proteínas 
neuronales como la proteína tau, el β-amiloide o la transglutaminasa. Además, este 
cambio de expresión proteica va acompañado del crecimiento de neuritas.  Tras el 
tratamiento y por medio de microscopía, se contó el número de células con neuritas 
con una longitud mayor que dos cuerpos celulares. Los resultados obtenidos 
indicaron que el silenciamiento de DISC1 produce un claro déficit en el crecimiento 
de neuritas en células SH-SY5Y tratadas con ácido retinoico, indicado por una 
importante reducción en el número y el tamaño de las mismas. Este defecto en la 
diferenciación de la línea celular concuerda con los datos obtenidos en el estudio 
proteómico en el que la falta de DISC1 conlleva cambios en los niveles de proteínas 
que participan en el crecimiento de neuritas en neuronas. Así, puede ser que en el 
caso de las células SH-SY5Y los cambios morfológicos observados tras la 
eliminación de DISC1 se deban a una desregulación de dichas proteínas. Por otro 
lado, otro importante efecto del ácido retinoico sobre las células SH-SY5Y es el 
aumento de la transcripción de TrkB, el receptor para BDNF. Como consecuencia, el 
ácido retinoico produce un incremento de la activación de la ruta PI3K/AKT. Como 
fue sido descrito anteriormente, el “knock-down” de DISC1 derivó en un importante 
descenso en la actividad de dicha ruta en los dos modelos celulares estudiados. De 
este modo, es lógico pensar que el efecto de DISC1 en el crecimiento de las neuritas 
también podría ser parcialmente mediado a través de VGF. DISC1 sería por lo tanto 
un importante factor en el mantenimiento de los niveles apropiados de VGF en 
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neuronas necesarios para el correcto crecimiento das neuritas demostrando la 
existencia de un circuito regulador entre estas dos moléculas.   
 
En conclusión, de este trabajo se pueden extraer varias conclusiones. Primera: la 
falta de DISC1 produce una importante disminución de los niveles del precursor 
neuropeptídico VGF tanto en neuronas primarias de ratón como en la línea celular de 
neuroblastoma humano SH-SY5Y. Segunda: esta regulación de VGF por parte de 
DISC1 parece ser llevada a cabo a través de la ruta de señalización 
PI3K/AKT/CREB, independientemente de BNDF. Tercera: en células SH-SY5Y la 
ausencia de DISC1 produce un descenso de los niveles de Grb2, que es esencial 
para la activación de PI3K. Sin embargo, el silenciamiento de DISC1 no produce este 
efecto sobre los niveles de Grb2 en células de córtex e hipocampo de ratón. Cuarta: 
el silenciamiento de DISC1 produce cambios en la cantidad y nos niveles de 
fosforilación de GSK3β en neuronas primarias de ratón. Esto parece indicar una 
desregulación de la actividad normal de dicha quinasa en la ausencia de DISC1. Sin 
embargo la inhibición de GSK3β no tiene efectos sobre los niveles de VGF 
sugiriendo que esta quinasa no está directamente implicada en la modulación de los 
niveles de VGF por parte de DISC1. Quinta: el estudio proteómico aporta información 
sobre una nueva función de DISC1 regulando la cantidad total de proteínas 
relacionadas con el neurodesarrollo y la función sináptica. Sexta: el silenciamiento de 
DISC1 produce un déficit en el crecimiento de las neuritas en células SHSY5Y 
comparado con células control.  
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SUMMARY  
 
Since Disrupted in schizophrenia 1 (Disc1) was discovered, it has become one of the 
most convincing risk factors for major mental illness. Disc1 was first identified in a 
large Scottish family in which a genomic translocation affecting this gene 
cosegregated with major psychiatric diseases including schizophrenia, major 
depression and bipolar disorder. The protein encoded (DISC1) is highly expressed in 
the brain and, to date, no evidence of enzymatic activity has been reported. However, 
DISC1 binds more than 200 different proteins and acts as a molecular scaffold 
regulating the activity of such proteins. Thus, through these interactions, DISC1 
participates in several processes in the brain such as neuronal proliferation, migration 
and differentiation as well as neurite outgrowth and synapse regulation. 
 
In order to gain new insight into the functions of DISC1, knock-down of the gene was 
performed in primary cortex and hippocampus mouse neurons as well as in the 
human neuroblastoma SH-SY5Y cell line by means of infection with small hairpin 
RNA (shRNA)-carrying lentivirus.  
 
In the present study DISC1 knock-down was found to lead to an important decrease 
in the levels of the neuropeptide VGF (non-acronymic) in SH-SY5Y cells as well as in 
primary cortical and hippocampal mouse neurons. Of note, VGF displays 
antidepressant properties and has been also shown to be implicated in different 
neuropsychiatric disorders including depression, bipolar disorder and schizophrenia. 
The fall of VGF levels produced by DISC1 knock-down seems to be mediated by a 
drop in the activity of the PI3K/AKT/CREB signalling as indicated by decreased levels 
of the active forms of PI3K, AKT and CREB. Additionally, a reduction in the levels of 
Grb2, an essential protein for PI3K activation and the subsequent signalling route, 
was observed in SH-SY5Y cells. In addition, knock-down of DISC1 was found to 
result in changes in the quantity and phosphorylation of GSK3β in primary mouse 
neurons suggesting the deregulation of the activity of the kinase. Furthermore, by 
means of a proteomic approach, the knock-down of DISC1 was observed to cause 
the differential regulation of a number of proteins in primary mouse neurons. Twelve 
 17 
 
of the proteins affected by the decrease of DISC1 are involved in neurodevelopment 
and twelve participate in different aspects of the synapses. Of note, seven of these 
proteins share functions in both processes. Some of these proteins are known DISC1 
binding partners; however, this is the first time that their expression is described to be 
dependent on DISC1. Supporting a role for DISC1 in neurodevelopment, its knock-
down also produced deficits in the neurite outgrowth in SH-SY5Y cells treated with 
retinoic acid to induce their differentiation.  
 
The DISC1-VGF connection showed in the present study might be important for the 
development of new therapies for the treatment of mental diseases. In addition, the 
results show a new mechanism by which DISC1 regulates the activity of several 
proteins in neurons through the regulation of their levels. 
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Major mental illnesses such schizophrenia, major depression and bipolar disorders 
are devastating diseases that affect a high percentage of the world’s population. In 
fact, mental and behavioural disorders are estimated to account for the 7.4% of the 
causes of global adult disability around the world. Specifically, schizophrenia and 
bipolar disorder are ranked 9
th
 and 6
th
 in the World Health Organization (WHO) in the 
estimates for disease-related lifetime disabilities. For instance data obtained from the 
US National Institute for Mental Health (NIMH) indicated that in 2012 1.1% of adult 
US population was affected by schizophrenia, 2.6% by bipolar disorder and 6.9% by 
major depression (http://www.nimh.nih.gov/health/statistics/index.shtml). Accordingly, 
in European Union (EU) the statistics indicate that 27% of the adult population had 
experience at least one episode of mental disorder in the past year. Specifically, in a 
study performed in 2002, unipolar depressive disorder alone was found to be 
responsible for 13.7% of disability, making it by far the leading cause of chronic 
conditions in Europe. On the other hand, schizophrenia and bipolar disorder were 
described each responsible for 2.3% of all disability in Europe 
(http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health).  
 
Apart from the devastating effects in the affected individuals and their families, mental 
diseases also have a huge impact on our society on both medical and financial levels. 
Indeed, only in the US the estimated total expenditure in mental health in 2006 was of 
$57.5 billion accounting for the 6.2% of the total health care expenditure. In European 
Region, data vary considerably between countries, but on average, mental health 
takes up the 5.8% of the health expenditure budget. This makes the neuropsychiatric 
disorders the third most costly medical condition around the world. The elevated 
burden is explained by the direct charges elicited by mental health services and the 
treatment itself, as well as the indirect costs produced by expenditure and loses 
related to disability. 
  
Despite the diversity of antipsychotic, antidepressant and mood stabilizing drugs, the 
treatment of mental diseases continues to be difficult due to certain limitations. In fact 
approximately 30% of patients do not respond to these drugs and their overall 
efficacy is poor. Additionally, most of the drugs ameliorate a subset of symptoms but 
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not the core pathology. For instance, classical antipsychotics are effective in 
correcting and preventing the positive symptoms (delusions, hallucinations and 
though distortion) of schizophrenia. Nevertheless, they present limited efficacy 
against negative symptoms (loss of motivation, social withdrawal, deficient affective 
expression, etc.) and cognitive deficits. This limitation appears to have been partially 
overcome with the advent of second generation or atypical antipsychotics; however, 
most of the patients require the combination of different drugs that frequently exhibit 
important side effects to achieve a general improvement of symptoms.  
 
Although family and twin studies have determined the high importance of inherited 
factors in the risk of suffering some of these disorders, their etiology is highly complex 
etiology. In this respect, mental illnesses can be caused by alteration in one specific 
gene; nevertheless, in most of the cases they are thought to present polygenic origin. 
In addition, environmental factors are also crucial elements in the onset of the clinical 
picture. In this regard, current diagnostic manuals for mental disorders such as 
Diagnostic and Statistical Manual (DSM) might be obsolete from the biological point 
of view. These diagnostic boundaries tend to create static limits between diseases; 
when in fact, shared genetic risk variants have been reported for different conditions 
such as schizophrenia, bipolar disorder, depression or autism. Indeed, 
neuropsychiatric illnesses seem to share alterations in common features in the brain 
such as neurogenesis, synaptic activity or myelination.  
 
Given these points, a deeper knowledge of the etiology of mental illness and the 
identification of common triggers is necessary in order to obtain a better 
understanding of the alterations that these diseases produce in the nervous system, 
and to develop more effective drugs.  
 
In this respect, Disrupted in schizophrenia (DISC1) is one of the few genes that have 
been identified as a convincing risk factor for different chronic mental illnesses in a 
high number of independent studies. Since its identification in 2000, alterations in this 
gene have been subsequently demonstrated to have a causal relationship in some 
cases of schizophrenia, schizoaffective disorders, major depression, bipolar disorder 
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or autism spectrum disorders. This makes DISC1 an important subject of study in 
order to identify the molecular mechanisms underlying the pathophysiology of mental 
conditions.  
 
 
1. DISC1 DISCOVERY 
 
In 1990 St. Clair and coworkers described in a large Scottish family a genomic 
translocation between chromosomes 1 and 11 that cosegregated with major 
psychiatric disorders [1]. A psychiatric evaluation report was available for 29 carriers 
of the translocation, 38 non carriers and the 2 founders.  Within the group of the 
mutation carriers 7 individuals were diagnosed with schizophrenia, 1 with bipolar 
disorder and 10 with recurrent major depression. In addition, relatives with the same 
mutation were diagnosed with minor mental disorders: 2 cases of adolescent 
conduct- and-emotional disorder and 1 case of minor depression. In the non-carrier 
group no major psychiatric disorder was diagnosed, nevertheless, there were found 1 
case of adolescent conduct-and-emotional disorder, 3 cases of depression and 1 
case of alcoholism. The study showed a strong relation between the translocation and 
mental illness in this family. Figure 1 shows the pedigree obtained from karyotyping 
the members of the Scottish family and their psychiatric diagnoses.  
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Figure 1: Pedigree of the Scottish family showing the inheritance of the balanced translocation (1;11) (q42; 
q14.3) and clinical diagnoses within the family (Brandon et al, 2009, The Journal of Neuroscience). 
 
In 2000, the sequence of the breakpoint of the (1;11) (q42.1;q14.3) translocation was 
defined. Three genes were demonstrated to be truncated by this genetic 
rearrangement in chromosome 1: Disrupted in schizophrenia 1 (Disc1), Disrupted in 
schizophrenia 2 (Disc2) and Translin-associated factor X (TSNAX) [2]. Linkage 
analysis showed that the chromosomal rearrangement present in this family 
segregated with schizophrenia, bipolar disorder and recurrent major depression in a 
significant statistical manner (LOD score 7.1). Remarkably, the linkage of the 
translocation was found to be also highly significant with schizophrenia (LOD score 
3.6) and major effective disorders (LOD score 4.5) separately. According to these 
data, inheritance of the translocation confers significantly increased risk of developing 
these mental illnesses [3]. 
 
Additionally, there is another disrupted gene on chromosome 11; the DISC1 Fusion 
Partner 1 (DISC1FP1, also known as Boymaw). Like DISC2, Boymaw is a  non-
coding and brain-expressed gene [4] and expression of the DISC1-Boymaw fusion 
gene may reduce protein translation impairing brain functions and, thereby, 
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contributing to the pathogenesis of major psychiatric disorders [5]. Loss of normal 
function of all these genes may thus contribute to the mechanism of the disease. 
 
 
2. LINKAGE AND ASSOCIATION STUDIES 
 
A large number of independent genetic studies have supported the relationship of the 
DISC1 region with psychiatric illness as reviewed by Chubb [6]. In 2001 Ekelund et al. 
conducted a population-based study using 221 Finnish families. Evidence for linkage 
with mental disease was found for the D1S2709 locus (maximum LOD score = 3.21). 
Importantly, this marker is located 80kb from the breakpoint of the t(1;11) 
translocation and within an intron of the DISC1 gene [7].  Also in a Finnish 
subpopulation Hovatta and coworkers studied over 20 families with schizophrenia and 
they reported a maximum LOD score of 3.7 at 1q32-41 [8]. Since then, numerous 
studies have also supported linkage of similar chromosome regions to mental illness 
in different populations from Taiwan [9], Britain [10], Ireland [11] and Scotland [12]. 
 
In 2003 Hennah et al. reported in the Finnish population four DISC1 haplotypes 
extending between exon 1 and exon 9 that were associated with schizophrenia, 
schizoaffective disorder, and bipolar disorder. One of them, HEP3, a two single 
nucleotide polymorphism (SNPs) haplotype spanning from intron 1 to exon 2 of 
DISC1, is significantly under-transmitted to schizophrenic women and associates with 
features of the phenotype of schizophrenia such us delusions, hallucinations and 
negative symptoms [13].  The underrepresentation of the HEP3 haplotype in 
individuals with schizoaffective disorder was also confirmed in North American 
populations [14]. Evidences for association of this genetic region with this type of 
mental illnesses previous mentioned and some of their typical phenotypes have been 
also found in Chinese [15]–[17], Scottish [18], [19], Taiwanese [20] and Japanese [21] 
populations. 
Remarkably, a recent GWAS study of DISC1 genetic variants found a relationship 
with the structure and functional connectivity of the precuneus in schizophrenia [22]. 
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However, despite these genetic evidences indicating the involvement of DISC1 in 
mental disorders, a few reports did not show association between this locus and 
psychiatric disease. This is the case of a recent meta-analysis that failed to find 
significant association between DISC1 and schizophrenia [23]. 
 
 
3. THE DISC1 GENE  
 
The human DISC1 gene (Ensembl ID: ENSG00000162946) is located on 
chromosome 1 in the q42 region and its genomic structure is well conserved among 
most of the species in which the gene was identified to date. DISC1 comprises 
414.458kb of genomic DNA (UCSC genome browser, March 2006). The gene is 
divided in 13 major and several minor exons and the full length transcript produced 
corresponds approximately to 7.5kb. The protein codified consists of 854 amino acids 
[2], [24]. One characteristic of DISC1 in primates is the presence of the exon 9a. 
Intron 9 is surprisingly large in most of the species, suggesting that it possess some 
special function. The potential role of this intron in humans could be related to DISC2, 
a non-coding structural RNA gene. DISC2 produces an antisense RNA that overlaps 
exon 9 of DISC1 and may locate its 5’ within the intron 9 regulating DISC1 
transcription [2]. 
 
Initially, the transcription of the human DISC1 gene was found to produce at least four 
principal mRNA splicing variants determined by the presence or lack of one or more 
exons [25]. The Long form (L) (EMBL AF222950) is encoded by the whole 13 exons. 
The Long variant (Lv) (EMBL AB007926) transcript excludes the distal 66 nucleotides 
of exon 11. The Short splicing form (S) (EMBL AJ06177) uses an alternative 3’ UTR 
in intron 9 (9a) and the Extremely short transcript (Es) (EMBL AJ506178) contains an 
alternative spliced exon 1a and terminates transcription two intronic codons after 
exon 3. More recently, Nakata and coworkers characterized more than 50 DISC1 
mRNA variants (Figure 2), produced by alternative splicing in adult and fetal human 
brain [26]. However, it is yet unknown which of these variants are finally translated. 
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Figure 2: Representation of the genomic alternative splice variants of the human DISC1 gene (Nakata et 
al., 2009, PNAS). 
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4. DISC1 PROTEIN 
 
Multiple DISC1 protein variants have been identified by western blotting using 
different antibodies. The four initially described transcripts result in four predicted 
isoforms of the protein. The long transcript (L) encodes the full length protein, 
translated from the whole 13 exons of the gene, consisting in 854 amino acid 
residues with a molecular weight of 93.6kDa. The long variant transcript (Lv) is 
predicted to produce a protein of 91.1kDa formed by 832 amino acid residues. The 
short (S) isoform is predicted to contain approximately 678 amino acids (73.9kDa) 
and the extremely short Es variant is predicted to consist on 369 (38.5kDa). However, 
the most commonly described variants of DISC1 have a molecular weight of 100 and 
75kDa respectively. The discrepancies between the predicted and the detected 
molecular weight could be explained by the phosphorylation of DISC1 [27] that would 
increase its electrophoretic mobility; however, another possibility is the post-
translational cleavage of the protein. In addition, the lack of good and specific 
commercial antibodies makes the characterization of DISC1 species even more 
difficult.  
 
To date, the structure of DISC1 has not been solved. This is due to the difficulty of 
purifying a correctly folded full-length DISC1 protein, possibly because of the 
tendency to form large aggregates. A recent review of Soares and coworkers 
summarizes the available structural information about DISC1 [28]. In the meantime, 
the predicted structure of the full length human DISC1 based on its amino acid 
sequence is mainly divided in two different domains as shown in Figure 3. 
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Figure 3: Predicted structure of full length DISC1 protein (Chubb et al., 2008, Molecular Psychiatry). 
 
The N-terminal domain encompasses approximately from amino acid 1 to 350, 
encoded by exons 1 and 2. This section contains low-complexity segments that 
shape disorder regions in proteins that fail to self-fold into 3D structure and is referred 
to as the globular “head” domain. This part of the protein possesses two conserved 
regions among species: a nuclear localization signal (NLS) and a serine-
phenylalanine-rich (SF-rich) motif [25].  Although some regions correspond to 
predicted α-helices (residues 36 to 66, 108 to 123, 130 to 145, 206 to 217, 261 to 
277, 333 to C-terminus), almost the 89% of the N-terminal domain is predicted to be 
disordered according to MetaPrDOS (meta Protein DisOrder prediction System).  
 
The second domain of DISC1 corresponds to the C-terminal fragment that covers 
from amino acid residue 351 to 854 and is encoded by exons 3 to 13. The C-terminal 
region is predicted to have at least four coiled-coil regions combined with at least five 
regular alpha-helices. These coiled-coil regions were proposed to generate a self-
association domain [29]. Of note, DISC1 dimers and octamers have been described 
under physiological conditions in the brain of patients with mental illness [30]. A 
number of studies have identified different DISC1 fragments capable of multimerize 
(residues 403 to 504, 598 to 785, 598 to 854, 668 to 854 and 765 to 854). Besides, 
this region gives DISC1 the ability to bind a high number of proteins. This may be the 
reason for the high conservation of the N-terminal domain of the protein along 
evolution.  
 
 
 
 42 
 
5. DISC1 INTERACTIONS  
 
To date, no evidence of enzymatic activity has been reported for DISC1. However, as 
previously mentioned, the C-terminal fragment allows DISC1 to bind different proteins 
acting as a molecular scaffold. In fact, more than 200 proteins have been identified to 
interact with DISC1.  
 
In 2003 Morris and coworkers performed yeast two-hybrid (Y2H), mammalian two-
hybrid, and co-immunoprecipitation assays to identify DISC1-binding proteins. They 
divided the partners of DISC1 in three categories according to their location: proteins 
of the centrosome and cytoskeleton (MIPT3, MAP1A, NUDEL), proteins that localize 
receptors to the membrane (α-actnin2 and β4-spectrin) and proteins that transduce 
signals from membrane receptors (ATF4/5). Remarkably, the authors found that the 
truncated form of DISC1 fails to interact with some of these proteins. Moreover, 
deletion maps were performed to identify the different domains of DISC1 by which it is 
capable to bind the identified proteins [31].  
 
At the same time, in a different Y2H assay, Ozeki and coworkers also found a variety 
of DISC1 interactors associated with the cytoskeleton such as NUDEL, dynactin, 
spectrin or 14-3-3γ [32]. In a different study, Millar and coworkers used full-length 
human DISC1 protein to screen human and adult fetal brain libraries for the 
identification of DISC1 interacting partners by Y2H. They reported approximately 50 
interactors, some of them previously reported by Morris and Ozeki. Additionally, this 
study reinforced the idea that some of these proteins present coiled-coil regions on 
their structures; this is the case of KIAA0373, NUDE1, NUDEL or PPFIA4 among 
others [33]. The proteins found in this study participate in gene transcription, 
mitochondrial function, modulation of the actin cytoskeleton, neuronal migration, 
glutamate transmission and signal transduction. Furthermore, this group also reported 
the interaction between DISC1 and the Phosphodiesterase-4B (PDE4B) [34]. 
Finally, Camargo and coworkers published the “DISC1 Interactome”, consisting on an 
interaction network encompassing 127 proteins and 158 interactors. Once again, 
 43 
 
these proteins were broadly associated with cytoskeletal organization and biogenesis, 
mRNA/protein synthesis, cell cycle division, intracellular transport and signal 
transduction processes. Remarkably, in this study it was observed that some of the 
DISC1-interacting proteins share common protein-protein interactions with DISC1 [35] 
suggesting that they may act in functional clusters. 
 
 
6. TEMPORAL AND ANATOMICAL EXPRESSION 
OF DISC1 
 
By northern blot analysis DISC1 transcripts have been found in different tissues in 
mice, rat and humans such as brain, heart, placenta, pancreas, testes and kidney [2], 
[36]. 
 
DISC1 is highly expressed in the developing brain in mice but its expression after 
birth is only maintained in some restricted areas. Specifically, the highest levels of 
expression are found in the dentate gyrus (DG) of the hippocampus and, in lower 
extent, in other regions of the hippocampus, cerebral cortex, olfactory bulb and 
cerebellum [36]. These data agree with those obtained from brain of adult humans 
and other primates that show high expression of the protein in the same limbic 
regions, especially in the DG [2], [37], [38]. Curiously, the hippocampus has been 
strongly associated to schizophrenia [39] and lesions in this area in rodents and 
primates lead to cognitive and behavioural abnormalities similar to those found in 
schizophrenia [40], [41].  
 
The expression of DISC1 throughout different phases of the embryonic brain 
development was also characterized and was found to be dynamically regulated 
spatially and temporally [32], [42], [43]. During brain development in mice, the 100kDa 
DISC1 isoform has been observed to undergo two peaks of expression at embryonic 
day 13.5 and postnatal day 35; remarkably, these two phases correspond to periods 
of active neurogenesis and cellular migration, and the onset of puberty respectively 
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suggesting that DISC1 is actively involved in brain development and maturation both 
at fetal and adult stages [43]. This temporary regulation has also been observed in 
humans in which the highest DISC1 expression takes place during prenatal, neonatal 
and pubertal periods [44]. 
 
 
7. SUBCELLULAR DISC1 LOCALIZATION 
 
In the central nervous system DISC1 is not only expressed in neurons but also in glial 
cells. Different DISC1 isoforms have been found in multiple subcellular compartments 
and this variety indicates that the protein has different roles depending on the cellular 
compartment were it is located. Additionally, some studies reported changes in 
subcellular DISC1 localization during the different phases of neuronal differentiation 
[32], [45].  
 
 
7.1. Centrosome and cytoskeleton 
 
Multiple DISC1 binding proteins localize at the centrosome as assessed by 
independent yeast two-hybrid screens. DISC1 was initially observed to associate with 
MAP1A, MIPT3, ATF4/5 and NUDEL, all of them proteins of the cytoskeleton and 
centrosome system, participating in axonal and neurite outgrowth [31]. Moreover, 
immunofluorescence showed colocalization of DISC1 and the centrosome marker γ-
tubulin. The association of DISC1 with the centrosome was found to be disrupted by 
the truncation present in the Scottish family. The association between DISC1 and 
NUDEL was later supported by different studies [33], [42]. Centrosomal proteins 
kendrin [46] and platelet-activating factor acetylhydrolase IB subunit β (LIS-1) [47] 
have been also shown to colocalize with DISC1. 
 
In 2005 Kamiya demonstrated that DISC1 is essential for maintaining the 
microtubule-associated dynein motor complex at the centrosome for proper 
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microtubule dynamics [48]. Brashdaw and coworkers demonstrated that DISC1 
recruits the NDE1/NUDEL1/LIS-1/dynein complex to the centrosome where it binds to 
PDE4 suggesting that the regulation of the function of this complex might be 
modulated by cAMP [49], [50]. 
 
 
7.2. Growth cones 
 
By Y2H study Miyoshi described actin-binding protein FEZ1 (involved in axonal 
outgrowth) as an interacting partner of DISC1 [51]. In rat cultured hippocampal 
neurons these two proteins were found to localize at the neurite growth cones 
indicating a possible role of DISC1 in neurite extension. Furthermore, different studies 
support the idea that DISC1 is responsible for the localization of a number of proteins 
involved in axon elongation in primary hippocampal neurons such as the NUDEL/LIS-
1/14-3-3ε complex [47], growth factor receptor bound protein 2 (Grb2) [52] and Girdin 
[53].  
 
 
7.3. Mitochondria 
 
In 2003 Ozeki et al. described by immunofluorescence the presence of DISC1 in 
mitochondria in HeLa, PC12 and COS-7 cells [32]. One year later, James and 
collaborators published that this organelle was the predominant site of endogenous 
DISC1 expression in different cellular lines [45]. Besides, Brandon et al. reported the 
association of DISC1 with mitochondria in primary mouse cortical neurons, and 
identified a putative mitochondrial localization signal in the N- terminal region of the 
protein [54]. The same year, Millar and coworkers reported that aberrant DISC1 could 
change the distribution of the organelle in the cell and consequently, influence 
mitochondrial dynamics [55]. Remarkably, DISC1 has been reported to promote 
anterograde mitochondrial trafficking by binding transport complexes including 
TRAK1 and Miro1 [56] and changes in the expression of DISC1 were described to 
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produce alterations in the trafficking of the mitochondria along axons in cultured 
hippocampal neurons [29]. This role of DISC1 is highly important due to the need of a 
correct mitochondria position at the synapses for correct development and signalling 
[57]. 
 
Finally, Park and coworkers found evidences showing that DISC1 regulates the 
stability of the mitochondrial inner membrane protein Mitofilin. In their experimental 
model, silencing of DISC1 or expression of truncated DISC1 forms caused 
mitochondrial dysfunction demonstrated by deficits in the normal mitochondrial NADH 
dehydrogenase and monoamine oxidase (MAO) activities and decreases in the ATP 
content in the cell [58].  
 
 
7.4. Cilia 
 
Primary cilia are composed of microtubule prolongations that project from the cell 
body of most of the mammalian cell types during growth arrest. Increasing evidence 
suggests that primary cilia are coordinators of signalling pathways during 
development. In this regard, one study reported the presence of DISC1 near the base 
of primary cilia in NIH3T3 cells. In this study knock-down of endogenous DISC1 
resulted in a marked decrease of the formation of this organelle [59]. 
 
 
7.5. Synaptic structures 
 
An enrichment of DISC1 at the postsynaptic density in human post-mortem cortex 
samples has been  described [60].  In rat, it has been shown that the complex formed 
by DISC1 and the synaptic proteins Kal-7 and Rac-1 is involved in the regulation of 
synaptic spines outgrowth in response to the activation of NMDA glutamate receptors 
[61], [62]. In fact, studies of in vivo knock-down models suggest that a loss of DISC1 
leads to an overactivated NMDAR synaptic response [63]. At the same location, 
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DISC1 has also been described to bind to PDE4B and NDE1 [64]. Finally, DISC1 has 
been found to colocalize and inhibit TNIK at the post-synaptic density (PSD) leading 
to degradation of key synaptic proteins and consequently regulating the synaptic 
function [65]. 
 
 
7.6. Nucleus 
 
A Nuclear Localization Signal (NLS) in the N-terminal domain of DISC1 determines 
the presence of the protein in the nucleus [55]. In 2005 Sawamura et al. reported an 
isoform of DISC1 enriched in the nucleus in human post-mortem brains, and this 
distribution was found altered in brains of schizophrenia and major depression 
patients as well as in subjects with substance and alcohol abuse [66]. Years later the 
same group found that in mammalian cells DISC1 colocalizes in the nucleus with 
promyelocytic leukemia (PLM) bodies, a nuclear compartment for gene transcription. 
At that location, DISC1 was shown to interact with the transcriptional regulatory 
proteins ATF4/CREB2 and N-CoR indicating that DISC1 modulates CRE-mediated 
gene transcription [67].  
 
 
7.7. Golgi apparatus 
 
Kuroda et al. found that DISC1 localize to the Golgi apparatus associated with the 
membrane structure of this organelle in hippocampal neurons and astrocytes by 
means of immunoelectron microscopy [68]. This location has been recently confirmed 
by Lepagnol-Bestel and coworkers [69]. 
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7.8. Cell Membrane 
 
Although the literature is sparse, a subset of DISC1 has been found to localize at the 
cell membrane by interacting with the amyloid precursor protein (APP) [70]. 
 
 
8. DISC1 FUNCTIONS  
As has been mentioned, although the highest levels of DISC1 are reached during 
embryonic neurodevelopment, its expression is maintained in some specific areas of 
the adult brain where neuronal progenitor proliferation takes place. It must be noted 
that the existing data regarding DISC1 function derive from the understanding of the 
biology of DISC1 interactors and the function of these proteins and complexes. Some 
of the processes in which DISC1 was described to participate are detailed below:  
 
 
8.1. Neuronal proliferation and differentiation 
 
During the embryonic cortex development, progenitor cells are proliferating in the 
ventricular (VZ) and subventricular (SVZ) zones. In 2008 Shen and coworkers found 
that the truncation of DISC1 in mice during embryonic development produced a 
decrease in neuronal proliferation, implicating DISC1 in corticogenesis [71]. Agreeing 
with this result, Mao and coworkers found that knock-down of DISC1 in mice brain at 
embryonic day 13, resulted in the impairment of cortical progenitor cells proliferation 
and premature neuronal differentiation in the developing cortex [72]. In these cells 
there was found that the interaction of DISC1 with GSK3β was crucial to stabilize β-
catenin, a condition required for progenitor proliferation. DISC1 binds to GSK3β 
maintaining this kinase in a low activity form. When DISC1 is knocked-down, GSK3β 
activity increases and phosphorylates β-catenin leading to its degradation. This 
results in the impairment of proper progenitor neuronal cell proliferation. 
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8.2. Neuronal migration 
 
During corticogenesis newborn neurons migrate to well defined positions where they 
establish synaptic connections to allow correct brain function. Of note, this process is 
highly dependent on proper function of microtubule-centrosome machinery and, as 
has been noted, DISC1 interacts with a high number of proteins related with the 
cytoskeleton.   
 
In 2005 Kamiya and coworkers demonstrated that knock-down of DISC1 by in utero 
introduction of a short-hairpin RNA (shRNA) at embryonic day 14.5 results in defects 
in radial migration of neuronal precursor cells in the mouse cortex. This result is 
similar to that obtained with the knock-down of the DISC1 binding partners NDEL and 
LIS-1, two proteins whose malfunction has been implicated in neurodevelopmental 
disorders. Moreover, the expression of a truncated form of DISC1 similar to the one 
produced by the Scottish translocation was responsible for delayed migration of 
cortical pyramidal neurons [48]. In addition, amyloid precursor protein (APP) knock-
down has been later shown to produce the mislocalization of DISC1, impairing its 
binding to the NDEL/LIS-1 complex [70]. 
 
Further studies showed that cooperative action of DISC1 and BBS4 is required for 
accumulation of PCM1 to the centrosome, allowing proper neuronal radial migration 
in the developing cortex [73]. Indeed, two DISC1 mutations found in mental illness 
patients were shown to affect centrosomal PMC1 localization. 
 
Another DISC1-interacting protein implicated in neuronal migration is Coiled-coil 
protein Associated with MyosinII and DISC1 (CAMDI). Fukuda and coworkers 
demonstrated that CAMDI induces localization of phosphomyosin at the centrosome 
in a DISC1-dependent manner and this accumulation is essential for radial migration 
[74].  
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At the same time, Singh and coworkers showed that DIX domain containing protein-1 
(Dixdc1) regulates DISC1 activity during embryonic neural progenitor proliferation and 
neuronal migration. At early developmental stages Dixdc1 interacts with DISC1 
regulating neural progenitor proliferation by co-modulating Wnt/β-catenin signalling. 
However, in later embryonic stage Cdk5-mediated phosphorylation of Dixdc1 
promotes DISC1-NDEL1 interaction and consequently neuronal migration [75]. 
 
Furthermore, Steinecke and coworkers described the impairment of migration of 
interneurons and changes in their morphology after DISC1 suppression in mice at 
embryonic day E14.5 [76]. Recently, the same group has demonstrated that the 
knock-down of DISC1 also affects tangential migration of cortical neurons by affecting 
the actin cytoskeleton [77].  
 
Finally, Ishizuka and coworkers demonstrated that DISC1 acts dynamically in the 
developing mouse cortex promoting the switch from cell proliferation to migration. As 
previously discussed DISC1 binds to and inhibits GSK3β allowing progenitor cell 
proliferation via the Wnt/β-catenin pathway. Once DISC1 is phosphorylated at 
position serine 710, it loses its affinity by GSK3β that is activated and phosphorylates 
β-catenin leading to its degradation, impairing the cell proliferation. On the other 
hand, phosphorylated DISC1 (Ser710) binds preferentially to Bardet–Biedl syndrome 
proteins 1 and 4 (BBS1, BBS4) and produces their recruitment to the centrosome 
promoting neuronal migration. In summary, DISC1 controls the transition from 
neuronal progenitor proliferation to neuronal migration [78]. 
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8.3. Neurite outgrowth and arborization 
 
In neurons, the microtubule and cytoskeleton network also contribute to neurite 
outgrowth, a process in which DISC1 has been found to be involved in primary cell 
cultures and different cell lines.  
 
Initially, overexpression of a truncated form of DISC1 in PC12 was found to inhibit the 
neurite outgrowth due to the abrogation of DISC1 binding to NUDEL caused by the 
truncation [32]. Another protein involved in axon outgrowth that binds to DISC1 is 
fasciculation and elongation protein zeta-1 (FEZ-1), and both colocalize in neurite 
growth cones in rat hippocampal neurons. The interaction between these two proteins 
was found to be upregulated in PC12 cells during neuronal differentiation and 
inhibition of this union resulted in impaired neurite outgrowth. Conversely, 
overexpression of DISC1 in these cells actually resulted in the enhancement of this 
process [51]. Also in PC12 cells dissociation of the interaction of DISC1 with DISC1-
binding zinc-finger protein (DBZ) was shown to be necessary for neurite outgrowth 
[79].  
 
In primary neuronal cultures, DISC1 was described to promote the accumulation of 
NUDEL/LIS-1/14-3-3ε complex in axons in a kinesin-1 dependent manner. DISC1 
knock-down or expression of truncated forms of DISC1 lacking the C-terminal half of 
the protein that act as dominant negative forms, were found to impair the axon 
elongation by disruption of this complex [47]. Additionally, DISC1 was shown to 
mediate the localization of growth factor receptor bound protein 2 (Grb2) at the distal 
part of the axons. Grb2 associates with the activated Tyrosine kinase (Trk) receptors 
and recruits the proteins necessary for the activation of downstream signalling 
pathways promoting the neurotrophin-induced axon elongation. In hippocampal 
neurons, it was demonstrated that knock-down of DISC1 causes defective 
accumulation of Grb2 at the distal part of the axons impairing the Neurotrophin-3 (NT-
3)-induced ERK activation at distal axons and consequently, axon elongation [52].  
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Another study has reported that overexpression of DISC1 causes a rise of β-integrin 
levels among other proteins that produce an increase in the neurite outgrowth [80]. 
 
More recently Bradshaw and coworkers demonstrated that the interaction between 
DISC1 and PDE4 regulates the PKA-induced NDE1 phosphorylation modulating its 
interaction with NDEL1 and LIS-1. This is another evidence of the control of neurite 
outgrowth through this complex in a DISC1-dependent way [50]. 
 
Of note, a mouse model (known as DISC1
TmKara
) expressing a truncated form of 
DISC1 that models the Scottish mutation, exhibits hippocampal neurons with less 
complexity of the dendritic and axonal network compared with wild type hippocampal 
cells. Nevertheless, this effect was not observed in cortical neurons [69] although, two 
different mutant mice with two DISC1 point mutations (Q31L and L100P) display 
shorter dendrites in frontal cortex [81]. 
 
 
8.4. Synaptic activity 
 
Decreased spine density is a common finding in post-mortem studies of brain of 
patients with schizophrenia [82] and synaptic pathology has been confirmed in 
different DISC1 mouse models. The Y2H study of the “DISC1 interactome” published 
by Camargo and coworkers, confirmed that a high number of DISC1 partners are 
regulators of synaptic maturation and plasticity [35]. In human post-mortem cortex, 
DISC1 has been found at the synapses, more specifically at the PSD [60]. This 
localization has been also described in rat and mouse cortical and hippocampal cell 
cultures by different groups [61], [62], [65] and different molecular roles for DISC1 in 
synapses have been reported. 
 
One of the proteins that colocalize with DISC1 at the synapse is kalirin-7 (Kal-7). This 
protein is crucial for spine formation and function and its expression was observed to 
be downregulated in patients with schizophrenia. Hayashi-Takagi described that 
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knock-down of DISC1 in cortical rat neurons leads to an increase in the formation of 
spines and GluR1-expessing synapses, in a Kal-7 dependent manner. At basal 
conditions DISC1 binds to Kal-7 blocking the free access of Kal-7 to Rac1. When 
NMDA receptors are activated, this interaction is weaker and allow the interaction of 
Kal-7 and Rac1 leading to its activation, that is crucial for synapse formation. 
However, the excessive activation of Rac1 produces synaptic shrinkage. As 
expected, long-term silencing of DISC1 resulted in a reduction in the spine size 
accompanied by a decrease in GluR1 expression and frequency of miniature 
excitatory postsynaptic currents (mEPSCs) [61]. These changes in postsynaptic 
currents reflect deficits in the synaptic function considered primary molecular insults 
that lead to diseases like autism and schizophrenia. In this regard, a mutant mouse 
model with deficiency in NMDA receptors has been recently described to show a 
reduction in synaptic spine density and a decrease in the levels of synaptic DISC1 
and its interactor 14-3-3ε. These data indicate that DISC1 acts downstream NMDA 
receptors in the regulation of synapse formation [62].  
 
More information about the role of DISC1 in the synapses comes through its binding-
partner at PSDs Traf- and nck-interacting kinase (TNIK). TNIK is known to regulate 
levels of glutamate receptors and other PSD proteins at the synapse.  At this location, 
DISC1 binds to TNIK inhibiting its kinase activity, which results in the degradation of 
several PSD proteins, such as PSD95 and GluR1 and decreases in the amplitude 
and frequency of mEPSCs [65].  
 
On the other hand, the study recently published by Maher and LoTurco described a 
presynaptic role for DISC1 in cortical layer 2/3 pyramidal neurons. These authors 
found that DISC1 regulates glutamate release from presynaptic terminals and that its 
truncation enhances the frequency of mEPSCs and disrupts the normal pattern of 
evoked glutamate release [83].  
 
In summary, although in the literature we can find contradictory results regarding the 
participation of DISC1 in the synapses, there is clear evidence that it is an active 
 54 
 
element in synaptic spine formation and glutamate synaptic function in the 
mammalian brain. 
 
  
8.5. Adult neurogenesis 
 
Neurogenesis is the generation of new neurons from neural stem cells (NSCs). 
Although this process begins during the embryonic brain development, it continues 
throughout life in some restricted areas of the brain in response to intrinsic and 
extrinsic factors either physiological or pathological.  
 
The generation of new neurons from NSCs during adulthood takes place mainly in 
two areas of the brain: the subgranular zone in the DG of the hippocampus, 
producing dentate granule cells (DGCs), and the SVZ for interneurons of the olfactory 
bulb. After being generated in these areas, the newborn cells suffer processes of 
migration, axon and dendrites growth, and synapse formation to finally integrate into 
pre-existing neuronal circuits [84].  
 
The neurons generated in the adult brain show the same morphological, histological 
and physiological properties as those born during embryonic or early-postnatal 
neurogenesis. As reviewed by Duan in 2008 the only known difference is that 
neurons generated during the adulthood take more time to integrate, indicating that 
the appropriate rhythm of new cell development is of great importance to regulate 
adult neurogenesis [84]. Accordingly, this tempo has been shown to be crucial for 
some brain functions such as spatial memory. Moreover, impairments in adult 
neurogenesis have been related to learning, memory disorders and mental disease.  
 
High levels of DISC1 are found in granule cells in the DG and interneurons in the 
olfactory bulb [37]; moreover, during development in mouse, peaks of expression 
have been detected corresponding with active neurogenesis periods both at 
embryonic and adult stages [43]. Thus, DISC1 localization and temporal expression 
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patterns make of this protein a candidate to participate in the different steps of adult 
neurogenesis. In this regard, a clear relationship between DISC1 and adult 
neurogenesis has been found [85]. 
 
In a first study, in agreement with previous results, knock-down of DISC1 at 
embryonic day E13.5 resulted in less extended migration of cortical neurons. On the 
contrary, DISC1 knock-down in adult DGCs leads to accelerated morphological 
development of newborn neurons resulting in turn in soma hypertrophy and increased 
dendritic outgrowth. Additionally, these new neurons were found to be mispositioned 
due to overextended migration. Furthermore, the same group found that the absence 
of DISC1 in the adult brain produces a rise in excitability as well as accelerated 
formation of functional GABAergic and glutamatergic synaptic inputs [86]. These 
results indicate that DISC1 is necessary for maintaining the proper tempo for newborn 
neuron integration into the preexisting circuits and that the role of DISC1 varies from 
embryonic neurodevelopment to adult neurogenesis.  
 
In addition, Mao et al. perceived a marked decrease in adult hippocampal progenitor 
cells proliferation when DISC1 was knocked-down. This indicates that DISC1 is 
required for normal proliferation of these cells. Additionally, this process was found to 
be regulated by GSK3β. 
 
Recently, Kang and coworkers showed that interaction of DISC1 and FEZ1 regulates 
dendritic development of newborn DGCs in the adult mouse hippocampus. Moreover 
they showed that this association complements the parallel DISC1-NDEL1 binding, 
which regulates positioning and morphogenesis of newborn neurons adding more 
evidences for time-dependent DISC1 roles [87].  
 
Interestingly, Kim and coworkers found that overactivation of the AKT/mTOR pathway 
in DISC1 knock-down cells was responsible for the observed accelerated dendritic 
development during adult neurogenesis. According to this, under physiological 
conditions DISC1 prevents excessive girdin-induced AKT/mTOR signalling in 
newborn neurons [88]. Later, the same group concluded that this phenotype requires 
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the induction of GABA and a NKCC1-dependent depolarization that converge to 
activate AKT/mTOR pathway [89]. Curiously, Namba and coworkers demonstrated 
that the NMDA-Receptor signalling pathway governs the migration of newborn 
neurons in adult hippocampus by regulating expression of DISC1 in the DG [90]. 
These two last studies reinforce the idea that extrinsic (i.e. GABA, NMDA) and 
intrinsic (DISC1) factors play together in a variety of ways to regulate proper 
neurogenesis. 
 
 
8.6. Oligodendrocyte development/ myelination  
 
Numerous lines of evidence have identified oligodendrocytes as critical elements for 
proper neuronal function, as recently reviewed by Mighdoll and collaborators [91]. 
Indeed, a number of clinical, genetic and post-mortem human brain imaging studies 
show alterations in these cells and myelin dysfunction in a broad range of mental 
diseases such as autism, major depression, schizophrenia or other related psychoses 
[91].  
 
The majority of the research aimed to elucidate DISC1 function is focused on its role 
in neurons. However, at this moment it is known that DISC1 also plays an important 
role in oligodendrocytes. Wood and coworkers have identified the zebrafish 
orthologues of DISC1 and Neuregulin1 as key proteins for oligodendrocyte 
development [92].  
 
Interestingly, as assessed by Seshadri, DISC1 is also expressed in oligodendrocytes 
in human and rat [93] and was shown to be necessary for the development of these 
cells in the rat cortex. DISC1 expression was found to be temporary regulated in 
oligodendrocyte precursors timing the process of progenitor cells differentiation. 
Specifically, DISC1 knock-down and truncation were described to cause accelerated 
differentiation through deregulation of expression of different transcription factors. The 
study of the role of DISC1 in oligodendroglial lineage would be of great interest to 
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elucidate the specific impact of proper myelination of defective neuronal 
communication, suggested as a component of the pathophysiology of psychiatric 
disorders.  
 
 
8.7. cAMP signalling pathway 
 
DISC1 was suggested to modulate cAMP signalling by its interaction with members of 
the phosphodiesterase-4 family (PDE4A-D). This family of proteins has been broadly 
described to be involved in mental disorders such as schizophrenia, depression or 
autism. Indeed, their function is the hydrolysis of cAMP, a second messenger 
involved in learning, memory and mood. Besides, rolipram, an antidepressant drug, is 
a selective inhibitor of this family of proteins [94], [95]. In addition, mice deficient in 
PDE4D behave as if they were taking antidepressants [96]. Millar and coworkers 
have described that the interaction between DISC1 and phosphodiesterase-4B is 
dynamic and directly depended on cAMP levels. The observations of this study 
support a model in which DISC1 sequesters PDE4B in a low-activity form until cAMP 
signalling is switched on. In response to this rise in cAMP, PDE4B is released and 
hydrolyzes this second messenger to turn off the signalling cascade [34]. 
 
More recently it has been demonstrated that the 100kDa full-length DISC1 isoform (fl-
DISC1) binds to PDE4 isoforms from each of the four PDE4 gene families (PDE4A-
D). This study reveals PDE4 subfamily-specific differences in the interaction and 
release-cAMP-dependent from DISC1 making the understanding of the role of DISC1 
in the regulation of cAMP much more complex [97]. 
 
Furthermore, it has been reported that the interaction between DISC1 and PDE4 
regulates the organization of the NDE1/NDEL1/LIS-1/dynein complex involved in 
neural progenitor proliferation, migration and neurite outgrowth [50]. Accordingly, 
PKA-dependent phosphorylation of the mentioned complex is modulated by DISC1-
PDE4 interaction. When DISC1 was not present or was aberrantly expressed, an 
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increase in NDE1 phosphorylation PKA-dependent was observed, due to the 
activation of PDE4.  
 
 
9. DISC1 ANIMAL MODELS 
 
Some human diseases present phenotypic traits that are difficult to measure in animal 
models. This is specially complicated in mental disorders, since numerous symptoms 
seem to be exclusive to humans such as delusions, hallucinations or mood swing. 
Nevertheless, anatomical, histological, cognitive or behavioral abnormalities similar to 
those found in patients can be distinguished in different animal models of mental 
illness. 
 
In the last few years a number of DISC1-mutant mouse models have been described. 
All of them present defects in their neuroanatomy and behavioral alterations that in 
some cases are coincident among the groups, although several differences can be 
observed across the models.  
 
 
9.1. Missense mutants 
 
By means of N-mitroso-N-ethylurea (ENU) mutagenesis, Clapcote and coworkers 
introduced two point mutations in the exon 2 of DISC1, present in all known splice 
isoforms and encoding most of the protein head domain. One of the mutants presents 
a 127A/T transition that results in the change of the amino acid glutamine (Q) to 
leucine (L) at position 31 (Q31L) of the protein. The other model has a 334T/C shift 
that results in the change of leucine (L) to proline (P) at position 100 (L100P).  
Although both mutations take place in the same exon, the observed phenotypes are 
clearly different. 
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L100P mutants show a schizophrenic-like phenotype, indicated by alterations in their 
latent inhibition (LI) and prepulse inhibition (PPI). These two neurological processes 
inhibit memory formation and the reactions elicited by familiar or weak stimuli 
preventing information overload. These processes allow the filtration of unnecessary 
information and their malfunction is a hallmark of some illnesses such as 
schizophrenia or Alzheimer’s disease. Additionally, L100P mice also show working 
memory (WM) deficits similar to that found in schizophrenic patients. WM is a type of 
short-term memory that deals with visual images and verbal information. Remarkably 
LI, PPI and WM deficits in L100P mice were found to be ameliorated by typical 
(Haloperidol) and atypical (Clozapine) antipsychotic drugs as well as by the 
antidepressant rolipram administration [98]. Another characteristic of these mutants is 
their hyperactivity, consistent with the enhanced sensitivity to amphetamine found in 
these mice. Amphetamine elicits the liberation of dopamine (DA) suggesting that this 
model presents hypersensitivity to DA. Indeed, the DISC1-L100P mutant shows a 
two-fold increase in the proportion of D2 DA receptors in their striatum [99]. 
Additionally these mice present in their brain reduced interaction of DISC1 with 
PDE4B and GSK-3, two downstream proteins in the DA signalling cascade [100]. 
Remarkably, treatment of these mice with PDE4B and GSK3 inhibitors corrects the 
behavioral deficits. 
 
Summarizing, agreeing with the dopaminergic origin of schizophrenia hypothesis 
[101], [102] the L100P mouse phenotype resembles several symptoms of 
schizophrenia associated with hypersensitivity to DA such as disrupted PPI and LI, 
hyperactivity, enhanced sensitivity to amphetamine and disruption of the signalling 
cascade of DA.   
 
On the other hand, the Q31L genetic model presents a depressive-like phenotype. 
Similar to the previous model, these mice present deficits in PPI, LI and WM. 
However, they also show features of depression such as increase of immobility time 
in the forced swim test (FST), decrease in sociability and decrease in reward 
responsiveness, indicative of anhedonia, a well-known endophenotype of depression 
[98]. Apart from these behavioral abnormalities, Q31L mice present alterations in 
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neurochemical functions reflected by a decrease of the levels of DA, serotonin (5-HT) 
and norepinephrine. Besides, in this genetic model β-arrestin-1,2 and total CREB 
levels are decreased compared to wild type mice [103]. Remarkably, these proteins 
have been implicated in signalling pathways relevant for the pathogenesis of 
depression and the mechanisms of action of antidepressants. Additionally, synaptic 
function seems to be also altered in this model due to a reduction of spine density, 
that results in the impairment of synaptic connectivity [81]. Indeed, reduced spine 
plasticity is suggested to underlie some neuropsychiatric disorders such as anxiety, 
depression or drug abuse. 
 
Although these two models present differences at the behavioral and molecular 
levels, they share some features such as reduction in neurogenesis in the cortex, 
aberrant positioning of pyramidal neurons on cortex and hippocampus as well as 
shorter dendrites and spines. Moreover, a reduction of brain volume of 6% in Q31L 
mutants and 13% in P100L was described, agreeing with the observation of small but 
significant reductions in brain volume of patients with schizophrenia. These volume 
variations are found in cortex, entorhinal cortex, thalamus and particularly cerebellum. 
Remarkably, all these areas have been implicated in the pathophysiology of 
schizophrenia and depression. 
 
 
9.2. Deletion mutants. Δ25bp/ stop codon 
 
The 129S6/SvEv mice strain has a natural polymorphism in the DISC1 gene 
consisting in a 25bp-deletion in exon 6. This deletion causes a shift in the reading 
frame that results in 13 novel amino-acids and is followed by a premature stop codon 
in exon 7 that causes the truncation of the protein. Although the DISC1 transcript can 
be detected in 129S6/SvEv mice, the truncated protein is undetectable in early 
postnatal or adult brain lysates, indicating that this species is relatively unstable [104].  
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Gogos´ group transferred a 129S6/SvEv mutant-DISC1 allele into a C57BL/6J 
background. As expected these mice (named Disc1
TmKara
) lack of full-length DISC1 in 
their brains [105]. This genetic model, similar to the DISC1 missense mutants 
previously discussed, presents working memory impairment that indicates frontal 
deficits. Anatomically, Disc1
TmKara 
presents a small decrease in prefrontal cortex 
(PFC) volume in and reduction of the neurogenesis in the DG. Newborn DGCs show 
less dendritic complexity when compared to wild type together with defects in the 
positioning and orientation of apical dendrites and axonal projections [69]. 
Furthermore, this mutant mouse presents a reduction in the volume of vesicles at 
presynaptic boutons and a decrease in the frequency facilitation (form of short-term 
synaptic plasticity). Frequency facilitation increases the potentials evoked by 
subsequent impulses producing a rise in the probability of neurotransmitter release. 
This phenomenon is involved in simple learning, information processing and sound-
source location. In this model, DGCs are less excitable as demonstrated by their firing 
properties. Remarkably the Disc1
TmKara 
model exhibits a significant decrease in 
different PDE4 isoforms at the protein level and as a result, a decrease of PDE4 
activity of 50% in homozygotes. Once again, variations in PDE4 activity and 
consequently, in cAMP metabolism, appear to be involved in the phenotype observed 
in these DISC1 mutant mice [106]. 
 
 
9.3.  Dominant negative transgenic mice  
 
DISC1 truncation by the translocation t(1;11) in the Scottish family results in a broad 
spectrum of psychiatric illness; however, the mechanism by which this happen is 
unknown and three major hypothesis have been proposed to the moment. On the one 
hand the translocation leads to a C-terminal truncated DISC1 protein that could act in 
a dominant negative (DN)-manner. However, the existence of this product has not 
been proved in the brain of translocation carriers [48]. On the other hand, this 
truncated form of DISC1 might be degraded leading to a haploinsufficiency. 
Remarkably, no truncated DISC1 protein is found in lymphoblasts from the Scottish 
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family [34]. These two possibilities would produce in the end a loss of DISC1 function. 
Finally, the truncation might produce a fusion protein with products of chromosome 1 
and 11 which has been shown to be amyloidogenic and could have a toxic effect [92].  
 
In order to solve this enigma several mice with truncation of DISC1 have been 
generated. 
 
9.3.1. CaMK-DN  
 
Hikida et al. and Pletnikov et al. described two models in which a truncated dominant 
negative form of DISC1 (DN-DISC1) is exogenously expressed under a 
calcium/calmodulin-dependent kinase II (CaMKII) promoter preferentially expressed 
in pyramidal neurons of cortex and hippocampus.   
 
The Pletnikov model contains a tet-off system that allows the inducible expression of 
the truncated human DISC1 (hDISC1). In this model, mutant hDISC1 expression 
causes no gross abnormalities in the brain morphology at an early stage; however, 
although the total brain volume remains unchanged, these mice present a significant 
increase in the volume of lateral ventricles at later postnatal phases. Moreover, these 
mice exhibit less neurite complexity in cortex and hippocampus [107]. In addition, 
these mice show decreased levels of cortical DA [108], suggesting once again, a role 
for DISC1 in the dopaminergic system.  
 
In this model, under normal conditions no major behavioral abnormalities are found 
but increased amphetamine sensitivity. However, the treatment with 
polyinosinic:polycytidylic (poly I:C), that mimics maternal immune activation, has 
severe effects on the behavior of these mice. The administration of this environmental 
stressor results in elevated anxiety, depression-like responses, altered pattern of 
sociability and attenuated reactivity to stress when compared with mutant mice 
treated with saline. These data show the influence of the environment in a genetic risk 
background [109].  
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In contrast, the Hikida model, expresses the truncated DN-DISC1 in a constitutive 
manner [110]. This genetic model presents enlargement of the lateral ventricles and 
asymmetrical changes in the morphology of the brain at 6 weeks. Moreover, DN-
DISC1 mice present deficits in cortical parvalbumin neurons. This is a subgroup of 
GABAergic inhibitory interneurons essential for neuronal synchronization. 
Remarkably, the reduction of this type of neurons has been suggested to be a typical 
feature of schizophrenia in humans [111].  
 
Under basal conditions these animals present hyperactivity and possibly anhedonia. 
However, when these mice are treated with Poly I:C they also present NMDA 
hypersensitivity, abnormalities in sociability and impairments in short-term memory 
and fear response [112]. Results from PET, autoradiography and real-time PCR 
showed a small but consistent rise in the levels of the DA receptor D2R and the DA 
transporter (DAT) in the striatum of DN-DISC1 mice compared to WT mice. These 
results are consistent with the small but significant elevation of striatal D2 receptors in 
untreated SZ patients. Furthermore, in this model was also observed an upregulation 
of the mRNA of the dopamine D1 receptor [113]. 
 
9.3.2. BAC- DN 
 
Shen and coworkers generated a transgenic mouse carrying two copies of the 
truncated DISC1 encoding exons 1-8 using a bacterial artificial chromosome (BAC) 
[71]. At the behavioral level these mice have frontal deficits detected by alterations in 
LI, depression-like conduct and reduced sociability. This transgenic mutant shows 
some alterations in the brain such as reduced cortical thickness with reduced 
neurogenesis in this area, enlarged lateral ventricles and partial agenesis of corpus 
callosum. Additionally, they present reduced number of interneurons in the 
hippocampus and changes in their distribution in medial prefrontal cortex. Besides, 
this mutant exhibits a decrease in the neurite outgrowth. Finally, BAC-DN mice show 
significant reduction of parvalbumin neurons in the medial prefrontal cortex and 
hippocampus. 
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9.3.3. CAMK-cc 
 
A different DISC1 truncated model is the one generated by Li and coworkers. In this 
model an inducible and reversible transgenic system allows the expression of the 
DISC1 C-terminal fragment. This is the region of the protein lost in the Scottish t(1;11) 
translocation. In this case, the authors also used the CaMKII promoter for the 
generation of this mutant. Early postnatal, but not adult, induction of the expression of 
DISC1 C-terminal fraction results in reduced hippocampal dendritic complexity, 
depressive-like behavior, abnormal spatial WM, and reduced sociability [114]. This 
animal model agrees with other DISC1 mutants in which disruption of DISC1 during 
development impacts on adult phenotype. 
 
 
9.4. In utero DISC1 knock-down 
 
Niwa and coworkers performed in utero electroporation to transfer a DISC1 short-
hairpin RNA (shRNA) expression construct to a lineage of pyramidal neurons in the 
PFC of mice embryos at day E14 [115]. The knock-down of DISC1 is transient and it 
is no longer effective 3 weeks after the procedure.  At postnatal day 14 (P14), 
pyramidal neurons without DISC1 present abnormal dendritic morphology. At P56, 
this knock-down model presents a marked decrease in the levels of DA in the medial 
prefrontal cortex that may indicate disturbed maturation of dopaminergic neurons. 
Moreover this model exhibits a deficit of interneurons in adulthood. Neonatal 
pyramidal neuron deficit produced by knock-down of DISC1 led to disturbances in 
dopamine neurons, pyramidal neurons, and interneurons manifested only after 
puberty. 
 
At the behavioral level, DISC1 knock-down adult mice present deficits in PPI, at least 
in part, associated with decreased levels of DA that are improved by administration of 
clozapine. Moreover they display hypersensitivity to methamphetamine.  
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Summarizing this model offers a good tool to investigate how DISC1 suppression 
during the first stages of neurodevelopment affects to postnatal maturation and brain 
function in adulthood. 
 
 
9.5. Knock-out DISC1(Δ2-3)mice 
 
Kaibuchi’s group has recently generated a mouse lacking exons 2 and 3 of the Disc1 
gene, needed for the generation of all known DISC1 isoforms [68]. Of note these two 
exons encode a region of the DISC1 necessary for interaction with a number of 
proteins such as PDE4B, girdin or GSK3β among others.  
 
At the electrophysiological level this mutant presents abnormalities in long-term 
potentiation (LTP) indicating impairment of synaptic plasticity. Moreover, adult DISC1 
(Δ2-3) mice show increased social interaction, hypersensitivity to methamphetamine, 
lower anxiety and/or higher impulsivity compared to control mice. This last trait is 
consistent with clinical features of schizophrenic patients. Remarkably, the low 
anxiety and high impulsivity are attenuated by treatment with the antipsychotic 
Clozapine. In addition, gender-specific behavioral alterations have been observed: 
female mice show deficiency in PPI and enhanced response to methamphetamine 
while males do not. This abnormality in female behavior was proposed to be 
associated to imbalance in the GABAergic and dopaminergic systems. Indeed, 
female DISC1 (Δ2-3) exhibit reduction of the total number of GABAergic neurons in 
the hippocampus and increased expression of DA D1 and D2 receptors in the 
nucleus accumbens [116]. 
 
 
10. HUMAN DISC1 SEQUENCE VARIATIONS 
 
Apart from the Scottish truncation, numerous DISC1 non-synonymous sequence 
polymorphisms in humans have been described and associated to mental illness.  
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To date, three common amino acid variants in DISC1 have been identified and 
associated with psychiatric illness: R264Q, L607F and S704C. The 264Q allele has 
been associated to reduction of cortical thickness and carriers of the F607 allele show 
reduced gray matter and they suffer more severe positive symptoms of schizophrenia 
[117]. Furthermore, in vitro studies demonstrated that expression of the F607 variant 
of DISC1 associates with reduced noradrenaline release, lower levels of the DISC1 
partner PCM1 at the centrosome as well as mitochondrial trafficking defects [118]. It 
has also been reported that carriers of this allele present lower levels of a DISC1 
specific transcript whose expression is altered in schizophrenia patients [26]. 
Regarding the C704 allele, this variant has been associated with morphological and 
functional changes in the brain, altered PCM1 localization and schizophrenia-related 
DISC1 transcript expression. Additionally, this allele is associated with reduced 
activity of ERK1 and AKT [21], altered binding affinities of DISC1,NDE1 and NDEL1 
and variation in DISC1 oligomeric status [119]. 
 
Apart from these common variants, ultrarare mutations in the DISC1 gene have been 
also described. Song and coworkers analyzed the gene in 288 schizophrenic patients 
and 288 controls. In the patients´ group, they discovered five ultrarare missense 
variants that where not found in controls and in a pool of 10,000 unrelated control 
alleles. In this study, the authors deduced that DISC1 ultrarare-variants are 
associated with an attributed risk of 2% for schizophrenia. The non-synonymous 
variants found were G41A, R37W, S90L, R418H and T603I. These mutations are 
located in the binding regions of DISC1 with some other proteins such as PCM1, 
PDE4B, ATF5, BBS1/4, girdin, GSK3β or FEZ-1 [120].  
 
This group performed a similar study analyzing the DISC1 gene in 504 patients with 
bipolar spectrum disorder and 576 controls. 5 patients were found heterozygous for 
ultrarare protein structural variants absent in controls. These variants were found to 
associate with an estimated attributed risk for bipolar spectrum disorder of 0.5%. The 
reported ultrarare non-synonymous variants were S209R, R338Q, R418H (also found 
in the previous study of DISC1 in schizophrenia) and T754S. These variants also 
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localize in the DISC1 binding region for some proteins such as girdin, LIS-1, or PMC1 
[121]. 
 
Finally, Green and coworkers sequenced exon 11 in 506 patients with schizoaffective 
disorder and 1211 controls searching for variants in this region. The variants T754S 
(also described by Song) and P758R were found only in cases of schizoaffective 
disorder and not in controls [122]. 
 
 
11. DISC1 AND VGF 
 
In a recent unbiased proteomic study, our group reported that DISC1 knock-down in 
SH-SY5Y cells produces a significant downregulation of 14 VGF forms with a fold 
change between 2 and 11.5 [123]. VGF is a secreted polypeptide widely expressed in 
neurons in brain, spinal cord and neuroendocrine organs. After its synthesis, VGF is 
processed into more than 10 mature peptides that have been found to be involved in 
the regulation of energy homeostasis, metabolism and synaptic plasticity. 
Remarkably, this peptide has been shown to be implicated in depression, bipolar 
disorder and schizophrenia. 
 
 
11.1. The Vgf gene 
 
The Vgf gene was first identified due to its rapid induction by exposure to NGF in 
PC12 cells [124]. Subsequently, Vgf expression was demonstrated to be highly 
induced by neurotrophins such as Neurotrophin-3 (NT-3) or Brain Derived 
Neurotrophic Factor (BDNF) [125]. Remarkably, Vgf was also demonstrated to be 
induced by 5-HT and drugs that elevate the level of this neurotransmitter in 
hippocampal rat neurons [126]. Furthermore, VGF expression has been shown to 
respond to feeding/ fasting, salt loading, adrenalectomy, circadian and seasonal 
rhythm, estrous cycle and photoperiod in different tissues [127]. 
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The Vgf gene is located on chromosome 7q22 in humans and in chromosome 5 in 
mouse and is highly conserved along the evolution. Although the gene is composed 
of three exons and undergoes alternative splicing, the protein sequence is encoded 
only for the third exon, common to all the spliced transcripts. Vgf contains several 
consensus motifs for transcriptional regulators within its promoter. Some of these 
consensus sequences are a CCAAT box, various SP-1 (specific protein 1) and AP-2 
(transcription factor AP-2 alpha) consensus binding sites, a putative silencer element, 
a cAMP response element (CRE), and a CREB binding site [128]. These last two 
regions are critical for the neurotrophin-induced VGF expression. 
 
The expression of Vgf starts in discrete neurotrophin-responsive neurons in central 
and peripheral nervous system in early stages of embryogenesis. A trend of 
expansion of Vgf expression is evident during all the embryonic development and 
after birth with a peak of VGF mRNA levels detected during the first two weeks of 
postnatal development. In adult rat brain, VGF mRNA is widely distributed and 
particularly abundant in neurons of the hypothalamus, hippocampus, olfactory 
system, cerebral cortex and in thalamic, septal, amigdaloid and brainstem nuclei. 
Moreover, VGF mRNA is also found in spinal cord, in motor and sensory neurons and 
in neuroendocrine organs including pituitary, adrenal gland, pancreatic islets and 
stomach [129].  
 
Vgf is an activity dependent gene, since its expression is upregulated in the brain 
during peak periods of increased activity such as learning [130] long-term potentiation 
(LTP) [131], synaptogenesis [132] or electroconvulsive shock [133]. Moreover, lesions 
in the central nervous system produce a rapid VGF upregulation probably as a result 
of the global increase in electrical activity characteristic of seizures [131].  
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11.2. The VGF protein 
 
The primary VGF product is a 617 and 615 amino acid precursor in rats/mice and 
humans respectively with a predicted molecular weight of 68kDa. VGF is translocated 
to the endoplasmic reticulum, enters in the secretory pathway and is released in 
response to depolarizing stimuli.  VGF migrates as a doublet with an apparent MW of 
80-90kDa in SDS-PAGE. This discrepancy with its predicted molecular weight can be 
due to posttranslational modifications or to the high content in proline resulting in 
reduced electrophoretic mobility [127].  
 
The primary VGF precursor is subsequently processed into more than 10 different 
neuropeptides by the neuroendocrine-specific prohormone convertases PC1/3 and 
PC2.  Figure 4 shows the VGF-derived peptides that have been described to possess 
a biological function to the moment. 
 
 
 
Figure 4: VGF-derived peptides with a known biological function (Toshinai et al.,2009, Cellular and 
Molecular Life Science). 
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11.3. Bioactive VGF peptides 
 
After proteolytic post-translational processing, VGF-derived peptides are preferentially 
released in response to different stimuli and participate in a number of processes 
including:  
 
 Food intake: TLQP-21 increases energy expenditure, prevents diet induced 
obesity in mice and stimulates catabolic pathways [134]. NERP-2 increases 
food intake as well as locomotor activity, body temperature and oxygen 
consumption [135].  
 
 Water balance: NERP-1/2 produces changes in physiological regulation of 
water homeostasis [136]. 
 
 Reproduction: Several VGF-peptides induce rat penile erection. Moreover 
TLQP-21 administration induces release of different sexual hormones in 
pubertal and adult cultured tissues [137]. 
 
 Gastrointestinal tract motor function: TLQP-21 decreases gastric acid 
secretion and gastric emptying [138].  
 
 Pain modulation: peripheral injection of TLQP-21 results in hyperalgesia and 
its central administration has analgesic effect [139]. TLQP-62 induces long 
lasting mechanical and cold allodynia (pain produced by a stimulus that 
wouldn't normally cause pain) [140]. AQEE-30 produces thermal hyperalgesia 
[141].  
 
 Neuroprotection: TLQP-21 prevents apoptosis of cerebellar granule cell 
cultures induced by serum deprivation [142]. AQEE-30 in PC12 cells 
produces the increase of the expression of genes mediating neuronal 
protection [143]. Besides, VGF significantly attenuates exocytotoxic injury 
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and its pharmacological inducer SUN N8075 was shown to exert protective 
effects against endoplasmic reticulum stress induced cell death [144].  
 
 Neurogenesis: TLQP-62 enhances proliferation of cultured hippocampus cells 
[126]. More specifically, this peptide was shown to activate the proliferation of 
neural progenitor cells in the subgranullar zone of the hippocampus [145] and 
in the DG [146] of mice.  
 
 Synaptic activity: Acute treatment with TLQP-62 an AQEE-30 produces an 
increase in synaptic activity in rat and mice hippocampal neurons [130], [147]. 
Furthermore, AQEE-30 addition to PC12 cells enhances the transcription of 
genes that increase synaptic plasticity. Besides, the increase of synaptic 
activity is accompanied by the induction of the expression of genes involved 
in synaptogenesis and synaptic remodeling such as synapsin 1, Grb2 and 
ERG [143].  
 
As has been noted, mouse models have been a very useful tool for the elucidation of 
VGF function. However, the biggest trouble found for the study of VGF roles in the 
cell is the lack of known receptor/s. Regarding this issue, two proteins have been 
recently found to bind the VGF-derived peptide TLQP-21 in rodent cells and proposed 
as the peptide receptor: C3AR1 [148] and gC1qR [149] both known as receptors for 
proteins of the complement system. However, the receptor/s for VGF or VGF-derived 
peptides in human cells is still unknown.  
 
 
11.4. VGF in mental illness 
 
VGF expression pattern has been found to be altered in different neurological and 
psychiatric human illnesses. In fact, it has been proposed as a candidate biomarker 
for frontotemporal dementia [150], amyotrophic lateral sclerosis (ALS) [151], 
Parkinson’s and Alzheimer’s diseases [152], or acute encephalopathy [153]. Besides, 
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VGF has been broadly found to be involved in depression, bipolar disorder or 
schizophrenia: 
 
The levels of VGF are decreased in the brain of animal models of depression [126] 
and prenatal stress [154]. The expression of VGF was found to be upregulated by 
antidepressant factors such as electroconvulsive shock [133], [155] and chronic 
antidepressant treatment such as imipramine or serotonin [126] in rodents. Similarly, 
voluntary exercise (a mood stimulator in humans and antidepressant factor in 
animals) was also found to upregulate VGF in the hippocampus of mice. Conversely, 
this effect was not observed in Vgf +/- mice, suggesting that endogenous VGF is 
essential for mood regulation [143]. In addition, administration of AQEE-30 was 
shown to produce a robust antidepressant response in murine paradigms of 
depression.  
 
Remarkably, evidence for implication of VGF in depression has been also described 
in humans. VGF mRNA levels were found significantly decreased in leukocytes 
extracted from drug-free depressed patients compared with controls [154]. In that 
study, treatment with antidepressants was seen to improve the symptoms along with 
an increase of Vgf expression. This result supports the involvement of VGF deficits in 
depression not only in animals but also in humans.  
 
In addition, abnormal activity in the hippocampus, due to defective neuronal 
communication, has been proposed to play an important role in the origin of 
depression. Indeed, evidences suggest that neurotransmission is disrupted in major 
depression patients due to changes in synaptic activity [156]. As previously noted, 
administration to hippocampal cells of two VGF derived peptides (TLQP-62 and 
AQEE-30), produced an increase in the synaptic charge indicating the enhancement 
of synaptic activity [130]. This fact could explain the antidepressant effect of both 
peptides. Remarkably, voluntary exercise also increases synaptic activity [143].  
 
It has been recently reported that chronic TLQP-62 administration induces the 
activation BDNF/TrkB/CREB signalling pathway in mice and this route has been 
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suggested to mediate the antidepressant-like effects of the peptide.  Besides, this 
induction was found to increase the proliferation rate of neuronal progenitor cells in 
the hippocampus agreeing with previous evidences [146].  
 
Although most of the research regarding VGF and mental disease focuses on 
depression, a study published in 2010 describes a decrease of VGF mRNA levels in 
post-mortem hippocampus and prefrontal cortex samples of bipolar disorder patients 
compared to healthy brains. Moreover, this paper suggests that VGF contributes to 
the beneficial effects of lithium (prototypical treatment for bipolar disorder) in mice in 
the deficits in behavioral tests. Remarkably, VGF was shown to be necessary for the 
lithium induced MAPK/AKT cascade by which lithium exerts its mood-stabilizing 
properties [157].  
 
With regard to schizophrenia, data are conflicting. During the search for disease 
biomarkers in cerebrospinal fluid of patients with first-onset of psychoses, Huang and 
coworkers found an increase of a VGF-derived peptide in samples obtained from 
patients with schizophrenia [158]. In contrast, these data are in conflict with studies 
from the Stanley Medical Research Institute (SMRI) Genomic Database which 
showed the levels of VGF mRNA actually decreased in prefrontal cortex of 
schizophrenic patients [157]. Agreeing with this results a drop in the density of VGF-
immunoreactive neurons has been recently reported in the hypothalamus of 
individuals with schizophrenia [159].  Remarkably, we recently found a decline in VGF 
levels in cortical tissue of patients with chronic mental disease (major depression, 
bipolar disorder and schizophrenia) compared with those from healthy controls [123]. 
Moreover, we also observed that VGF is genetically associated with social 
anhedonia, an endophenotype of a wide range of major mental illness. 
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11.5. VGF Knock-Out mice 
 
Genetic ablation of VGF results in deficits in energy balance. Vgf-KO mice are thin 
small, hyperactive and hypermetabolic with reduced body weight and highly 
decreased body fat. They show increased insulin sensitivity increased lipolysis, 
impaired lipid storage and fatty acid trapping in adipose tissue. Moreover, these mice 
also present a 50% increase in calorie intake per gram body weight and consume 
twice as much oxygen.  Additionally they are infertile [160]. Apart from the metabolic 
changes, the lack of VGF produces a depressive like phenotype in heterozygous 
mice (Vgf
+/-
) when submitted to behavioral tests [143]. Additionally these mice present 
deficits in synaptic plasticity and memory that reflect hippocampal dysfunction [147]. 
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The main objectives of this study were: 
 
 The elucidation of the molecular signalling pathway(s) by which DISC1 
regulates the expression of the neuropeptide VGF in neurons.  
 
 Obtaining new knowledge about DISC1 function by means of a proteomic 
approach.   
 
  
 78 
 
  
 79 
 
 
 
MATERIALS AND 
METHODS 
  
 80 
 
 
 
  
 81 
 
1. EXPERIMENTS WITH THE SH-SY5Y CELL 
LINE 
 
1.1. SH-SY5Y CULTURE 
 
The human derived neuroblastoma SH-SY5Y cell line was obtained from the 
European Collection of Cell Cultures (ECACC) (Catalogue number: 90430304). Cells 
were maintained in Earle’s Balanced Salt Solution (EBSS) (Sigma-Aldrich) and 
F12HAM (Sigma-Aldrich) media in proportion 1:1. The medium was supplemented 
with 15% Fetal Bovine Serum (FBS) (Gibco, Life Technologies), 1% L-glutamine 
200mM (Gibco, Life Technologies), 1% MEM-Non Essential Aminoacids (NEAA) 
(Gibco, Life Technologies), 1% penicillin-streptomycin (P/S) (Gibco, Life 
Technologies). 
 
A stable SH-SY5Y line with DISC1 knock-down was used for this study. The 
establishment of this cell line was performed as recently published by our group [123]. 
The line selected for the performance of this study was the one named as Silenced 1. 
SH-SY5Y cells were never used in a passage higher than 20, since this cell line loses 
its neuronal characteristics with increasing passages. 
 
 
1.2. NEURITE OUTGROWTH ASSAY  
 
This experiment was performed in collaboration with Robert Kypta and Irantzu 
Gorroño Etxebarria (CiC Biogune, Derio, Bizkaia, Spain). SH-SY5Y cell lines with 
stable knock-down of DISC1, named in the literature Silenced 1 and Silenced 4 [123] 
and control cells were submitted to a neurite outgrowth assay. Cells were grown as it 
was described in section 1.1. To differentiate them, cells were grown during 7 or 14 
days in medium containing retinoic acid (Sigma-Aldrich) to a final concentration of 10 
μM. For morphological analysis, images of live cells were taken under microscope 
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were analyzed using ImageJ software http://rsb.info.nih.gov/ij. The number of cells 
with and without neurites longer than two cell bodies was counted in 
photomicrographs. Three fields of 100 cells were analyzed for each condition and the 
experiment was performed twice (n = 2). All data were analyzed as means ± standard 
deviation (SD). Statistical analysis was performed with the Excel program (Microsoft) 
using a non-parametric unpaired Mann-Whitney U-test (two-tailed); results were 
considered significant with p < 0.05. 
 
 
1.3. DISC1 OVEREXPRESSION 
 
Inducible-DISC1 overexpressing SH-SY5Y cells were a kind gift from the Carsten 
Korth Laboratory (Düsseldorf, Germany). The overexpression of DISC1 was 
accomplished by adding 1µg/mL of doxycycline (Sigma-Aldrich) to the cell medium. 
Cells were treated during 48h and then lysed (see below). Cellular extracts were 
stored at -80ºC until they were analyzed by western blot.   
 
 
2. DISC1 KNOCK-DOWN IN MOUSE PRIMARY 
NEURONS 
 
2.1. Mouse neuronal primary cultures 
 
E14-15 (embryonic day 14-15) cortex and hippocampi were obtained from timed-
pregnant ICR Swiss mice. Pregnant females were killed by cervical dislocation 
according to institutional guidelines for care and use of animals. Embryos were 
maintained and dissected in Dulbecco's phosphate-buffered saline DPBS (Gibco, Life 
Technologies) dissolved in milliQ water supplemented with glucose 0.6% (Sigma-
Aldrich). Cortex and hippocampi were isolated from the rest of the brain and the 
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meninges were removed under a zoom stereo microscope (SZ-STS Olympus). 
Fragments were deposited in a glass Petri dish, previous cleaned with ethanol, where 
they were mechanically triturated with two scalpels. Pooled tissue was resuspended 
in DPBS-glucose and placed in a 15mL Falcon tube. Cells were allowed to sediment 
and supernatant was removed taking care of not discard any portion of the sediment. 
This wash step was repeated twice. The cellular sediment was digested with Trypsin 
0.5% -EDTA (10X) (Invitrogen) dissolved in DPBS-Glucose, previously warmed at 
37ºC. The mixture was incubated at 37ºC during 15 minutes with periodic agitation 
every two or three minutes.  The added volume was 3mL for each group of 10 
embryos. Trypsin was inactivated by adding a quarter of the final volume of horse 
serum to the tissue solution (Gibco, Life Technologies) and shaking the mixture. Cells 
were allowed to sediment. The supernatant was removed and 2mL of DNAse I 
Recombinant Grade I (100U/mL) (Roche), dissolved in DPBS glucose was added for 
each set of 10 embryos at 37ºC. To isolate the embryonic neuronal cells the mixture 
was homogenized with pipette and Neurobasal medium (-) L-Glutamine (Gibco, Life 
Technologies) was added up to 10mL. The sample was centrifuged at 1000g for 5 
minutes and the supernatant was discarded. The pellet was resuspended in 
Neurobasal medium supplemented with 5% of horse serum (only for 24 hours), 1% 
penicillin/streptomycin (Gibco, Life Technologies), 1% L-glutamine (Gibco, Life 
Technologies), 1.22 mL D-glucose (Sigma-Aldrich), 0.58 mL sodium bicarbonate 
(Gibco, Life Technologies) and 2% B27 (Gibco, Life Technologies at 37ºC).  
 
3x10
6
 cells were plated per 10cm Petri dish previously coated with Poly-D-lysine 
(Roche). The cells were maintained in serum free medium at 37ºC in 95% air/ 5% 
CO2 in a humidified incubator. 
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2.2. Lentiviral production  
 
In order to produce the lentiviral particles, HEK293FT cells (Invitrogen) were used. 
The HEK293FT cell line is a fast-growing, highly transfectable clonal isolate derived 
from human embryonic kidney cells transformed with the SV40 large T antigen. 
These cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) - high 
glucose (Sigma-Aldrich) supplemented with with 10% FBS (Gibco, Life 
Technologies), 1% sodium pyruvate 100mM solution (Gibco, Life Technologies), 1% 
NEAA (Gibco, Life Technologies), 1% L- glutamine (200mM) (Gibco, Life 
Technologies), 1% penicillin/streptomycin (Gibco, Life Technologies) and 500 µg/ml 
of Geneticin selective antibiotic (G418 Sulfate) (Gibco, Life Technologies). 
 
Three pLKO.1-Puro-CMV-tGFP shRNA plasmids (Sigma Aldrich) were used to create 
lentiviruses. The sequences of the plasmids are shown in table 1. The non-target 
shRNA (SHC002. Sigma Aldrich) was used as a control.  
 
Table 1: shRNAs used for DISC1 knock-down in neurons. 
 
shRNA SEQUENCE 
Silenced N1 
(DISC1 RNAi #1) 
5’-GGCAAACACTGTGAAGTGC-3’ 
Silenced N2 5’-GCCTTTATGTTCCAAGGCAAT-3’ 
Silenced N3 5’-CCTCGGATACTGTCTTCTCTT-3’ 
 
 
HEK293FT cells were transfected using the calcium phosphate method for lentiviral 
packaging. Plasmids pLKO.1-Puro-CMV-tGFP against DISC1 and non-target shRNA, 
used as control, were co-transfected with the helper constructs pCMV-VSVG and 
pCMV-ΔR8.9 into 293FT packaging cells. Helper plasmids were a kind gift from 
Carsten Korth, University of Düsseldorf, Germany.  Calcium phosphate co-
transfection was performed as follows:  
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- 24h before the transfection, 293FT cells in low passage were plated at 
10
6
cells/10 cm plate with 500μg/mL of G418. 
 
- The cell medium of the 293FT cells was replaced by a fresh one without 
antibiotic 1 hour before the transfection.  
 
- Solutions for transfection were prepared as follows:   
 
Tube A: 750 µL of HBBS solution (50 mM HEPES, 10 mM KCl, 12 mM 
glucose, 280 mM NaCl, 1.5mM Na2HPO4, pH 7.05) 
 
Tube B:  
350µL of calcium phosphate 0.5M 
15 µg of shRNA (silencing or control) 
15 µg of VsVg plasmid  
15 µg ofΔR8.9 plasmid  
Water up to 750 µl 
 
- The contents of tube B were added over the tube A dropwise while in the A 
tube bubbles were produced with an automatic pipette. The mixture was 
bubbled during 30 seconds more and then it was incubated for 20 minutes at 
room temperature. Subsequently, 750μL of the mixture were pipetted to each 
293FT plate in a dropwise manner.  
 
- After 16 hours the medium was replaced, this time by medium containing 
G418 (50μg/mL).  
 
- The supernatant containing the viruses was collected at 36 and 48 hours 
after transfection and filtered with 0.45μm filters (Invitrogen). Viruses were 
finally concentrated by ultracentrifugation of the supernatant over a 20% 
sucrose cushion at 35000rpm for 75 minutes in a 50.2Ti rotor (Beckman) at 
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4ºC. The supernatant was discarded and the viral pellet was resuspended in 
cold Neurobasal-supplemented Medium (Gibco, Life Technologies). 
 
 
2.3. Neuronal infection and DISC1 knock-down 
 
The viral solution was added to the culture medium of murine neurons at 7 DIV. This 
virus-containing medium was discarded after 24h and cells were maintained for 72h 
in Neurobasal medium supplemented as previously described. Viral efficiency was 
tested analyzing the presence of green fluorescence in the cultured cells by means of 
a fluorescence microscope (Olympus IX70). 
 
 
3. PROTEIN EXTRACTION 
 
SH-SY5Y and neuron cell plates were washed twice with cold PBS and solubilized in 
lysis buffer  (20mM HEPES pH 7.4, 2mM EGTA pH7.4, 1mM orthovanadate, 1% 
Triton-X-100, 10% glycerol, 2µM leupeptin, 400 µM PMSF,  50mM β-
glycerolphosphate, 1mM DTT, 100µg/mL aprotinin). Cells were scrapped during 10 
minutes on ice and incubated for 30 minutes with periodic vortexing every 5 minutes. 
Cell extracts were centrifuged 20 minutes at 14000g, 4ºC. The supernatant was 
collected and the pellet was discarded. Protein supernatant concentration was 
determined using the Bradford protein assay kit (Bio-Rad).  
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4. PROTEOMIC STUDY IN DISC1 SILENCED 
NEURONS 
 
4.1. Sample preparation 
 
Proteins in cell homogenates obtained from DISC1 silenced and control murine 
neurons were precipitated with 60% trichloroacetic acid (TCA) in acetone as follows: 
 
Frozen extracts were mixed with 60% TCA-acetone to a final concentration of 20% 
and shook gently until the samples were completely thawed. Samples were then 
incubated during 45 minutes on ice. The samples were subsequently centrifuged 
during 2 minutes at 10000g and 4ºC. The supernatant was discarded and the pellet 
was resuspended in 500µL of cold acetone and sonicated with 3-4 pulses in the 
ultrasonic cell disruptor Sonifier 150 (Branson) until it was broken up. To maintain the 
samples cold they were kept on ice. The samples were then centrifuged at 10000g 
1minute at 4ºC. The supernatant was discarded and two more washes with 500µL of 
cold acetone were carried out under the same conditions. Finally, the supernatant 
was discarded and the pellet was left to air dry. The dry pellet was resuspended in a 
minimum volume of 2D sample buffer (5M urea, 2M thiourea, 2mM tributyl-phosphine, 
65mM DTT, 65mM CHAPS, 0.15M non-detergent sulfobetaine (NDSB-256), 1mM 
sodium vanadate, 0.1mM sodium fluoride, and 1mM benzamidine).  
 
Protein quantification was performed with the Coomassie Plus protein reagent 
(Thermo Scientific), compatible with the 2D buffer used. Quantitation was carried out 
as follows:  
 
To prepare the standard calibration curve six different points were constructed in 
duplicate with serial dilutions of a BSA solution (1mg/mL) in 2-DE sample buffer. The 
first point was obtained by mixing 20µL of 2-DE sample buffer and 20µL of BSA 
solution (2mg/mL). The six points of the standard curve had the following 
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concentrations of BSA: 1000, 500, 250, 125, 62.5 and 31.25µg/mL. 600µL of 
Coomassie reagent were added to each tube. Absorbance was measured at 595nm 
in a Genesis 20of spectrophotometer (Thermo Scientific). Each standard was 
measured in duplicate; in case that both measurements diverged more than 10%, the 
sample was prepared and measured again. With all the measurements, a standard 
calibration curve was constructed with the Excel program (Microsoft). The blank was 
prepared by mixing 20µl of 2-DE sample buffer and 600μL of Coomassie reagent. 
600µL of Coomassie reagent were added to 2µL of each sample to determine their 
concentrations. The mixture was let stand at room temperature for 5 minutes before 
quantitation. 
 
 
4.2. Bidimensional gel electrophoresis (2-DGE) 
 
4.2.1. Rehydration of IPG strips 
 
4 replicas of each neuronal sample (DISC1 knock-down and control) were subjected 
to proteomic study. For this reason, 8 strips with a pH4-7 gradient and 24cm (GE 
Healthcare) were selected to perform this part of the experiment.  
 
For each gel, 600μg of each sample were mixed with 1,6% (v/v) of ampholytes (pH 4-
7) (Serva Electrophoresis GmbH). 2-DEG buffer was added to a final volume of 
500μl. The mixture was vortexed and centrifuged during 5 minutes at 10000g to 
eliminate any impurities present. Samples were pipetted in a lane of the rehydration 
tray (Immobiline Dry Strip Reswelling Tray, GE Healthcare) in contact with the gel 
fragment on the strip. Then, strips were covered with mineral oil Dry Strip Cover Fluid 
(GE Healthcare) to avoid evaporation of the samples and were left in 500μl of 
rehydration buffer overnight. The following day, the strips were blotted with a filter 
paper to eliminate the oil and placed in a Multiphor II electrophoresis unit (GE 
Healthcare) with the gel face up to run the first dimension separation.  
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4.2.2. First dimension: Isoelectrofocusing 
 
Pieces of 2cm of electrode paper were humidified in milliQ water and placed in each 
end of the strips to absorb remaining salts. The IPG strips were covered with mineral 
oil. Electrodes were set in place and the first dimension was carried out at 17ºC 
according to the program showed in table 2: 
 
Table 2: Selected conditions for the isoelectro focusing. 
 
PHASE VOLTAGE (V) AMPERAGE (mA) WATTAGE (W) TIME 
1 300 3 50 1 minute 
2 300 10 50 2 hours 
3 3500 10 50 3 hours 
4 3500 10 50 21 hours 
 
 
4.2.3. Equilibration  
 
Once the first dimension was finished, proteins in the strips were equilibrated, 
reduced and alkylated: Strips were incubated during 15 minutes at room temperature 
and in agitation with equilibration buffer (50mM Tris pH 8.8, 4M rea, 30% (v/v) 
glycerol,  2% (w/v) SDS, traces of bromophenol blue and water) supplemented with 
2% (w/v) DTT. Then, strips were washed with milliQ water and incubated 15 minutes 
at room temperature and in agitation in alkylating buffer containing 2.5% (w/v) 
iodoacetamide. Alkylation after reduction prevents the regeneration of disulfide 
bonds. Strips were washed once again with milliQ water.  
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4.2.4. Second dimension: SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
The second dimension was performed on 10% large polyacrylamide gels of 25x20cm. 
Gels were prepared the previous day and allowed to polymerize during 5 hours at RT 
in a DALT six Gel Caster system (GE Healthcare). They were kept at 4ºC overnight in 
storage solution (0.1% SDS, 375mM Tris pH 8.8) to avoid dehydration. This system 
allows preparing 6 gels at the same time getting higher reproducibility. Bis-acrylamide 
(30% w/v) was used in the presence of N,N,N’,N’-tetrametil-etilendiamine (TEMED) 
and ammonium persulfate (APS). The volumes of the reagents used to prepare the 
gels are shown in Table 3: 
 
Table 3: Volumes of the reagents used to prepare the polyacrylamide gels. 
 
REAGENTS 6 gels 10% 
Bis-Acrylamide 150mL 
Tris pH8.8, 1.5M 113mL 
SDS 10% 4.50L 
MilliQ water 147,23 
APS (10%) 4.50mL 
TEMED (10%) 0.77mL 
Rhinohide 30mL 
 
Equilibrated strips were immersed in an agarose solution 0.5% (w/v) previously 
placed above the polyacrylamide gels avoiding bubbles between the strip and the gel. 
 
The second dimension was carried out in the EttanDALT six system apparatus (GE 
Healthcare), with electrophoresis buffer (0.25 M Tris BASE, 1.92 M Glycine, 1% (w/v) 
SDS) at 10ºC with the program detailed in table 4:  
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Table 4: Selected conditions for the second dimension. 
 
PHASE VOLTAGE (V) AMPERAGE (mA) WATTAGE (W) TIME 
1 80 20/gel 2/gel 1 hour 
2 500 40/gel 17/gel (100 
maximum) 
6 hours 
 
 
4.2.5. Staining and scanning. 
 
Gels were stained with Sypro Ruby fluorescent dye (Lonza) according to the following 
protocol:  
 
- Once the second dimension of the 2D electrophoresis was finished, the gels 
were removed from the glass plates and washed in agitation with 300mL of 
milliQ water during 10 minutes.  
 
- Gels were then washed for 1 hour in agitation with 300mL of 10%methanol / 
7% acetic acid. 
 
- Gels were stained overnight with Sypro Ruby solution in agitation, protected 
from the light in boxes covered with a black plastic bag. 
 
- Gels were washed again with 300mL of 10% methanol/7% acetic acid during 
1 hour in agitation. 
 
- Gels were washed with 300mL of milliQ water during 10 minutes in agitation.  
Finally the gels were scanned in a Typhoon 9410 scanner (GE healthcare), using the 
Typhoon Scanner Control, version 5.0 program and the following parameters: 
resolution 200μm, blue laser with an excitation wavelength of 488nm, filter 610 nm, 
medium sensitivity, and photomultiplier 600V. Scanned images were converted to the 
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high resolution TIF format and imported to the image analysis software Ludesi 
REDFIN 3 Solo software (Ludesi, Malmö, Sweden). Gels were kept in plastic bags in 
vacuum at 4ºC until spot excision. 
  
4.2.6. Differential image analysis  
 
Ludesi REDFIN 3 Solo software allows detection of every protein spot in different gel 
replicas and to assign to them a volume (see below) in each image. Four different 
gels from each sample (control and silenced) were processed. The steps followed to 
perform this analysis were:  
 
4.2.6.1. Image alignment and composite image 
 
The manipulation of the gels can cause distortions which would result in light 
differences between the replicas. To compare gels of different conditions, the first 
step consists in matching every spot corresponding to a unique protein in all of the gel 
images. Coincident points in the images will be used as reference to match all the 
spot positions on the different gels. Images can be "warped" by the software to reach 
a complete overlap of each spot position in all the gels. Ludesi Redfin Solo uses a 
semi-automatic approach. A human operator indicates matching points in the images 
that are subsequently improved by computer algorithms. One gel is selected as the 
reference gel, and all other gels are aligned with it. A composite image is created by 
merging all the gel images into a single representative image of all the gels. 
 
4.2.6.2. Spot detection  
 
Spot detection involves algorithms to find all real protein spots in the images, avoiding 
false signals that do not correspond with any protein. The detected spot positions 
should be checked for both false positives and undetected spots.  
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4.2.6.3. Segmentation  
 
This step limits the borders of each single spot in the image. With the Redfin SOLO 
software the spots borders are determined in the composite image and then they are 
applied to the individual images. Thus, the spot limits must be checked individually 
and adjusted if necessary to every image.  
 
4.2.6.4. Quantification 
 
This process consists in the measurement of the staining intensity contained within 
each spot that corresponds to the relative protein volume. The surrounding 
background level is deducted from the staining level, and this corrected intensity 
reflects the protein volume.  
 
4.2.6.5. Normalization 
 
This process makes the spot volumes comparable between gel images taking into 
account possible differences in staining, scanning or initial sample quantity, among 
others. For normalization Ludesi software works with gel pairs and a normalization 
factor is established for each gel:  
 
- All coincidences between the two gels matched are extracted and the top 
50% coincidences, based on the spot volumes, are kept.  
 
- A spot volume ratio is calculated between each spot pair. A pair-wise 
normalization factor between the gels is computed by taking the median of 
these ratios.  
 
- Each gel normalization factor is computed by optimizing an over-determined 
equation system, resulting from the pair-wise normalization factors. 
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- Finally, the spot volumes in each gel are multiplied with the corresponding gel 
normalization factor.  
 
 
4.2.7. Statistical analysis  
 
To determine statistically significant differences between groups of samples the One-
way ANOVA ("Analysis Of Variance") method was employed. For each spot, ANOVA 
p-value was calculated using the quantified and normalized volumes for the matched 
spot in each of the images. ANOVA is a parametric method that assumes 
independency and normal distribution of all values. For comparisons between two 
groups, the ANOVA becomes equivalent to the two-tailed Student's t-test. In this 
study differential expression of proteins was defined on the basis of >2-fold change 
between group averages and p<0.05. 
 
 
4.3. Mass spectrometric analysis 
 
Protein identification was achieved by means of mass spectrometric analysis. The 
spots of interest were manually excised from the gels with a pipette tip and manually 
in-gel digested with trypsin following the protocol previously described by Shevchenko 
[161].  
 
Excised spots were washed three times with 100μL of ammonium bicarbonate 50mM 
in 50% methanol (HPLC grade, Scharlau) and reduced with 10mM DTT (Serva 
Electrophoresis GmbH). Immediately protein spots were again washed three times 
with ammonium bicarbonate, dried by centrifugal evaporation (SpeedVac, Thermo 
Scientific) and alkylated with iodoacetamide 55mM (Sigma-Aldrich). Three washes 
with ammonium bicarbonate were performed and gel fragments were dehydrated with 
acetonitrile and dried in the Speed Vac. Porcine modified trypsin (Promega) was 
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added to a final concentration of 20ng/mL in ammonium bicarbonate 20mM. Trypsin 
digestion was carried out overnight at 37ºC. 
 
Peptide extraction from the gel fragments was performed with 40μL of 60% 
acetonitrile in 0.5% formic acid three times. Extracted peptides were dried in the 
Speed Vac and stored at -20ºC.  
 
Spots were identified in a 4800 MALDITOF/TOF mass spectrometer (ABSciex, 
Framinghan, MA, USA) at the Proteomics Lab of the Fundación IDICHUS (Hospital 
Clínico Universitario de Santiago de Compostela). Peptides were dissolved in 4mL of 
formic acid 0.5%. 0.5μL of peptide and matrix solution (3mg alpha-cyano-4-
hydroxycinnamic acid (α-CHCA) dissolved on 1mL of acetonitrile 50%, trifluoroacetic 
acid 0.1%) and were deposited using the thin layer method onto a 384 Opti-TOF 
MALDI plate (Applied Biosystems). MS spectra were obtained in reflectron positive 
ion mode with a Nd:YAG, 355nm wavelength laser, averaging 1000 laser shots and 
using at least three trypsin autolysis peaks for internal calibration. MS/MS spectra 
were performed by selecting the precursorions with a relative resolution of 300 
(FWHM) and metastable suppression. For automated analysis of mass data the 4000 
SeriesExplorer Software V3.5. MS and MS/MS spectra data were combined through 
the GPS Explorer Software v3.6. Database search was performed with the Mascot 
v2.1 search tool (Matrix Science, London, UK) screening SwissProt (release 56.0).  
 
Searching was restricted to human taxonomy, setting carbamidomethyl cysteine as 
fixed modification and oxidized methionine as potential variable modification. 
Precursor mass tolerance and the MS/MS tolerance were set at 30ppm and 0.35 Da, 
respectively, allowing 1 missed tryptic cleavage site. All spectra and database results 
were manually inspected in detail using the above software. 
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5. INGENUITY PATHWAY 
 
Ingenuity Pathway Analysis software (Ingenuity Systems, CA) was used to investigate 
potential interactions between all the identified proteins. Interactive pathways were 
generated to observe direct and indirect relations among the differentially regulated 
proteins. The parameters were selected as follows: 
 
- Ingenuity Knowledge Data Base: Genes only 
 
- Direct and indirect relationships 
 
- Molecules per network: 140 
 
- Network per analysis: 25 
- Species: All 
 
- Tissues and lines: All 
 
- Data sources: All 
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6. WESTERN BLOTTING 
 
Mono- (1D) and bi-dimensional (2D) western blot techniques were used for the study 
of some of the proteins differentially regulated in the proteomic study of control and 
DISC1 silenced-cells. Furthermore, the identification of the pathway by which DISC1 
regulates VGF expression in SH-SY5Y and neurons was achieved by mono-
dimensional Western blot. 
 
 
6.1. Monodimensional (1D) SDS-PAGE 
 
50µg of the neuronal or SH-SY5Y protein extracts were mixed with Laemmli sample 
buffer (BioRad) with 5% β-mercaptoethanol. Samples were boiled for 10 minutes at 
100ºC and loaded to 10% SDS-PAGE gels. The reagents and their volumes for gel 
preparation are shown in Table 5: 
 
Table 5: Volume of reagents used to prepare polyacrylamide gels. 
 
REAGENTS RESOLVING. 2 GELS 10% STACKING. 2 GELS 4% 
H2O 4 mL 2.2mL 
30% Acrilamide mix 
(Bio-Rad) 
3.3 mL 670 µL 
Tris-HCl 2.5mL (1.5M pH8.8) 1mL (0.5M pH6.8) 
10% SDS 100µL 40µL 
10% APS 100µL 40µL 
TEMED 4µL 4 µL 
 
 
Molecular weight Precision Plus Protein Standards (Bio-Rad) were included. Samples 
were subjected to electrophoresis in Mini-PROTEAN 3 Cell electrophoresis system 
(Bio-Rad) with 1D electrophoresis buffer (0.25M Tris Base, 1.92M glycine, 1% w/v 
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SDS). The electrophoretic conditions were 200V, 1h. In some cases, 4-12% gradient 
NuPAGE polyacrylamide gels (Invitrogen) and commercial electrophoresis buffer 
MOPS (Invitrogen) were used. Samples, containing 30 µg of protein, were dissolved 
in Laemmli buffer and were loaded in each line of the gel. Molecular weight Precision 
Plus Protein Standards (Bio-Rad) were included. The electrophoresis system used 
was the XCell Sure Lock system (Invitrogen) with an initial voltage of 80V during 5 
min, increased to 120V over 1hour 30 min. 
 
 
6.2. Bidimensional (2D) SDS-PAGE 
 
This technique was selected for the validation of some proteins found to be 
differentially regulated in DISC1 knock-down and control neurons in the proteomic 
study. The protocol used for 2D-electrophoresis is the same that was used for the 
proteomic studies with the following differences:  
 
- 7cm pH 4-7 IPG strips were used and 50 µg of protein were loaded in each 
gel. 
 
- 8x8cm Commercial gels NuPAGE (Invitrogen) and commercial 
electrophoresis buffer MOPS (Invitrogen) were used.  
 
- Electrophoresis was performed in the XCell Sure Lock system (Invitrogen). 
 
- Molecular weight Precision Plus Protein Standards (Bio-Rad) were added.  
 
The selected program for the first dimension is showed in the Table 6: 
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Table 6: Conditions selected for the first dimension of the bidimensional SDS-PAGE. 
 
PHASE VOLTAGE 
(V) 
AMPERAGE 
(mA) 
WATTAGE 
(W) 
TIME 
1 200 3 5 1 minute 
2 3500 10 5 1hour 30 minutes 
3 3500 10 5 1 hour 40 minutes 
 
In this case the second dimension was performed with constant voltage of 120V 
during 1h and 45 min.   
 
 
6.3. Transfer and immunodetection 
 
Proteins in 1D and 2D gels were transferred to polyvinylidene fluoride (PVDF) 
membranes (Millipore, Bedford, MA). Transfer was performed in a Trans-Blot SD 
semi-dry transfer cell (Bio-Rad) with transfer buffer (48mM Tris Base, 39mM glycine, 
1.3mM SDS, pH 9.2 and 20% methanol v/v) according to the following conditions: 
0.8mA/cm
2
, 90 minutes.  
 
PVDF membranes were blocked in 5% Skim Milk Powder (Sigma-Aldrich) in PBS-
0.1% Tween 20 (Sigma-Aldrich) solution overnight at 4ºC. The following day, 4 
washes of 5 minutes in PBS - 0.1%Tween-20 were performed and membranes were 
incubated 1 hour at room temperature with the primary antibody diluted in 1 or 
5%BSA in PBS - 0.1%Tween-20. Antibody dilutions are listed in Table 7. Four 
washes of 5 minutes were repeated and membranes were incubated with the 
corresponding peroxidase-conjugated secondary antibody (Table 8) diluted in 1 or 5% 
BSA in PBS-0.1% Tween 20 during 1 hour.  
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Membranes were incubated with the chemiluminiscent substrate Luminata Forte 
Westerm HRP substrate (Merck Millipore). The development of the membranes was 
performed using a BioMax Cassette (Kodak) and Amersham Hyperfilm ECL (GE 
Healthcare). 
 
Table 7: Primary antibodies. 
 
ANTIBODY COMPANY DILUTION %BSA 
14F2 Carsten Korth  Lab, 
Duesseldorf, Germany 
1:1000 5% 
14-3-3ε Cell Signaling 1:1000 5% 
AKT Cell Signaling 1:1000 5% 
BDNF Santa Cruz 1:200 1% 
CREB Cell Signaling 1:500 1% 
CRMP2 Cell Signaling 1:1000 5% 
D27 MERCK 1:200 1% 
GAPDH Sigma-Aldrich 1:10000 5% 
Grb2 MBL 1:200 1% 
GSK3beta Cell Signaling 1:1000 5% 
LIS-1 O. Reiner, Weizman 
Institute, Rehovot, Israel 
1:2000 5% 
P44/42 MAPK (Erk1/2) Cell Signaling 1:1000 5% 
Phospho-AKT (Ser473) Cell Signaling 1:1000 5% 
Phospho-CREB (Ser129) Signalway Antibody 1:1000 1% 
Phospho-CREB (Ser133) Cell Signaling 1:500 1% 
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Phospho-CRMP-2 (Thr 514) Cell Signaling 1:1000 5% 
Phspho-GSK3beta (Ser9) Cell Signaling 1:500 1% 
Phospho-GSK3beta (Tyr216) Invitrogen 1:1000 5% 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr 202/Tyr 204) 
Cell Signaling 1:1000 5% 
Phospho-PI3K p85 
(Tyr458)/p55 (Tyr 199) 
Cell Signaling 1:1000 1% 
Phospho-stathmin (Ser 38) Cell Signaling 1:1000 5% 
PI3K p85 Cell Signaling 1:1000 1% 
Stathmin Cell Signaling 1:1000 5% 
Tubulin Sigma-Aldrich 1:10000 5% 
VGF Santa Cruz 1:200 1% 
 
 
Table 8: Secondary antibodies*. 
 
ANTIBODY COMPANY DILUTION 
Polyclonal sheep anti-mouse GE (Amersham) 1:5000 
Polyclonal goat anti-rabbit DAKO 1:2000 
Polyclonal donkey anti-goat Santa Cruz 1:2000 
 
*Concentration of the BSA solution in which the secondary antibody was diluted was 
selected in accordance to that used for the primary antibody dilution. 
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6.4. Densitometric analysis 
 
Densitometric analysis was performed using Image J software 
(http://imagej.nih.gov/ij/). 
 
 
6.5. Statistical analysis 
 
Results are expressed as mean ± SD. Student’s t test was used for statistical 
comparisons between groups with a minimum of 3 independent experiments as 
indicated for each case in figure legends. 
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RESULTS 
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 BLOCK I:   
 
1. DISC1 REGULATES VGF LEVELS IN  
SH-SY5Y CELLS 
 
The background of the results of this section is a previous study in which SH-SY5Y 
cells with DISC1 knock-down were subjected to a proteomic study. SH-SY5Y is a 
human thrice-cloned cell sub-line, derived from the SK-N-SH cell line obtained from a 
bone marrow biopsy of a female neuroblastoma patient. This cell type is often used 
as an in vitro model of neuronal function and differentiation due to the fact that it 
shows neuron-like characteristics such as dopamine-beta-hydroxylase activity and 
ability to convert glutamate to GABA. Furthermore, these cells allowed the generation 
of a stable cell line with DISC1 silenced. 
 
The expression of endogenous DISC1 was knocked-down in SH-SY5Y cells by 
means of infection with commercial lentiviral particles carrying short-hairpin RNA 
(shRNA) as previously published [123]. Cell extracts were subjected to proteomic 
analysis. With this approach, proteins whose expression was altered in DISC1 
silenced cells were identified by mass spectrometry. As mentioned, among all the 
proteins showing significant changes in their expression, 14 different spots were 
found to correspond to VGF displaying a downregulation with a fold change between 
2 and 11.5.  
 
 
1.1. Signalling pathway connecting DISC1 and VGF in 
SH-SY5Y cells 
 
Taking into account these results, and in an attempt to elucidate the pathway or 
pathways by which DISC1 modulates Vgf expression, different signalling routes were 
studied in this DISC1-silenced model taking in consideration what is known about 
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VGF regulation. To perform the knock-down, SH-SY5Y cells were infected with 
lentivirus carrying a shRNA against human DISC1 sequence as previously described 
[123]. The effectiveness of the silencing was confirmed by western blot with an 
antibody recognising human DISC1 (DISC1-14F2) (Figure 5A, B). In agreement with 
previous results, a decrease in VGF levels was observed by western blot in those 
cells in which DISC1 expression had been knocked-down compared to cells infected 
with control virus (Figure 5). 
 
 
 
Figure 5: DISC1 knock-down in SH-SY5Y results in decreased levels of VGF. A) Western blots 
showing the effectiveness of lentivirus-mediated DISC1 silencing (DISC1-14F2 antibody) and the 
downregulation of VGF in SH-SY5Y cells. B) Densitometric analysis of the results obtained in panel A for 
DISC1 and VGF. Figures are representative of n=3 independent experiments. Error bars represent SD. 
Total protein was normalized to GAPDH. Statistical analysis was carried out by the (paired) two-tailed 
Student’s t-test **p<0.01, ***p<0.001 
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Brain Derived Neurotrophic Factor (BDNF) acts in the nervous system and has been 
shown to induce Vgf expression among other neurotrophins [130]. Western blotting 
did not reveal any change in BDNF level when DISC1 was silenced in SH-SY5Y cells 
(Figure 6A) suggesting that the regulation of Vgf expression by DISC1 is not 
mediated by BDNF. 
 
Vgf gene presents a binding site for cAMP-response element binding protein (CREB) 
within its promoter. This sequence is critical for neurotrophin-induced Vgf  
transcription in primary neurons [162]. For this reason, the status of activation of 
CREB was assessed in control and DISC1 knock-down SH-SY5Y cells.  The level of 
total CREB remained unchanged in both conditions. However, the level of the active 
form of CREB, indicated by its phosphorylation at serine 133 (Ser133) was found to 
suffer a decrease in DISC1 silenced cells when compared to control ones (Figure 6A, 
B). This decrease in the activation of CREB explains the drop in the levels of VGF 
when DISC1 is reduced in SH-SY5Y cells and strongly suggests that this is a link 
between these two proteins. Protein kinase B (AKT) regulates CREB activity by 
phosphorylating it at Ser133. Since CREB phosphorylation was found decreased in 
silenced SH-SY5Y cells, levels of active AKT (phosphorylated at Ser473) were also 
assessed by western blot. Phosphorylation status of AKT was found to be reduced in 
those cells in which DISC1 had been knocked-down (Figure 6A, B), indicating that the 
regulation of VGF by DISC1 involves the AKT/CREB signalling pathway. 
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Figure 6: DISC1 knock-down in SH-SY5Y results in lower activation of the AKT/CREB cascade. A) 
Western blots showing the levels of BDNF, CREB and AKT total protein and CREB and AKT 
phosphorylated forms in control (Control shRNA) and DISC1-silenced (DISC1 shRNA) SH-SY5Y cells. B) 
Densitometric analysis of the results obtained for phospho-CREB (Ser133) and phospho-AKT (Ser473) 
normalized to total protein. Figures are representative of n=3 independent experiments. Error bars 
represent SD. Every protein was normalized to tubulin. Statistical analysis was carried out by the (paired) 
two-tailed Student’s t-test. *p<0.05, **p<0.01 
 
Taking this into account, levels of growth factor receptor-bound protein 2 (Grb2) were 
assessed by western blot in these cellular extracts. Grb2 is a well-known DISC1 
binding partner and it is upstream AKT. Remarkably, this protein was observed to be 
differentially regulated in control and DISC1-silenced SH-SY5Y cells, finding Grb2 
down-regulated in cells in which DISC1 had been knocked-down (Figure 7).  
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Figure 7: Grb2 expression in SH-SY5Y cells. A) Western blot showing Grb2 levels in SH-SY5Y cells 
transfected both with Control-shRNA and DISC1-shRNA. B) Densitometric analysis of data presented in A 
(n=4 independent experiments). Total protein was normalized to GAPDH. Error bars represent SD. 
Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. ***p<0.001 
 
 
1.2. DISC1 over-expression 
 
To further confirm that the changes in the quantity of VGF are due to the lack of 
DISC1, the levels of this neuropeptide were tested by western blot in SH-SY5Y cells 
over-expressing DISC1. These cells contain the full-length human DISC1 sequence 
that can be induced by doxycycline. As shown in figure 8, overexpression of DISC1 
results in a significant increase of VGF in these cells indicating that variations in the 
quantity of DISC1 result in changes of VGF levels in the same direction. 
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Figure 8: Induction of DISC1 produces an increase in VGF expression. A) Western blots showing 
DISC1 and VGF levels after DISC1 induction (Tet-on DISC1) B) Densitometric analysis of data presented 
in A obtained for VGF (n=3 independent experiments). Total protein was normalized to GAPDH. Error bars 
represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. **p<0.01 
 
In summary, the experiments preformed in SH-SY5Y cells indicate that DISC1 
regulates expression of the neuropeptide precursor VGF in this neuron-like cell line. 
Additionally, the results obtained show that this regulation takes place through the 
AKT/CREB cascade in a BDNF-independent manner.  
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2. DISC1 REGULATES VGF LEVELS IN  
PRIMARY NEURONS 
 
Although all the changes in VGF levels due to manipulation of DISC1 expression 
were confirmed in a number of independent experiments, some reproducibility 
problems appeared when the batch of the fetal bovine serum added to the SH-SY5Y 
cells was changed. As has been noted, SH-SY5Y is a cancerous cell line and even 
though it presents neuron-like characteristics, its oncologic origin may cause 
alterations in the normal physiology of the cells. In fact, in our hands, these cells 
proved to be highly influenced by the growth factors in the medium. The lack of 
reproducibility was avoided with the use of primary cortex and hippocampus mouse 
neurons. Additionally, this model is more representative of what happens in vivo. 
Taking this into account, the relationship between DISC1 and VGF was assessed in 
primary mouse neurons.    
 
 
2.1. Silencing DISC1 in primary neuronal cell culture 
 
Neurons were extracted from cortex and hippocampus of mice embryos, two areas 
with high expression of DISC1  during embryonic stage and adulthood. Knock-down 
of DISC1 was achieved by infecting the neurons with lentiviral particles carrying three 
different shRNAs against mouse DISC1 sequence. The effectiveness of the 
silencencing was confirmed by western blot using the D27 antibody recognising 
mouse DISC1 (Figure 9).  
 
Knock-down of DISC1 with the three shRNA led to a sharp decrease in the levels of 
VGF when compared to neurons infected with lentiviruses carrying scramble shRNA 
(Figure 9). The “silenced N1” construct, named “DISC1 RNAi #1”, was chosen for the 
rest of the experiments, due to the fact that this construct has been previously used 
by other researchers [61], which should allow comparisons. This result agrees to that 
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obtained in SH-SY5Y cells reinforcing the idea that DISC1 is crucial for VGF levels 
maintenance also in neurons.  
 
 
 
Figure 9: DISC1 knock-down in neurons results in decreased levels of VGF. A) Western blot showing 
the effectiveness of lentivirus-mediated DISC1 silencing and downregulation of VGF with the three 
interference RNAs in mouse primary neurons. B) DISC1 knock-down in mouse primary neurons and VGF 
downregulation with the DISC1 RNAi#1 construct. C) Densitometric analysis of the results obtained in 
panel B. Figures are representative of n=3 independent experiments. Error bars represent SD. Total 
protein was normalized to tubulin. Statistical analysis was carried out by the (paired) two-tailed Student’s t-
test. **p<0.01, ****p<0.0001 
 
 
2.2. Signalling pathway connecting DISC1 and VGF in 
neurons 
 
The next step was to determine if the pathway responsible for the regulation of VGF 
involving DISC1 in neurons is the same to that acting in SH-SY5Y. Levels of BDNF, 
CREB, phospho-CREB (Ser133), AKT and phospho-AKT (Ser473) were measured by 
western blot. As in the previous model, the silencing of DISC1 had no effect on the 
levels of BDNF in murine cultured neurons (Figure 10A). However, once again, active 
phosphorylated CREB form experienced a decrease of 60% approximately agreeing 
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with the drop in VGF levels, while the total protein levels remained unchanged. In this 
model there was also found a significant decrease in the levels of active AKT 
confirming the results obtained in SH-SY5Y (Figure 10A, B).  
 
Besides AKT, P44/42 Mitogen-activated protein kinase (ERK1/2) also participates in 
the control of the activity of CREB by phosphorylation of the protein at Ser133 leading 
to its subsequent activation. Remarkably, this kinase has been previously related with 
VGF and DISC1. In order to assess the effect of DISC1 knock-down in the activity of 
ERK, the levels of phosphorylated (active) form of ERK were measured. Surprisingly, 
as shown in figure 10, the drop in DISC1 levels did not produce any change in 
phospho-ERK (Thr202/Tyr204) level. This finding suggests that the lack of DISC1 
does not affect to ERK activity.  
 
Phosphoinositide-3-kinase (PI3K) activation is essential for the phosphorylation of 
AKT at Ser473. For this reason, the levels of total PI3K and its activating 
phosphorylation at tyrosin 458 (Tyr458) were also assessed by western blot in control 
and DISC1 knock-down neurons. As shown in figure 10, the silencing of DISC1 
caused a 60% reduction of the levels of phosphorylated PI3K while the total protein 
remained unchanged indicating a clear drop in the activation status of the kinase. 
This result agrees with the previously observed reduction of the phosphorylation of 
AKT at Ser473 in these neurons.  
 
These data demonstrate that the silencing of DISC1 produces a significant decrease 
of the activation of the PI3K/AKT/CREB signaling cascade that eventually leads to a 
fall of the levels of the neuropeptide VGF.   
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Figure 10: DISC1 knock-down in neurons results in reduced activation of the CREB/AKT cascade. 
A) Western blots showing the levels of BDNF, CREB, AKT, ERK and PI3K total protein as well as their 
phosphorylated forms in control and DISC1-silenced neurons. B) Densitometric analysis of the results 
obtained for BDNF, phospho-CREB (Ser133), phospho-AKT (Ser473), phospho-ERK (Thr202/Tyr204) and 
phospho-PI3K p85 (Tyr458) normalized to the total protein. All figures are representative of a minimum of 
n=3 independent experiments. Error bars represent SD. Phosphorylated and total protein was normalized 
to GAPDH. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. *p<0.05, **p<0.01, 
n.s. non-significant 
 
The role of PI3K in the regulation of the levels of VGF was further confirmed by in 
vitro inhibition of the kinase in murine primary cultured neurons. For this purpouse the 
cells were treated for 1 hour with the PI3K selective inhibitor LY294002. As shown in 
figure 11 a decrease in the phosphorylation of AKT at Ser473 was observed 
confirming the effectiveness of the inhibition. Furthermore, a significant decrease in 
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VGF expression was also found in cells treated with LY294002 compared to those 
treated with the vehicle (DMSO) (Fig. 11A, B). This result confirms that PI3K activity 
is involved in the regulation of VGF expression by DISC1. 
 
 
 
Figure 11: Effect of PI3K and GSK3β on VGF expression.  A) Western blot showing VGF levels in 
mouse neuron primary cells treated with LY294002 or CHIR-99021 to inhibit PI3K and GSK3β, 
respectively. The effectiveness of the treatments was assessed measuring phospho-AKT (Ser473) and 
phospho-GSK3β (Tyr216). B) Densitometric analysis of VGF on LY294002 treated cells (n=5 independent 
experiments). C) Densitometric analysis of VGF on CHIR-99021 treated cells (n=5 independent 
experiments). Total protein was normalized to GAPDH. Error bars represent SD. Statistical analysis was 
carried out by the (paired) two-tailed Student’s t-test. ***p<0.001, n.s. non-significant 
 
 
As has been noted, a possible link between DISC1 and the PI3K/AKT route is Grb2. 
This protein participates in neurotrophin signalling by direct binding to Tyrosin kinase 
(Trk) receptors, promoting the activation of downstream pathways, some of which 
include PI3K. Knock-down of DISC1 in SH-SY5Y cells led to a decrease in the levels 
of Grb2; for this reason, the levels of Grb2 were assessed by western blot in cultured 
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neurons. Remarkably, in contrast to the previous model, the levels of Grb2 remained 
unchanged when DISC1 was knocked-down in neurons (Figure 12): 
 
 
 
Figure 12: Grb2 expression in mouse primary neurons.  A) Western blot showing Grb2 levels in 
neurons transfected both with Control-RNAi and DISC1-RNAi#1. B) Densitometric analysis of data 
presented in A (n=4 independent experiments). Total protein was normalized to GAPDH. Error bars 
represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. n.s. non-
significant 
 
The data obtained strongly suggest that the drop of VGF levels observed in DISC1 
knock-down cells is caused by the downregulation of the PI3K/AKT/CREB signalling 
route. However, the possibility of different points of regulation of such pathway by 
DISC1 cannot be excluded.  
 
In this regard, glycogen synthase kinase-3 beta (GSK3β) was also thought to be 
possibly involved in the regulation of VGF expression by DISC1. In fact, this kinase is 
inhibited by DISC1 by direct binding and its activity was found to be regulated by 
VGF. Furthermore, active AKT is capable of phosphorylate GSK3β at serine 9 (Ser9), 
which in turn results in its inactivation. Additionally, GSK3β has been found to 
phosphorylate CREB taking part in the control of CREB activity. On the other hand, 
auto-phoshorylation of GSK3β at tyrosine 216 (Tyr216) produces the activation of the 
kinase. For these reasons, levels of total GSK3β and its phosphorylations at Ser9 and 
Tyr216 were determined by western blot (Figure 13). In this respect, a decrease in 
the total level of the protein was observed. Furthermore, the level of inhibitory GSK3β 
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phosphorylation at Ser9 was also found to be reduced, in agreement with a drop in 
the active form of AKT. However, its activating auto-phosphorylation at Tyr216 did not 
change significantly.  
 
 
 
Figure 13: GSK3β expression and phosphorylation in murine neuron primary cell culture. A) 
Western blots showing GSK3β total levels, phospho-GSK3β (Ser9) and phospho-GSK3β (Tyr216) in 
primary neuronal cells transfected both with Control-RNAi and DISC1-RNAi #1. Densitometric analysis of 
B) total GSK3β, C) phospho-GSK3β (Ser9) and D) phospho-GSK3β (Tyr 216). All figures are 
representative of n=3 independent experiments. Total protein was normalized to GAPDH. Error bars 
represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. ***p<0.001, n.s. 
non-significant 
 
 
These results indicate that the decline of DISC1 produces changes in the quantity 
and phosphorylation of GSK3β in cortical and hippocampal cultured neurons. 
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However, the data obtained do not allow to conclude whether such miss-regulation 
contribute to the decreased phosphorylation of CREB seen in the experimental 
model, given that the decrease in total GSK3β might compensate the decrease in the 
inhibitory phosphorylation at Ser9. To further assess this point, murine neurons were 
treated in vitro with CHIR-99021, a selective GSK3β inhibitor, during 1 hour. The 
effectiveness of the treatment was confirmed by a decrease of the phosphorylation of 
the kinase at Tyr216 (Figure 11A). However, GSK3β inhibition did not lead to any 
change in VGF protein levels (Figure 11A, C). This result indicates that, despite the 
effects of DISC1 on GSK3β, this kinase is not likely to contribute to DISC1 regulation 
of VGF expression. 
 
Finally, another level at which DISC1 might be acting is through phosphodiesterase-4 
(PDE4). As was previously stated, DISC1 binds members of the PDE4 families and 
this interaction is disrupted in response to high levels of cAMP. The release of PDE4 
leads to the hydrolysis of cAMP, a key inducer of CREB activation. As previously 
shown, the absence of DISC1 leads to a decrease in the activation of CREB, which 
could be mediated by over-activated PDE4.  For these reasons, mouse primary 
neurons were treated with the PDE4 inhibitor rolipram. As shown in figure 14, the 
treatment was effective demonstrated by a significant increase CREB 
phosphorylation at Ser133. Rolipram administration to the cells resulted in an 
increase in the levels of VGF; however, this rise does not reach statistical significance 
(Figure 14 A, C). Nevertheless, the possibility that this treatment could reach 
statistical significance in different conditions of time and/or concentration cannot be 
excluded. 
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Figure 14: Effect of rolipram on VGF expression. A) Western blots showing VGF levels in murine 
neuron primary cells treated with rolipram. The effectiveness of the treatment was assessed measuring 
phospho-CREB (Ser133) levels. B) Densitometric analysis of phospho-CREB (Ser133) on rolipram treated 
cells (n=9 independent experiments). C) Densitometry of VGF on rolipram treated cells (n=6 independent 
experiments). Total protein was normalized to GAPDH. Error bars represent SD. Statistical analysis was 
carried out by the (paired) two-tailed Student’s t-test. *p<0.05, n.s. non-significant 
 
 
In summary, DISC1 was found to regulate VGF expression in mouse primary neurons 
through the PI3K/AKT/CREB cascade in a BDNF-independent manner, in agreement 
with the data obtained in SH-SY5Y. 
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BLOCK II: 
 
1. PROTEOMIC STUDY IN NEURONS  
 
To test the possible effect of DISC1 in the proteome of our neuronal model, cell 
extracts from control and DISC1 knock-down mouse primary neurons were subjected 
to proteomic analysis. Four gels for the silenced condition versus four gels for the 
control condition were analyzed. With the Ludesi REDFIN 3 Solo software, 3474 
spots were detected per gel. Figure 15 shows an image representative of all the gels 
obtained. Among these spots, 68 were found to be differentially regulated
 (1)
 with a 
fold change ≥2 and a p value < 0.05. These spots were found to correspond to 48 
proteins by means of mass spectrometry (see Annex I for complete table of identified 
proteins affected by DISC1 knock-down). Some of the proteins identified were 
validated by 1D-SDS-PAGE and 2-DGE and western blot to confirm the proteomic 
results. Remarkably in some cases this approach allowed the identification of post-
translational modifications. 
 
 
 
 
 
 
 
 
 
 
 
 
(1)
 “Spots differentially regulated” refers to those spots whose intensity is different in 
both conditions (control and DISC1 knock-down). 
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Figure 15: Representative images of gels obtained from control (Control RNAi) and DISC1 silenced 
(DISC1 RNAi #1) neurons in the proteomic analysis. Detected spots with a fold change >2 are 
highlighted by a blue line. 
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Among the proteins found differentially regulated by DISC1 knock-down, twelve are 
related to neurodevelopmental processes (Table 9), and twelve to synaptic function 
(Table 10). Besides, seven of the identified proteins are involved in both processes. 
According to these results it can be concluded that DISC1 is involved in these two 
processes. Remarkably, some of the proteins identified are well known DISC1 binding 
partners such as 14-3-3 proteins, microtubule-associated protein 1B (MAPB1) or 
platelet-activating factor acetylhydrolase IB subunit β (LIS-1). However, this is the first 
time that these proteins have been reported to be under the control of DISC1. 
Additionally, some proteins identified as being regulated by DISC1 have important 
roles in neurosignalling, for example syntaxin-binding protein 1 (STXB1 or MUNC18), 
neuronal calcium sensor 1 (NCS-1) or Rab proteins. 
 
MAP1B, LIS-1, Stathmin or 14-3-3ε are some of the proteins involved in 
neurodevelopmental processes that were found to be differentially regulated in 
DISC1-silenced cells (Figure 16). 
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Figure 16: Spots corresponding to proteins involved in neurodevelopment showing altered 
regulation in DISC1-silenced neurons: A) Microtubule associated protein. B) 14-3-3 epsilon. C) 
Stathmin. D) LIS-1. Control samples are represented in red, DISC1 silenced samples are represented in 
green. Error bars represent SD. Spot volumes are represented in arbitrary units (A.U.). **p<0.01, 
***p<0.001. 
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Levels of MAP1B, a key regulator of microtubule dynamics, were found increased in 
cells with DISC1 knock-down. Conversely, LIS-1 was found to be downregulated in 
DISC1 silenced-cells compared to control (Figure 16). However, 1D western blot did 
not show any change in the total levels of the protein suggesting that the spot 
observed to be decreased in the proteomic study might correspond to an isoform of 
LIS-1 (Figure 17).  
 
 
 
Figure 17: Confirmation of proteomic results: 1D - western blot showing levels of total LIS-1 in control 
and DISC1- silenced cells. GAPDH was used as load control.  
 
 
In the case of 14-3-3, two spots corresponding to 14-3-3ε, eight spots corresponding 
to 14-3-3θ/Δ, and two corresponding to 14-3-3γ were found to be differentially 
expressed in silenced vs. control cells (Figure 16) (Table 9). 14-3-3ε was found to be 
upregulated in DISC1 knock-down cells, however, as shown in figure 18, no changes 
were found in its levels by means of 1D and 2D western blot. This suggests that the 
spot with higher intensity identified in the proteomic study might correspond to a form 
of 14-3-3ε with some post-translational modification. 
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Figure 18: Confirmation of proteomic results. A) 2D-western blot of 14-3-3ε in control and DISC1- 
silenced cells. B)  1D- western blot showing levels of 14-3-3ε in control and DISC1- silenced cells. GAPDH 
was used as load control.  
 
 
The stathmin family of proteins is upregulated in the nervous system during neuronal 
differentiation, plasticity and regeneration. Additionally, a number of studies have 
reported alterations of stathmins expression in pathologies in the nervous system 
such as Alzheimer’s and Parkinson’s diseases, autism, depression or schizophrenia 
[163]. In this proteomic study stathmin-1 was found down-regulated in DISC1-
silenced cells vs. control (Figure 16).  This result was confirmed by means of 2-DGE 
(Figure 19). However, in this case, no differences were observed with the phospho-
Stathmin (Ser38) antibody.  
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Figure 19: Confirmation of proteomic results: 2D western blot of A) stathmin and B) phosphorylated 
form of stathmin at Ser38 in control and DISC1- silenced cells.  
 
As shown in Figure 20, dihydropyrimidinase-related proteins, CRMP-1, CRMP-2, 
CRMP-3 and CRMP-5 were found to be upregulated in DISC1 silenced cells.  
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Figure 20: Spots corresponding to CRMP proteins showing altered expression in DISC1-silenced 
neurons:  Spots identified as CRMP-1, CRMP-2, CRMP-3, CRMP-5. Control samples are represented in 
red, DISC1-silenced samples are represented in green. Error bars represent standard deviation (SD). Spot 
volumes are represented in arbitrary units (A.U.) ***p<0.001 
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In the case of CRMP-2 (identified as a possible DISC1 binding protein by Camargo 
and coworkers [35]), differential post-translational modifications were observed by 
monodimensional western blot (Figure 21).  Differences in band pattern were 
detected in DISC1-silenced cells vs. control by using an antibody against the 
phosphorylated form of CRMP-2 (Thr514). The results showed how non-
phosphorylated forms were upregulated in DISC1-silenced cells and phosphorylated 
forms were downregulated.  
 
 
 
Figure 21: Confirmation of proteomic results: 1D western blots showing levels of total CRMP2 and its 
phosphorylated form at Thr 514. GAPDH was used as load control.  
 
 
It is worth mentioning that some of the proteins identified in this experiment are 
known substrates of GSK3β, namely CRMP-2, MAP1B or stathmin.  
 
On the other hand, a group of proteins related to synaptic function was found to be 
upregulated by DISC1 knock-down (Figure 22). This is the case of syntaxin-1 and 
MUNC-18, both related to exocytosis and endocytosis in the synapses. Another 
mediator of synaptic endocytosis is clathrin. Of note, proteins related to clathrin were 
also found upregulated in DISC1-silenced neurons such as adaptin ear-binding coat-
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associated protein 1 (NECAP-1) and dynamin-1. The synaptic regulator NCS-1 was 
also found upregulated in DISC1 silenced cells (Figure 22). On the contrary, N-
cadherin was found decreased in these cells. In the case of Rab proteins, two of them 
were upregulated and two downregulated (Figure 22). 
 
 
 
Figure 22: Proteins involved in synaptic function that show altered expression in DISC1-silenced 
neurons: A) Neuronal Calcium Sensor 1. B) Syntaxin-7. C) MUNC-18. D) NECAP-1. E) Dynamin-1. F) 
Rab-2A. G) Rab-11B. Control samples are represented in red, DISC1 silenced samples are represented in 
green. Error bars represent standard deviation (SD). Spot volumes are represented in arbitrary units (A.U.) 
* p<0.05, **p<0.01, ***p<0.001 
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Table 9: Proteins involved in neurodevelopment identified through proteomic analysis of primary 
neurons. All the proteins had a fold change >2 and p value <0.05. Fold change in red indicates that the 
protein is upregulated in DISC1 silenced cells, while fold change in black indicates a downregulation in 
DISC1 silenced cells. 
 
PROTEIN SPOT FUNCTION DISC1 
BINDING 
PARTNER 
FOLD 
CHANGE 
p value 
Dihydropyrimidinase-
related protein 5 
(CRMP-5) 
(DPYL5_MOUSE) 
58 Neuronal 
differentiation 
Neurite outgrowth 
Not 
described 
2.59 3.066x10
-5
 
Dihydropyrimidinase-
related protein 3 
(CRMP-3) 
(DPYL3_MOUSE) 
734,  
1168 
Neurite outgrowth 
Neural migration 
Not 
described 
3.12, 
2.23 
1.469x10
-4
 
2.894x10
-4
 
Dihydropyrimidinase-
related protein 2 
(CRMP-2) 
(DPYL2_MOUSE) 
80, 
175 
Neurite outgrowth 
Neural migration 
 
Not 
described 
2.21, 
2.03 
2.457x10
-4
 
0.059 
Dihydropyrimidinase-
related protein 1 
(CRMP-1) 
(DPYL1_MOUSE) 
376 Neurite outgrowth 
Neural migration 
Not 
described 
2.10 9.180x10
-5
 
Tubulin alpha-1A chain 
(TBA1A_MOUSE) 
 
336, 
563, 
853 
Neurite outgrowth 
Neural migration 
 
Not 
described 
2.01, 
2.99, 
2.13 
0.0043 
1.326x10
-4
 
4.067x10
-4
 
Tubulin beta-2B chain 
(TBB2B_MOUSE) 
1291, 
1669 
Neurite outgrowth 
Neural migration 
Not 
described 
Inf, 
2.42 
0.0065 
0.0156 
Microtubule-associated 
protein 
(MAP1B_MOUSE) 
453, 
1213, 
1596 
Neurite outgrowth 
 
Yes 2.04, 
2.20, 
3.03 
3.661x10
-7
 
2.894x10
-4
 
2.717x10
-5
 
14-3-3 protein épsilon 
(14-3-3ε) 
(1433E_MOUSE) 
676, 
972 
Neurite outgrowth Yes 2.67, 
3.19 
6.713x10
-5
 
1.854x10
-4
 
14-3-3 protein zeta/delta 
(14-3-3θ/Δ) 
(1433Z_MOUSE) 
169,  
239, 
599, 
933,  
943, 
Neurite outgrowth Not 
described 
8.42, 
2.63, 
3.26, 
3.88, 
3.89, 
3.028x10
-6
 
2.334x10
-4
 
1.579x10
-4
 
9.307x10
-4 
0.021 
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1388, 
1404,  
601 
6.81, 
3.82, 
6.20 
2.080x10
-5
 
0.0022 
2.572x10
-6
 
14-3-3 protein gamma 
(14-3-3γ) 
(1433G_MOUSE) 
286,  
2490 
 
Neurite outgrowth Yes 3.24, 
2.30 
6.104x10
-5
 
0.0084 
Platelet-activating factor 
acetylhydrolase IB subunit 
β Lis-1 
(PA1B2_MOUSE) 
686 Neurite outgrowth Yes 2.48 0.0049 
Stathmin 
(STMN1_MOUSE) 
829, 
828 
Neurite outgrowth Not 
described 
2.12, 
4.64 
8.206x10
-4 
1.021x10
-4
 
Tropomyosin alpha-3 
chain 
(TPM3_MOUSE) 
470 Neurite outgrowth 
Neural migration 
Not 
described 
2.88 0.0115 
Actin, cytoplasmic 2 
(ACTG_MOUSE) 
485,  
1312 
Neurite outgrowth 
Neural migration 
Not 
described 
4.94, 
2.95 
4.398x10
-5
 
1.081x10
-5
 
Cadherin-13 
(CAD13_MOUSE) 
804 Neurite outgrowth 
Neuronal migration 
Not described 2.31 0.0108 
Calreticulin 
(CALR_MOUSE) 
1342 Neurite outgrowth 
 
Not described 2.60 0.0088 
Septin-5 
(SEPT5_MOUSE) 
2750 Interacts with 
CRMPs  
Neurite outgrowth 
Neural migration 
Not described 2.15 0.0034 
Apolipoprotein A-I 
(APOA1_MOUSE) 
407 
 
Neurite outgrowth Not described 2.41 9.215x10
-5
 
Dynamin 1 
(DYN1_MOUSE) 
2230 Neurite outgrowth 
Neural migration 
Not described 4.33 1.440x10
-4
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Table 10: Proteins involved in synaptic function identified through proteomic analysis of primary 
neurons. All the proteins had a fold change >2 and p value <0.05. Fold change in red indicates that the 
protein is upregulated in DISC1 silenced cells, while fold change in black indicates a downregulation in 
DISC1 silenced cells. 
 
PROTEIN SPOT FUNCTION DISC1 
BINDING 
PARTNER 
FOLD 
CHANGE 
p value 
Dihydropyrimidinase-
related protein 5 
(CRMP-5) 
(DPYL5_MOUSE) 
58 Regulates synaptic 
plasticity. 
 
Not 
described 
2.59 3.066x10
-5
 
Dihydropyrimidinase-
relatedprotein 2 
(CRMP-2) 
(DPYL2_MOUSE) 
80, 
175 
Involved in synaptic 
vesicle transport. 
 
Not 
described 
2.21, 
2.03 
2.457x10
-4
 
0.059 
Microtubule-associated 
protein 
(MAP1B_MOUSE) 
453, 
1213, 
1596 
Synaptic maturation 
Autophagy 
 
Yes 2.04, 
2.20, 
3.03 
3.661x10
-7
 
2.894x10
-4
 
2.717x10
-5
 
Transitional endoplasmic 
Reticulum ATPase 
(TERA_MOUSE) 
240 Synaptic regulation 
Associates with 
clathrin 
Autophagy 
Not 
described 
2.21 5.537x10
-4
 
Stathmin 
(STMN1_MOUSE) 
829, 
828 
Involved in synapse 
formation 
Not 
described 
2.12, 
4.64 
8.206x10
-4 
1.021x10
-4
 
Syntaxin-binding protein 1 
(STXB1_MOUSE) 
460 Regulates synaptic 
vesicle transport 
Neurotransmission 
Not described 3.43 0.0010 
Syntaxin-7 
(STX7_MOUSE) 
812 Forms part of the 
SNARE complex 
Synaptic transport/ 
function 
Not described 2.13 0.0022 
Ras-related protein (Rab-
1A) 
(RAB1A_MOUSE) 
585 Transport from ER 
to AG 
Synaptic function 
Not described 2.01 0.0023 
Ras-related protein (Rab-
2A) 
(RAB2A_MOUSE) 
823 Transport from ER 
to AG 
Synaptic function 
Not described 2.43 4.164x10
-4
 
Ras-related protein (Rab- 988 Endosomal Not described 3.25 0.0305 
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11B) 
(RB11B_MOUSE) 
trafficking 
Synaptic function 
Ras-related protein (Rab-
18) 
(RAB18_MOUSE) 
2079 Endocytosis/ 
recycling 
Synaptic function 
Not described 3.23 5.527x10
-4
 
Cadherin-13 
(CAD13_MOUSE) 
804 Synapse formation. 
 
Not described 2.31 0.0108 
Rho GDP-dissociation 
inhibitor 2 
(GDIR2_MOUSE) 
841 Forms a 
heterodimer with 
Rac1. 
Synapse function 
Not described 2.28 1.061x10
-4
 
Phosphatidylethanolamine
-binding protein 1 
(HCNP) 
(PEBP1_MOUSE) 
1267, 
1495 
Synaptic function 
Inhibits neuropsin 
and RAF1 
 
Not described 3.84, 
6.49 
4.081x10
-
4
2.377x10
-
4
 
Calreticulin 
(CALR_MOUSE) 
1342 Interacts with 
GABARAP. 
Synaptic function 
Not described 2.60 0.0088 
Adaptin ear-binding coat-
associated protein 1 
(NECAP1) 
(NECP1_MOUSE) 
1689 Clatrhin mediated 
endocytosis 
Synaptic function 
Not described 2.51 6.028x10
-5
 
Neuronal calcium sensor 1 
(NCS1_MOUSE) 
2005 Synaptic function 
 
Not described 2.24 9.215x10
-5
 
Dynamin 1 
(DYN1_MOUSE) 
2230 Synaptic function 
It is regulated by 
Ndel1 
Not described 4.33 1.440x10
-4
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2. INGENUITY PATHWAY 
 
The program Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Redwood City, 
CA, EEUU) was used to analyze possible interactions among the proteins identified in 
the proteomic study. The IPA functional analysis related many of the proteins of our 
study to the functional categories “nervous system development and function” (Table 
11) and “cellular assembly and organization” (Table 12). 
 
Table 11: Proteins identified as members of the “Nervous system development and function” by 
Ingenuity Pathway Analysis Software. 
 
FUNCTIONS FUNCTIONS ANNOTATIONS p value PROTEINS INVOLVED 
Migration Migration of neurons 7,50E-05 MAP1B, PEX5, STMN1, TUBA1A, 
TUBB2B, YWHAE 
Neurodevelopment Outgrowth of neurites 2,65E-04 DPYSL2, DPYSL5, HBA1/HBA2, 
MAP1B, PDIA3, TUBA1A, YWHAZ 
 Axonogenesis 2,51E-03 DPYSL2, MAP1B, PDIA3, STMN1 
 Formation of supernumerary 
axons 
2,96E-03 DPYSL2 
 Induction of axons 2,96E-03 DPYSL2 
 Length of cortical neurons 2,96E-03 DPYSL3 
 Elongation of axons 3,31E-03 DPYSL2, MAP1B 
 Neuritogenesis 3,93E-03 CRMP1, DPYSL2, DPYSL, MAP1B, 
PDIA3, STMN1 
 Branching of neurites 4,42E-03 CRMP1,DPYSL2, 
MAP1B,PDIA3 
 Guidance of axons 1,14E-02 DPYSL2,DPYSL5,PDIA3 
 Formation of axon bundle 5,92E-03 MAP1B 
 Branching of cortical neurons 1,18E-02 DPYSL3 
 Branching of axons 1,54E-02 DPYSL2, PDIA3 
 Growth of axons 7,74E-03 DPYSL2, MAP1B, PDIA3 
 Outgrowth of axons 2,86E-02 DPYSL2, MAP1B 
 Length of axons 3,21E-02 DPYSL2 
Abnormal 
morphology 
Abnormal morphology of inferior 
olivary nucleus 
1,18E-02 MAP1B 
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 Abnormal morphology of parietal 
lobe 
1,18E-02 MAP1B 
 Abnormal morphology of 
hippocampus 
1,68E-02 MAP1B, YWHAE 
 Abnormal morphology of brain 2,62E-02 STMN1, YWHAE 
 Abnormal morphology of stratum 
pyramidale 
3,50E-02 YWHAE 
 Abnormal morphology of 
neurons 
4,57E-02 CRMP1, DNM1, MAP1B 
Polarization Polarization of hippocampal 
neurons 
1,77E-02 MAP1B 
Morphology Morphology of brain 2,06E-02 CRMP1, MAP1B, PEX5, STMN1, 
YWHAE 
 Morphology of dendrites 2,13E-02 DPYSL2, MAP1B 
 Morphology of nervous system 2,14E-02 CRMP1, DNM1, DPYSL2, MAP1B, 
PEX5, STMN1, YWHAE 
 Morphology of neuromuscular 
junctions 
2,35E-02 YWHAG 
 Morphology of brain cells 4,77E-02 CRMP1, MAP1B 
Thickness Thickness of cerebral cortex 3,21E-02 TUBA1A 
 Thickness of myelin sheath 3,21E-02 MAP1B 
Synaptic 
function 
Recycling of synaptic vesicles 4,92E-02 DNM1 
 Maturation of synaptic vesicles 1,77E-02 STXBP1 
 Synaptic transmission of 
neocortical neurons 
5,92E-03 STXBP1 
 
  
 138 
 
Table 12: Proteins identified as members of the “Cellular assembly and organization” function by 
Ingenuity Pathway Analysis Software. 
 
FUNCTION p value PROTEINS INVOLVED 
Depolymerization of microtubules 4.63E-06 CRMP1, DPYSL2, MAP1B, STMN1 
Organization of cytoskeleton 6.84E-05 ACTG1, ARHGDIB, CALR, CDH13, CRMP1, DNM1, 
DPYSL2, DPYSL3, DPYSL5, MAP1B, RAB2A, 
TMN1, TPM3 
Polarization of neurons 1.79E-04 DPYSL2, MAP1B 
Microtubule dynamics 3.10E-04 ACTG1, CDH13, CRMP1, DNM1, DPYSL2, DPYSL3, 
DPYSL5, MAP1B, RAB2A, STMAN1, TPM3 
Formation of filopodia 3.43E-04 DNM1, DPYSL3, DPYSL5, MAP1B 
Formation of microtubules 5.44E-04 DPYSL2, STMN1, MAP1B 
Destabilization of microtubules 6.75E-04 DPYSL2, STMN1 
Stabilization of microtubules 1.71E-03 DPYSL2, STMN1, MAP1B 
Elongation of axons 1.74E-03 DPYSL2, MAP1B 
Transport of vesicles 2.32E-03 APOA1, DPYSL2, STX7 
Morphogenesis of growth cones 2.96E-03 MAP1B 
Formation of axons 4.28E-03 DPYSL2, MAP1B 
Polymerization of microtubules 4.18E-03 MAP1B, STMN1 
Transport secretory vesicles 5.92E-03 APOA1 
Transport of synaptic vesicles 6.24E-03 DPYSL2, STX7 
Priming of synaptic vesicles 8.87E-03 STXBP1 
Targeting of synaptic vesicles 1.18E-02 SEPT5 
Neuritogenesis 1.35E-02 CRMP1, DPYSL2, DPYSL3, MAP1B, STMN1. 
Axonogenesis 1.50E-02 DPYSL2, MAP1B, STMN1. 
Maturation of synaptic vesicles 1.77E-02 STXBP1 
Outgrowth of neurites 1.97E-02 DPYSL2, HBA1/HBA2, MAP1B, YWHAZ 
Outgrowth of axons 2.35E-02 DPYSL2, MAP1B 
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3. DISC1 SILENCED SH-SY5Y CELLS SHOW 
IMPAIRED NEURITE OUTGROWTH  
 
Retinoic acid (RA) is known to promote SH-SY5Y differentiation into post-mitotic 
neuronal-like cells. In agreement with the data obtained in the IPA analysis, DISC1 
knock-down with two different shRNA (Silenced 1 and Silenced 4) was observed to 
produce morphological changes in SH-SY5Y cells when treated with retinoic acid as 
shown in Figure 23. Remarkably, DISC1-silenced cells exhibit fewer and shorter 
neurites at 7 and at 14 days of treatment with RA.  
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Figure 23: DISC1-silenced cells show morphological impairment in neurite outgrowth assays. Cells 
were treated with retinoic acid (RA) for 7 and 14 days and neurite length was measured using ImageJ. A) 
Fluorescence images of SH-SY5Y cells expressing control and DISC1 shRNAs (Silenced 1 and silenced 4) 
treated with RA for 7 days and immunostained for βIII-tubulin (red); nuclei were stained using DAPI (blue). 
(B, C) Average neurite length -/+ SD; * significantly different between control and DISC1-silenced cells (n > 
200 for each cell line). (D, E) Frequency (percentile) of cells according to neurite length at 7 days (D) and 
14 days (E) for each cell population; p<0.0001 control vs silenced 1 at 7 and 14 days, ****p<0.0001 control 
vs silenced 4 at 7 days, p<0.001 control vs silenced 4 at 14 days (Mann–Whitney U test).  
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1. DISC1 REGULATES THE EXPRESSION OF 
THE ANTIDEPRESSANT NEUROPEPTIDE VGF 
 
DISC1 has been solidly established as a risk factor for psychiatric disorders. One of 
the major findings of this study is the elucidation of the pathway by which DISC1 
regulates the expression of the neuropeptide VGF.  
 
As has been noted, after its synthesis VGF is processed into a number of different 
bioactive peptides that are released in response to specific stimuli. VGF-derived 
peptides have been demonstrated to regulate a broad spectrum of processes as 
diverse as food intake or pain modulation that make of this protein an interesting 
object of research. Some of the most important functions of VGF are the mediation of 
neuroprotection, the regulation of synaptic plasticity and enhancement of 
neurogenesis.  Indeed, deficits in these processes have been reported to be major 
features of major depression, bipolar disorder or schizophrenia, all of them serious 
debilitating diseases affecting a large number of people around the world. Regarding 
this, VGF alterations have been described in patients of a number of neurological and 
psychiatric illnesses including the disorders mentioned above. Taking all this in 
consideration, VGF is a very interesting target of study in order to expand the 
knowledge about the causes of neurodegenerative and psychiatric diseases.  
 
In a previous unbiased proteomic study, DISC1 knock-down in SH-SY5Y cells was 
found to produce a substantial decrease of VGF levels. In the present study, it was 
demonstrated that over-expression of DISC1 leads to a significant increase of VGF 
quantity in this neuroblastoma cell model. This indicates that the drop in VGF levels 
observed in DISC1-silenced SH-SY5Y cells is a consequence of the lack of DISC1. 
Remarkably, DISC1 and VGF have been demonstrated to be involved in similar 
mental diseases and neuronal processes such as neurogenesis or synapses. 
Additionally, these proteins display a similar expression pattern in the brain; 
specifically, they present high expression in cortex and hippocampus. Although it is 
well known that DISC1 regulates the activity of multiple proteins by direct binding, 
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based on the evidences, it is not unreasonable to think that some of the functions of 
DISC1 in the brain might be exerted through the regulation of VGF expression. For 
this reason, the elucidation of the pathway connecting these two proteins would be of 
great importance for the development of new therapies for the treatment of mental 
disorders.  
 
In the present study DISC1 knock-down was found to cause an important 
downregulation of VGF levels also in primary mouse neurons, similar to the results 
previously obtained in SH-SY5Y cells. The validation of this finding in primary 
neurons shows that the regulation of VGF levels by DISC1 is an extended function 
that it is not restricted solely to a specific cellular model. Moreover, primary neurons 
are a more representative model of what could be happening in vivo due to the fact 
that these cells lack the typical alterations of a cancerous cell line such as SH-SY5Y 
which could be affecting the results.  
 
As has been noted, some of the shared functions of VGF and DISC1 in vivo are the 
control of development of new neurons and their correct function. Neurotrophins also 
stimulate these processes through the neurotrophin signal transduction. This pathway 
begins with the activation of the Tyrosine kinase (Trk) receptors and ends with the 
activation of the transcription of several genes, some of them involved in 
neurodevelopment and synaptic function. One of these genes is Vgf [125]. Although 
VGF was first described as an NGF-induced peptide, different neurotrophins have 
been subsequently shown to stimulate its expression. Specifically, Brain Derived 
Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) were demonstrated to 
produce a robust and maintained expression of Vgf in cortical and hippocampal 
primary rat neurons. Importantly, BDNF treatment was thoroughly demonstrated to be 
an important inducer of Vgf expression also in vivo [130], [162].  
 
For this reason, in the present study the levels of BDNF were assessed in order to 
clarify if the drop in the quantity of VGF in DISC1-silenced cells was due to a 
decrease in the levels of BDNF. Contrary to what might be expected, western blotting 
did not reveal any change in the protein levels of BDNF when DISC1 was silenced in 
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SH-SY5Y cells or primary neurons. This result indicates that the regulation of Vgf 
expression by DISC1 is not mediated by BDNF in this model. Although BDNF is a 
well-known inducer of the expression of Vgf, this is not the first time that VGF 
induction BDNF-independent is described. Specifically, it has been reported that 
treatment of PC12 cells with the neuroprotective agent SUN N8075 produces a robust 
increase of VGF with unchanged expression of BDNF [144]. This confirms the 
existence of independent regulatory pathways for both neuropeptides despite sharing 
common signalling cascades and supports the results obtained in the present study. 
 
For the purpose of identifying the mechanisms by which DISC1 modulation results in 
changes in Vgf induction, cAMP-response element binding protein (CREB) was 
studied. CREB is a transcription factor that binds to the TGACGTCA sequence 
present in the promoter of more than 100 cAMP-responsive genes, including Vgf, and 
activates their transcription. In fact, the binding site for CREB within Vgf gene 
promoter is essential for its neurotrophin-induced expression in cooperation with other 
transcription factors [162]. In order to test a  possible involvement of CREB in the 
drop of VGF levels produced by DISC1 knock-down, the levels of total CREB and its 
active phosphorylated form at Ser133 were assessed in control and DISC1-silenced 
cells. Western blotting did not revealed any difference in the total protein levels 
between control and DISC1 knock-down SH-SY5Y cells and primary neurons. 
However DISC1 silencing was found to provoke a marked decrease in the levels of 
phospho-CREB (Ser133) in both cellular models. The drop in the active form of CREB 
explains a reduced activation of the transcription of Vgf that leads to the observed 
decrease of the levels of the neuropeptide. According to these results it can be 
concluded that reduction of the levels of DISC1 leads to VGF downregulation due to a 
reduction in the activation of CREB in a BDNF-independent manner. 
   
It must be noted that four studies have previously shown contradictory results 
suggesting a relationship between the activity of CREB and DISC1. DISC1 was 
shown to modulate CREB-mediated gene transcription by direct recruitment of ATF4 
a co-represor of CREB phosphorylation in Drosophila melanogaster [67]. Lipina and 
coworkers detected a downregulation of CREB levels in the nucleus accumbens of 
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the DISC1 mutant mouse Q31L, although CREB phosphorylated levels remained 
unchanged [103]. Opposite, the mutant mouse carrying a DISC1-truncated form 
Disc1
TmKara
 was observed to present enhanced CREB phosphorylation at Ser133 
[106]. Recently, knock-down of DISC1 was reported to cause a significant increase in 
CREB activity in rat cortical cultures [63]. The contradictions present in these studies 
might be explained by the use of different experimental models. Additionally, the 
possibility of a different regulation of CREB activity in different parts of the brain 
cannot be excluded.  
 
Having CREB as a starting point, different signalling pathways upstream of it were 
investigated. Several kinases regulate the activity of CREB by phosphorylation at 
different sites such as protein kinase A (PKA), AKT, ERK or GSK3β. Specifically AKT 
and ERK phosphorylate CREB at Ser133 leading to its activation. Remarkably, these 
two kinases have been found to be connected to DISC1 in different cases. Hashimoto 
and coworkers described the suppression of ERK activation produced by knocking-
down DISC1 in primary neuronal culture [21]. In the case of AKT, the literature 
supports mutual regulation between this kinase and DISC1; however the results 
obtained by different groups are contradictory. On the one hand, knock-down of 
DISC1 in progenitor hippocampus cells was shown to increase the levels of active 
AKT as demonstrated by an increase of its phosphorylation at Ser473 [88]. However, 
Hashimoto and coworkers observed the opposite effect on AKT when DISC1 was 
silenced in adult neurons [21]. These discrepancies might be due to differential, even 
opposite, AKT regulation, in progenitor cells and in mature post-mitotic neurons. In 
fact, as has been previously discussed, DISC1 function has been demonstrated to 
vary during normal neuronal development promoting, for example, the switch form 
neuronal precursor proliferation to neuronal migration [27]. 
 
In the present study the levels of ERK and AKT and their active phosphorylated forms 
were assessed by western blot in control and DISC1-silenced neurons. Levels of total 
and phospho-ERK (Thr202/Tyr204) were seen to remain unchanged. However, 
agreeing with Hashimoto results, active AKT was found decreased as shown by a 
decrease in the activating phosphorylation of the kinase at Ser473 in those cells in 
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which DISC1 knock-down was performed. This decrease in the activation of AKT 
explains the fall in the levels of phosphorylated CREB at Ser133 and strongly 
suggests that the regulation of VGF by DISC1 involves AKT/CREB signalling. In 
addition, this drop in phosphorylated form of AKT at Ser473 was also confirmed in 
SH-SY5Y.  
 
In order to find a connection between DISC1 and the AKT/CREB pathway, the levels 
of activation of PI3K were measured in the neuronal model. The activation of PI3K is 
necessary for the phosphorylation of AKT at Ser473, and consequently its activation 
[164]. While total levels of the protein remained unchanged, the activating 
phosphorylation of PI3K at Tyr458 was found decreased in those neurons in which 
DISC1 had been silenced. This drop in the activation of the kinase agrees with the 
observed fall in the phosphorylation of AKT in those cells. In addition, treatment of 
murine embryonic neurons with the selective PI3K inhibitor LY294002, led to a drop 
of VGF levels in the cells, the same effect observed with DISC1 knock-down. These 
results strongly suggest that PI3K is a necessary factor for the regulation of VGF 
expression by DISC1. Remarkably, it has been recently reported that inhibition of 
PI3K also prevents the antidepressant effect of acetil-L-carnitine together with a 
decrease in phospho-AKT (Ser473), VGF and BDNF [165].  
 
A possible link between DISC1 and PI3K is the DISC1 binding protein Grb2. This 
protein is an important molecular adapter due to the fact that it couples cell surface 
TrK receptor singaling to downstream targets. Consequently, Grb2 is essential for 
several cellular processes in neurons, including proliferation, transformation and 
differentiation. When Trk receptors are activated they recruit different factors 
necessary for the transduction of the signal. One of the recruited proteins is Grb2 that 
binds directly to the intracellular domain of these receptors [166]. When this happens, 
Grb2 recruits Grb2-associated binder 1 (Gab1), that mediates the activation of PI3K 
[167], [168]. As reported by Shinoda and coworkers, Grb2 is required for neurotrophin 
induced axon elongation. Besides, in that study, the interaction between Grb2 and 
DISC1 at the distal part of the axons was found essential for the promotion of axon 
extension. DISC1 was reported to regulate the localization of Grb2 at this place, 
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demonstrated by observed mislocalization of Grb2 when DISC1 was absent, and 
producing the impairment of the neurite outgrowth [52]. It is worth mentioning that 
some evidences have demonstrated a relationship between Grb2 and VGF. As has 
been mentioned, exercise produces an increase of Vgf transcription. Remarkably, 
after 1 week of exercise a rise in Grb2 expression was also seen in mouse 
hippocampus. Furthermore, the incubation of PC12 cells with the VGF-derived 
peptide AQEE-30 was shown to induce the upregulation of Grb2. This result was also 
observed after in vivo VGF infusion into the DG of rodents [143]. Besides, 
electroconvulsive seizure, the most effective treatment for depression, also increases 
the expression of several of the exercise- and VGF-induced genes including Grb2 
[155] as well as Vgf itself.  
 
With these evidences it is not unreasonable to think that Grb2 might be the protein 
linking DISC1 with the PI3K/AKT cascade. For this reason the levels of Grb2 were 
assessed by western blot in control and DISC1-silenced SH-SY5Y cells and primary 
neurons. In the present study, Grb2 was found markedly decreased in SH-SY5Y cells 
when DISC1 was knocked-down, indicating that in this specific cell model DISC1 
influences the expression of Grb2. In contrast, silencing of DISC1 in murine neurons 
did not produce any change in Grb2 levels. Remarkably, this last result in neurons 
agrees with the data obtained by Shinoda and coworkers in which knock-down of 
DISC1 in PC12 cells had no effect on Grb2 expression [52]. However, this group 
observed that the knock-down of DISC1 in rat hippocampal neurons leads to 
inhibition of Grb2 accumulation at the distal part of the axons and to the impairment of 
neurotrophin-induced axon elongation indicating that proper DISC1-dependent Grb2 
localization is necessary for this process.  
 
While the involvement of the PI3K/AKT/CREB signalling route is clear, two other 
DISC1 binding partners, GSK3β and PDE4, have possible connections with CREB, 
and therefore could be alternative entry points for DISC1 in the regulation of VGF. 
In this regard, GSK3β is one of the kinases that regulate CREB activity. GSK3β 
phosphorylates CREB at Ser129 producing the attenuation of the DNA binding 
activity of CREB [169]. At the same time, AKT phosphorylates GSK3β at Ser9 
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producing its inactivation. This way, AKT can upregulate CREB activity by a direct 
(phosphorylation of CREB) and indirect (through inhibition of GSK3β) manner. In this 
study the knock-down of DISC1 in primary neurons was found to result in a decrease 
of the relative levels of GSK3β inactivating phosphorylation when normalized to total 
protein (phospho-GSK3β (Ser9)/ GSK3β total). This result supports the observed 
decreased activation of AKT in DISC1 knock-down cells. However, the relative levels 
of the phosphorylation at Tyr216 experienced an increase although it did not reach 
statistical significance. This is not the first time that this is observed, since Lipina and 
coworkers described an increase of this auto-phosphorylation in the DISC1-Q31L 
mutant [170]. Surprisingly, the total levels of GKS3β were found reduced in neurons 
after DISC1 knock-down. The rise in the levels of the activating auto-phosphorylation 
of GSK3β could be due to a compensatory mechanism in order to counterbalance the 
loss of total protein. These data apparently suggest a net increase of active GSK3β in 
the silenced cells.   
 
GSK3β is inhibited by DISC1 direct binding for the regulation of β-catenin stability and 
consequently progenitor proliferation. DISC1 knock-down in neuronal progenitor cells 
has been found to produce an increase in GSK3β activity [72]. GSK3β inhibitors act 
as mood-stabilizing drugs such as lithium or sodium-valproate facilitating CREB 
activity. Remarkably, it has been demonstrated that VGF, similarly to other antimanic 
drugs upregulate the phosphorylation of GSK3β at serine 9 [157]. Therefore, VGF 
and AKT/GSK3β might be linked in a circular regulatory loop. In order to confirm a 
direct involvement of GSK3β on the control of VGF expression by DISC1, primary 
mouse cultured neurons cells were treated with the GSK3β inhibitor CHIR-99021. 
Based on the evidences, it would be logical to think that if the drop in VGF levels 
observed in cells with decreased quantity of DISC1 is due to a rise in the activity of 
GSK3β, the inhibition of GKS3β should produce the increase of VGF levels. 
Paradoxically, the inhibition of GSK3β in these cells did not have any effect on VGF 
levels. This indicates that in the present model the decrease in VGF expression 
caused by DISC1 knock-down is not likely to be an effect of changes in GSK3β 
activity.  
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Furthermore, the second messenger cAMP is another CREB regulator due to the fact 
that it promotes the PKA-dependent phosphorylation of CREB at Ser133. In response 
to high levels of cAMP in the cells the phosphodiesterase 4 (PDE4) is activated and 
hydrolyzes the second messenger. Remarkably, DISC1 selectively binds to isoforms 
of the PDE4 family sequestering them. DISC1 silencing could be leading to an 
overactivation of PDE4 resulting in increased cAMP hydrolysis and consequently 
decreased activation of CREB, producing the reduction of the quantity of VGF. In 
order to test if the drop in VGF levels is a result of PDE4 overactivation, primary 
mouse neurons were treated with the selective PDE4 inhibitor rolipram. It must be 
noted that this drug displays antidepressant-like properties. The treatment with 
rolipram produced an increase in the phosphorylation of CREB at Ser133. However, 
although rolipram addition to cell culture medium produced consistently slightly 
increased levels of VGF, the differences did not reach statistical significance. With 
these data, it cannot be excluded that under different time or concentration conditions 
the effect of the treatment with rolipram on VGF expression could be visible. In this 
way, it cannot be ruled out that DISC1 might exert an additional regulatory effect on 
VGF expression through regulation of PDE4 leading to sustained levels of cAMP and 
CREB activation. Either way, this is not the first time that acute rolipram treatment is 
shown to lack of effect on neurotrophin levels, contrary to what happens with other 
antidepressants [171].   
 
Taking into account these data, the model presented in Figure 20 is proposed with 
the purpose of explain the mechanism by which DISC1 can influence the expression 
of VGF.  
 
In normal conditions DISC1 would control the localization (or the quantity) of Grb2 in 
the cell at localized sites regulating its availability. When neurotrophins bind to and 
activate Trk receptors, Grb2 is recruited and it allows the activation of Grb2-
associated binder-1 (Gab1) that promotes the activation of the PI3K/AKT/CREB 
cascade that would eventually lead to the expression of the neuropeptide VGF. 
DISC1 absence or malfunction would result in defective Grb2 accumulation that 
would result in deficient Trk activation. This would explain the observed drop in PI3K, 
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AKT and CREB active phosphorylations in DISC1 knock-down cells that would 
eventually result in a decrease of VGF levels. Nevertheless, as has been previously 
discussed, the possibility that DISC1 could also modulate VGF levels through 
regulation of PDE4 cannot be excluded. Either way, the drop of VGF due to the lack 
of DISC1 could underlie some of the defects in cell biology observed when DISC1 is 
lacking and might explain its involvement in mental illness. Given the important roles 
of VGF and DISC1 in mental diseases, the connection between these two proteins is 
of great importance for the potential development of new therapies for this type of 
disorders.  
 
 
 
Figure 24: Proposed model for DISC1 regulation of VGF. By direct binding DISC1 controls the 
localization of Grb2 in the cell. When Trk receptors are activated by neurotrophins they recruit local Grb2 
and Gab2 leading to the activation of the PI3K/Akt/CREB pathway that results in an increase of VGF 
expression. Arrows indicate activating (green) or inhibitory (red) effects; phosphorylation is indicated with a 
dot; inhibitors are indicated in star-shaped enclosures. DISC1 binding to PDE4 and GSK3β inhibits their 
activities. 
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2.  DISC1 IS INVOLVED IN THE REGULATION OF 
NEURODEVEOPMENT AND SYNAPTIC 
PROCESSES 
 
In the last few years it has been demonstrated that different diseases such as 
schizophrenia, bipolar disorder or autism share common risk variants and evidences 
suggest that this type of disorders have neurodevelopmental and synaptic etiology. 
 
As previously described, DISC1 binds a high number of proteins participating in 
correct neuronal development as well as in formation and maintenance of synapses. 
Accordingly, the results obtained in the present study highlight the importance of 
DISC1 in both processes. However, this study describes for the first time DISC1 
regulation of the expression of several proteins involved in these two processes 
(Figure 21). Remarkably, some of these proteins are also DISC1 binding partners 
(See annex I for complete list of identified proteins). Thus, this is another powerful 
mechanism of action by which DISC1 takes part in the regulation of neural 
development and synapses. Hence, it should be taken into consideration when 
referring to the roles of DISC1 in mental disease. 
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Figure 25: Classification of the proteins identified in the proteomic study according to their 
functions. 
 
 
2.1. DISC1 regulates the expression of several proteins 
necessary for neurodevelopment 
 
Neurodevelopment involves different processes such neural progenitor cells 
proliferation, cell migration and differentiation of neurons. All these events require 
proper dynamics of cytoskeleton and, supporting a role for DISC1 in 
neurodevelopment; several proteins related to cytoskeleton function were found to be 
differentially regulated in DISC1 knock-down neurons by proteomic analysis.  
 
Microtubules, one of the major components of cytoskeleton, are composed of dimers 
of α- and β-tubulin. Remarkably, members of both α- and β- families of tubulin were 
found downregulated in DISC1-silenced neurons in the proteomic study. A number of 
proteins regulate microtubule dynamics; specifically Microtubule Associated Proteins 
(MAPs) stabilize microtubules by suppressing their depolymerization or facilitating 
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their reassembly. These proteins are highly expressed in the nervous system where 
they participate in the outgrowth of axons and in the determination of neuronal 
polarity. In the present study MAP1B, was found to be upregulated in cells with low 
DISC1 levels. Interestingly, MAP1B has also been found to be overexpressed in 
schizophrenic patients but downregulated in individuals suffering from bipolar disorder 
[172]. Curiously, MAP1A, closely related sequentially and functionally to MAP1B, has 
been identified as a DISC1 binding protein [31]. The activity of MAPs is regulated by 
phosphorylation. Remarkably, GSK3β phosphorylates MAP1B leading to a decrease 
in its microtubule-stabilizing properties [173] and, as discussed in the previous 
section, GSK3β activity was found to be altered by DISC1 knock-down in neurons. 
Thus, it is reasonable to think that the activity of MAP1B is also altered due to 
changes in its phosphorylation status. On the other hand, MAP1B binds to LIS-1, 
another DISC1 interacting factor [54], competing with the motor protein dynein and 
this binding is also dependent on GSK3β. When MAP1B is phosphorylated, the 
binding between this protein and LIS-1 is disturbed and LIS-1 can bind to dynein 
essential interaction for proper mitotic division in proliferating cells [174]. DISC1, LIS-
1, NUDEL and 14-3-3ε form a complex that positively regulates axon elongation. 
DISC1 transports this complex through kinesin-1 to the axon tips. DISC1 knock-down 
has been found to result in inadequate localization of the mentioned complex, 
although no difference in expression of any of the complex forming proteins was 
reported [47]. In contrast, decreased levels of endogenous mouse DISC1 and LIS-1 
were reported in a transgenic mouse model in which the expression of the mutant 
human DISC1 isoform was induced [107]. In the present study, LIS-1 was also found 
to be downregulated in DISC1 silenced cells. Therefore, it cannot be excluded that 
the neurodevelopmental changes previously observed upon DISC1 knock-down [48], 
[115] could be partially mediated by LIS-1, whose alteration results in dramatic 
alterations during the neurodevelopment such impaired cell migration or abnormal 
cortical layering [175], [176]. 
 
In the present study the levels of different 14-3-3 proteins were also found altered by 
the lack of DISC1 in primary neurons. More specifically, two spots corresponding to 
14-3-3ε, eight spots corresponding to 14-3-3θ/Δ, and two corresponding to 14-3-3γ 
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were found to be differentially regulated in silenced vs. control cells. These proteins 
interact with more than 100 partners displaying numerous roles. In particular, as 
previously commented, 14-3-3ε interacts with DISC1 taking part in axon elongation 
[47]. Interestingly, 14-3-3ε was recently found decreased in transgenic mice with 
impaired NMDA receptor transmission along with a decrease of DISC1 levels at 
synaptic fractions [62]. However, in a previous proteomic study, 14-3-3ε was also 
found upregulated in samples obtained from prefrontal cortex of schizophrenia and 
bipolar disorder patients [177]. Accordingly, in the present proteomic study, the spot 
corresponding to 14-3-3ε was also found to experience an upregulation in DISC1 
silenced cells. However, this spot might correspond to a form of 14-3-3ε with some 
post-translational modification, due to the fact that no changes were observed in total 
protein levels by 1D and 2D western blot.  
 
Another group of proteins differentially regulated in DISC1 knock-down cells is the 
Collapsin Response Mediator Protein (CRMP) family. CRMPs are five homologous 
cytosolic proteins (CRMP1-5) highly expressed in the adult nervous system with 
important roles during neuronal development and maturation. CRMPs themselves 
have no known enzymatic activity but they interact with a number of proteins 
modulating their function and taking part in neuronal migration, synapse formation 
and synaptic plasticity [178]. Several spots corresponding to CRMP-1, CRMP-2, 
CRMP-3 and CRMP-5 were found upregulated in silenced cells. Remarkably, CRMP-
2 is a DISC1 binding partner [35] and is involved in the axogenesis during neuronal 
polarization maintaining neuronal polarity. More specifically CRMP2 binds to tubulin 
heterodimers promoting microtubule assembly and promoting axon elongation [179]. 
In this regard, the overexpression of CRMP-2 was found to induce the formation of 
multiple neuronal processes containing axonal markers. Conversely, its deletion was 
observed to suppress the axon formation. Of note, the activity of CRMP-2 is regulated 
by phosphorylation; in fact, GSK3β phosphorylates CRMP2 at Thr-514 and 
inactivates it. In the present study, phosphorylated and non-phosphorylated forms of 
CRMP-2 were found differentially regulated as shown by monodimensional western 
blot. Specifically, phosphorylated CRMP2 at Thr514 was found downregulated and 
unphosphorylated protein was upregulated in DISC1 silenced cells (Fig. 16). This 
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agrees with the deregulation of GSK3β phosphorylation observed in the present study 
and with the data showing altered GSK3β activity in DISC1 silenced neurons [72]. 
Remarkably, CRMP-2 expression has been described to be altered in mental 
diseases in different studies; on the one hand, decreased levels of this protein were 
reported in the frontal cortex of patients with schizophrenia, bipolar disorder and 
major depression [180]. Nakata described polymorphisms in the CRMP2 gene 
associated with schizophrenia [181]. Finally, CRMP-1, closely related to CRMP-2, has 
also been linked to schizophrenia, by means of genetic and biochemical studies 
[182].   
 
CRMP proteins bind to Septin-5 binds that is thought to play an important role in 
neuronal differentiation and axon guidance through the control of mitochondrial 
function [183]. Of note, in the present study Septin-5 was found downregulated in 
DISC1 silenced neurons.  
 
Another group of proteins that regulate microtubule dynamics is the stathmin family. 
Stathmins act as microtubule-destabilizing factors by promoting microtubule 
disassembling and sequestering tubulin dimers [184]. This way, these proteins 
regulate neuronal sprouting and interneuronal connectivity. Stathmin presents 
different phosphorylation sites for different kinases [185], [186]. In this regard, its 
phosphorylation by GSK3β produces the increase of its microtubule depolymerizing 
activity. On the contrary, phosphorylations performed by PKA, ERK or cdc2 kinase 
produce the opposite effect. In the present study, the total level of statmin was found 
downregulated in DISC1 silenced cells. Additionally, a different pattern of expression 
of the protein was confirmed in control and DISC1 silenced cells by 2D western blot 
(Fig. 17). In this case, the use of an antibody recognizing stathmin phosphorylation 
produced by cdc2 kinase at Ser38 did not reveal any difference. This indicates that 
this is not the relevant phosphorylation site affected under the study conditions.  
 
In the present study not only the proteins involved in microtubule dynamics were 
found differentially regulated. Remarkably, two spots corresponding to actin were 
found downregulated in DISC1 silenced neurons. Actin microfilaments are one of the 
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major structural components of cytoskeleton and play an essential role in clue 
processes such cellular division, locomotion, or axon and dendritic formation in 
neuronal cells [187]. Additionally, tropomyosin, an actin binding protein implicated in 
the stabilization of acting filaments, was upregulated by DISC1 knock-down in 
neurons.  
 
 
2.2. DISC1 regulates the expression of several proteins 
necessary for synapse formation and maintenance 
 
Apart from its role in neurodevelopment, DISC1 was also shown to regulate the levels 
of proteins directly related to synaptic function confirming its involvement in synapses 
reported in previous studies. Of note, some of the proteins involved in 
neurodevelopment mentioned above also participate in synaptic processes. This is 
the case of stathmin that participates in synapse formation, MAP1B which is required 
for synaptic maturation, and CRMP-5 and CRMP-2 that regulate synaptic plasticity 
and synaptic vesicle transport respectively.  
 
One of the proteins identified in this study was Neuronal Calcium Sensor-1 (NCS-1). 
This protein modulates K
+
 and Ca
+2
 levels in neurons and controls the trafficking of 
cellular proteins regulating synaptic plasticity [188]. In the present study NCS-1 was 
observed to suffer a sharp increase in DISC1 silenced cells. Remarkably, an increase 
in NCS-1 levels in prefrontal cortex of schizophrenia and bipolar patients has been 
also reported [189]. Additionally, NCS-1 regulates the exocytosis of secretory and 
neurotransmitter vesicles, key for the process of neurotransmission. To make this 
possible, synaptic vesicle must be transported to the proximity of the presynaptic 
plasma membrane. Several proteins involved in the transport of these vesicles were 
found differentially regulated in the presence of decreased levels of DISC1. This is 
the case of CRMP-2, syntaxin, syntaxin binding protein (MUNC-18), Rab proteins and 
NECAP-1. At this location, the vesicles must fuse with the presynaptic membrane. 
Two families of proteins coordinate this process: soluble N-ethylmaleimide-sensitive 
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factor attachment protein receptors (SNARE proteins) that form the SNARE complex, 
and SM proteins [190].  Syntaxin 7 belongs to the SNARE complex and was found to 
be upregulated in DISC1 silenced cells.  The same result was obtained for the SM 
protein Syntaxin-binding protein (STXB1 or MUNC18). This might imply alteration of 
synaptic membrane trafficking as a consequence of the absence of DISC1. With 
these data it cannot be concluded whether the trafficking is up- or downregulated, 
however it has been previously reported that DISC1 knock-down produces a 
decrease in vesicle transport in primary cortical neurons. In this regard, DISC1 
interacts with FEZ-1 that also binds and activates the kinesin-1 motor which regulates 
vesicle transport [191].  
 
For proper functioning of synapses is essential the endocytosis of pre- and 
postsynaptic proteins including neurotransmitter receptors. In this regard, Ras related 
proteins (Rab) mediate endosomal trafficking and endocytosis [192]. In the present 
study four Rab proteins were found differentially regulated in DISC1 knock-down 
cells. Specifically two of them were found downregulated (Rab-1A and Rab-2A) and 
two upregulated (Rab-11B and Rab-18). Furthermore, Clathrin-mediated neuronal 
endocytosis might also be affected by DISC1 absence considering that several 
proteins that regulate this process were found differentially regulated in DISC1 knock-
down cells such NECAP-1 [193] and dynamin-1 [194]. These data provide more 
evidences of the involvement of DISC1 in vesicle transport. 
 
Another protein involved in synapses found to be downregulated in DISC1 silenced 
cells was Rho-GDP dissociation inhibitor (GDIR2). GDIR2 forms a heterodimer with 
Rac1, a protein involved in axonal branching, regulating Rac1 activation. Remarkably, 
DISC1 has been previously shown bind to Kal-7, a Rac1 activator. In such study, 
DISC1 knock-down was found to initially produce an increase in the number of 
dendritic spines, but in the long term it produced the opposite effect [61]. These data 
confirm that DISC1 not only regulates synaptic traffic but also synapse formation. In 
agreement with this role of DISC1, cadherin-13 was found downregulated in neurons 
with DISC1 silencing. Cadherins play an important role in neurite outgrowth and 
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neuronal migration, but remarkably, the cadherin family together with catenins plays a 
central role in the morphogenesis of synapse and in synaptic plasticity [195].   
 
With all these data it can be concluded that DISC1 plays two important roles at the 
synapses. One the one hand, DISC1 regulates the expression of proteins that control 
synapse formation and on the other; it modulates the expression of proteins involved 
in the synaptic vesicle transport.  
 
Summarizing, this study shows the importance of DISC1 as a key element in 
neurodevelopment and synaptic function by regulating the levels of important proteins 
involved in both processes. On the one hand, several proteins that control 
cytoskeleton dynamics have been found differentially regulated in DISC1 knock-down 
cells indicating a role for DISC1 in cell proliferation, migration and differentiation of 
neurons. Importantly, the principal components of microtubules and actin 
cytoskeleton, tubulin and actin respectively, were found downregulated in DISC1 
knock-down cells. In addition, the levels of a number of proteins directly involved in 
microtubule and actin dynamics were also found clearly altered in these cells; this is 
de case of MAP1B, CRMP proteins, stathmin or the alpha-3 chain of tropomyosin. 
These data clearly support a role for DISC1 in neurodevelopment by means of the 
regulation of the levels of proteins that participate in this process. On the other hand, 
proteins involved in important synaptic processes have been also found affected by 
the lack of DISC1. This is the case of NCS-1 that regulates synaptic plasticity. Other 
differentially regulated proteins were syntaxin, MUNC-18, Rab proteins that modulate 
synaptic vesicle transport as well as clathrin that mediates endocytosis.  
 
It must be noted, that some of the proteins differentially regulated in absence of 
DISC1 share functions in both neurodevelopmental and synaptic processes, 
indicating that these two events are not independent. This is the case of CRMP-2, 
CRMP-5, MAP1B, Stathmin, Dynamin1, Calreticulin or Cadherin-13. In fact, on the 
one hand, these proteins participate in neurite outgrowth and in the other hand they 
also regulate synaptic plasticity, synaptic maturation and the transport of synaptic 
vesicles. This suggest that DISC1 possess a central role in the regulation of proper 
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neurodevelopment and synapses formation and maintenance, different aspects 
essential for correct brain function.  
 
Remarkably, although the activity of some of these proteins has been previously 
described to be regulated by DISC1 by direct binding this is the first time that DISC1 
is found to regulate also the levels of such proteins. This result suggest a two-way 
regulatory mechanism of DISC1 upon proteins such CRMP-2, MAP1B, 14-3-3γ and 
LIS-1.  
 
Another important fact that must be taken into account is that some of the proteins 
found differentially regulated in DISC1 silenced cells, are also well-known targets of 
GSK3β such CRMP-2, MAP1B and LIS-1. As has been described DISC1 binds to 
GSK3β inhibiting it, but when the binding is disrupted the kinase is able to 
phosphorylate a number of substrates. As has been noted, according to the data 
obtained in the present study, knock-down of DISC1 seems to produce the 
deregulation of GSK3β activity. In this regard, DISC1 might be regulating once again 
the activity of the proteins mentioned above through modulation of GSK3β.   
 
 
2.3. DISC1 regulates proper SH-SY5Y differentiation into 
neuron-like cells upon retinoic acid treatment 
 
As has been noted, morphological changes have been observed in SH-SY5Y cells in 
which DISC1 had been silenced upon retinoic acid (RA) treatment (Figure 19). RA is 
commonly used for differentiation of SH-SY5Y neuroblastoma cells into post-mitotic 
neuronal-like cells. This transformation is due to the activation of the extrusion of 
neurites and the expression of neuronal proteins such as tau, β-amyloid or 
transglutaminase. In the present study, knock-down of DISC1 was found to produce a 
clear deficit in neurite outgrowth in RA-treated cells SH-SY5Y, indicated by a 
reduction of the number and the size of neurites. This result agrees to that reported 
by Pletnikov and coworkers in mouse model overexpressing mutant form of human 
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DISC1 (CaMK-DN) in which impairment of neurite outgrowth was observed [107]. 
Additionally, DISC1 overexpression in PC12 cells was also found to clearly enhance 
neurite outgrowth [51].  
 
Of note, as has been previously described, several proteins involved in neurite 
outgrowth were found differentially regulated in DISC1 knock-down neurons. Thus, it 
cannot be excluded that the deregulation of CRMP proteins, MAP1B, 14-3-3ε, LIS-1, 
stathmin or Septin-5 might be also contributing to the observed deficit in neurite 
outgrowth in DISC1 silenced SH-SY5Y cells upon RA treatment.  
 
Remarkably, another of the effects of RA treatment in SH-SY5Y cells is the increase 
of the transcription of TrkB, receptor for BDNF [196]. As a consequence, this 
treatment makes these cells responsive to BDNF and increases the activation of the 
PI3K/AKT pathway.  In fact, the inhibition of this pathway was found to impair neurite 
outgrowth in such cell line even in presence of RA [197]. As has been described, 
DISC1 knock-down was found to result in a solid decrease in the activity of this 
pathway not only in SH-SY5Y cells but also in primary neurons. Once again, it is not 
unreasonable to think that the effect of DISC1 on neurite outgrowth is at least partially 
mediated through VGF. In fact, it must be taken into account that, although VGF has 
been described to be induced by BDNF, the induction has also been shown to occur 
in the opposite direction. Hence, VGF-derived peptide TLQP-62 was demonstrated to 
produce antidepressant-like effects by increasing BDNF expression [146]. This 
demonstrated the existence of a regulatory loop between these two molecules and 
supports DISC1 as an important factor maintaining appropriate VGF levels in neurons 
for the correct function of this circuitry.  
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- DISC1 knock-down produces an important downregulation of the levels of the 
neuropeptide precursor VGF in primary cortical and hippocampal mouse 
neurons confirming the results obtained in SH-SY5Y cells.  
 
- DISC1 knock-down in neurons leads to a drop in the activation of the 
PI3K/AKT/CREB that explains the decrease of VGF levels in a BDNF- 
independent manner.  
 
- DISC1 regulates the levels of Grb2 in SH-SY5Y cells, an essential element 
for PI3K activation and the subsequent signalling route, but DISC1 knock-
down does not affect Grb2 total levels in primary mouse neurons. 
 
- DISC1 might be modulating also the expression of VGF also through the 
regulation of the activity of PDE4.  
 
- The knock-down of DISC1 produces changes in the quantity and 
phosphorylation of GSK3β in primary mouse neurons suggesting the 
deregulation of the activity of the kinase.  
 
- GSK3β inhibition does not produce any change in VGF protein levels 
indicating that DISC1 is not likely to regulate VGF expression via GSK3β.  
 
- Proteomic study revealed for the first time that DISC1 knock-down in neurons 
produces changes in the levels of a number of DISC1 binding proteins.  
 
- Among the differentially regulated spots in the proteomic study, twelve unique 
spots correspond to proteins related to neurodevelopmental processes and 
twelve unique proteins related to synaptic function. Additionally seven 
proteins have shared functions.   
 
- DISC1 knock-down produces a deficit in the neurite outgrowth in SH-SY5Y 
cells treated with retinoic acid. 
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Proteins identified through proteomic analysis of primary neurons: All the proteins had a fold change 
>2 and p value <0.05. Fold change in red indicates that the protein is upregulated in DISC1 silenced cells, 
while fold change in black indicates a downregulation in DISC1 silenced cells. 
 
Protein Spot Funtion Binding 
partner DISC1 
Fold 
change 
P Value 
Dihydropyrimidinase-
related protein 5 
(CRMP-5) 
(DPYL5_MOUSE) 
 
58, Neuronal 
differentiation 
Neurite 
outgrowth 
Synaptic function. 
Not 
described 
2.59, 3.066x10
-5
 
Dihydropyrimidinase-
related protein 3 
(CRMP-3) 
(DPYL3_MOUSE) 
734, 
1168 
Neurite 
outgrowth 
Neural migration 
Not 
described 
3.12, 
2.23 
1.469x10
-4
 
2.894x10
-4
 
Dihydropyrimidinase-
relatedprotein 2 
(CRMP-2) 
(DPYL2_MOUSE) 
80, 
175 
Neurite 
outgrowth 
Neural migration 
Synaptic function 
Not 
described 
2.21, 
2.03 
2.457x10
-4
 
0.059 
Dihydropyrimidinase-
related protein 1 
(CRMP-1) 
(DPYL1_MOUSE) 
376 Neurite 
outgrowth 
Neural migration 
Not 
described 
2.10 9.180x10
-5
 
Tubulin alpha-1A chain 
TBA1A_MOUSE 
 
336, 
563, 
853 
Neurite outgrowth 
Neural migration 
 
Not 
described 
2.01, 
2.99, 
2.13 
0.0043 
1.326x10
-4
 
4.067x10
-4
 
Tubulin beta-2B chain 
(TBB2B_MOUSE) 
1291, 
1669 
Neurite outgrowth 
Neural migration 
Not 
described 
Inf, 
2.42 
0.0065 
0.0156 
Microtubule-associated 
protein 
(MAP1B_MOUSE) 
453, 
1213, 
1596 
Neurite outgrowth 
Synaptic maturation 
Autophagy 
Yes 2.04,  
2.20, 
3.03 
3.661x10
-7
 
2.894x10
-4
 
2.717x10
-5
 
14-3-3 protein épsilon 
(14-3-3ε) 
(1433E_MOUSE) 
676, 
972 
Neurite outgrowth Yes 2.67, 
3.19 
6.713x10
-5
 
1.854x10
-4
 
14-3-3 protein zeta/delta 
(14-3-3θ/Δ) 
(1433Z_MOUSE) 
169, 239, 
599, 
933, 943, 
1388, 
1404, 
601 
Neurite 
outgrowth 
Not 
described 
8.42, 
2.63, 
3.26, 
3.88, 
3.89, 
6.81, 
3.028x10
-6
 
2.334x10
-4
 
1.579x10
-4
 
9.307x10
-4 
0.021 
2.080x10
-5
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3.82, 
6.20 
0.0022 
2.572x10
-6
 
14-3-3 protein gamma 
(14-3-3γ) 
(1433G_MOUSE) 
286, 
2490 
 
Neurite 
outgrowth 
Yes 3.24, 
2.30 
6.104x10
-5
 
0.0084 
Platelet-activating factor 
acetylhydrolase IB 
subunit beta 
(Lis-1) 
(PA1B2_MOUSE) 
686 Neurite outgrowth Yes 2.48 0.0049 
Hydroxymethylglutaryl-
CoA synthase, 
cytoplasmic 
(HMCS1_MOUSE) 
327 Related 
with GSK3beta 
 
Not 
described 
2.28 0.0036 
Transitional 
endoplasmic 
Reticulum ATPase 
(TERA_MOUSE) 
 
240 Synaptic regulation 
Associates with 
clathrin 
Autophagy 
Not 
described 
2.21 5.537x10
-4
 
Stathmin 
(STMN1_MOUSE) 
829, 
828 
Neurite outgrowth 
Synaptic function 
Not 
described 
2.12, 
4.64 
8.206x10
-4 
1.021x10
-4
 
Protein SET 
(SET_MOUSE) 
 
214 Inhibits CREBBP 
(protein that 
enhacespCREB 
activity) 
Apoptosis 
Not 
described 
2.11 0.0026 
Phosphoglycerate 
mutase 1 
(PGAM1_MOUSE) 
437  Not 
described 
2.22 0.0124 
Gamma-enolase 
(ENOG_MOUSE) 
444 Neurotrophic and 
neuroprotective 
protein 
Not described 2.60 7.966x10
-4
 
Syntaxin-binding protein 
1 
(STXB1_MOUSE) 
460 Regulates synaptic 
vesicle transport 
Neurotransmission 
Not described 3.43 0.0010 
Syntaxin-7 
(STX7_MOUSE) 
812 Forms part of the 
SNARE complex 
Synaptic transport/ 
function 
Not described 2.13 0.0022 
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Neurite outgrowth 
Tropomyosin alpha-3 
chain 
(TPM3_MOUSE) 
470 Neurite 
outgrowth 
Neural migration 
Not 
described 
2.88 0.0115 
Actin, cytoplasmic 2 
(ACTG_MOUSE) 
485, 
1312 
Neurite 
outgrowth 
Neural migration 
Not 
described 
4.94, 
2.95 
4.398x10
-5
 
1.081x10
-5
 
Ras-related protein Rab-
1A 
(RAB1A_MOUSE) 
585 Transport from ER to 
AG 
Synaptic function 
Not described 2.01 0.0023 
Ras-related protein Rab-
2A 
(RAB2A_MOUSE) 
823 Transport from ER to 
AG 
Synaptic function 
Not described 2.43 4.164x10
-4
 
Ras-related protein Rab-
11B 
(RB11B_MOUSE) 
988 Endosomal trafficking 
Synaptic function 
Not described 3.25 0.0305 
Ras-related protein Rab-
18 
(RAB18_MOUSE) 
2079 Endocytosis/recycling 
Cytokinesis 
Synaptic function 
Not described 3.23 5.527x10
-4
 
Cadherin-13 
(CAD13_MOUSE) 
 
804 Neurite outgrowth 
Neuronal migration 
Synaptic function. 
 
Not described 2.31 0.0108 
Rho GDP-dissociation 
inhibitor 2 
(GDIR2_MOUSE) 
841 Forms a heterodimer 
with Rac1. 
Synapse function 
 
Not described 2.28 1.061x10
-4
 
Heme-binding protein 1 
(HEBP1_MOUSE) 
1118  Not described 2.68 3.224x10
-6
 
Peroxiredoxin-2 
(PRDX2_MOUSE) 
1130,159
4 
Apoptosis Not described 2.44, 
2.16 
2.712x10
-5 
0.0072 
GrpE protein homolog 1, 
mitochondrial 
(GRPE1_MOUSE) 
1253 Mitochondrial function Not described 2.08 3.669x10
-4
 
Phosphatidylethanolami
ne-binding protein 1 
(HCNP) 
(PEBP1_MOUSE) 
1267, 
1495 
Synaptic function 
Inhibits neuropsin 
and RAF1 
 
Not described 3.84, 
6.49 
4.081x10
-4
 
2.377x10
-4
 
Calreticulin 1342 Neurite outgrowth Not described 2.60 0.0088 
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(CALR_MOUSE) Interacts with 
GABARAPsynaptic 
function 
UV excision repair 
protein RAD23 homolog 
(RD23B_MOUSE) 
1384  Not described 2.08 7.334x10
-4
 
Protein disulfide-
isomerase 
(PDIA3_MOUSE) 
1443  Not described 
 
2.66 0.0080 
Protein phosphatase 1G 
(PPM1G_MOUSE) 
1567  Not described 2.70 4.467x10
-4
 
Peroxisomal targeting 
signal 1 receptor 
(PEX5_MOUSE) 
1648  Not described 2.03 8.976x10
-5
 
Adaptin ear-binding 
coat-associated protein 
1 
(NECP1_MOUSE) 
1689 Endocytosis 
Synaptic function 
Not described 2.51 6.028x10
-5
 
Ubiquitin-like modifier-
activating enzyme 1 
(UBA1_MOUSE) 
1698  Not described 2.73 0.0248 
Heterogeneous nuclear 
ribonucleoprotein K 
(HNRPK_MOUSE) 
2536 Pre-mRNA binding 
protein 
Transcriptional 
activator of 13-3-
3sigma 
Not described 2.42 0.0082 
Hemoglobin subunit 
alpha 
(HBA_MOUSE) 
2665  Not described 2.64 0.0085 
Hematological and 
neurological expressed 
1 protein 
(HN1_MOUSE) 
2695  Not described 3.02 1.543x10
-4
 
Septin-5 
(SEPT5_MOUSE) 
2750 Interacts with CRMP 
proteins 
Neurite outgrowth 
Neural migration 
Not described 2.15 0.0034 
Thioredoxin domain-
containing protein 12 
243  Not described 2.28 0.0027 
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(TXD12_MOUSE) 
Apolipoprotein A-I 
(APOA1_MOUSE) 
407 
 
Neurite outgrowth Not described 2.41 9.215x10
-5
 
Neuronal calcium 
sensor 1 
(NCS1_MOUSE) 
2005 Synaptic function 
 
Not described 2.24 9.215x10
-5
 
Heat shock protein HSP 
90-alpha 
(H90B3_MOUSE) 
2041 ATPase cycle and 
chaperone function 
Apoptosis 
Not described 2.44 0.0133 
Cytosolic 10-
formyltetrahydrofolate 
dehydrogenase 
(AL1L1_MOUSE) 
2105  Not described 2.48 1.061x10
-4
 
Dynamin 1 
(DYN1_MOUSE) 
2230 Neurite outgrowth 
Neural migration 
Synaptic function 
Not described 4.33 1.440x10
-4
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In a large Scottish pedigree, disruption of the gene coding for DISC1 clearly segregates withmajor depression,
schizophreniaand relatedmental conditions.Thus, studyofDISC1mayprovideaclue tounderstand thebiology
of major mental illness. A neuropeptide precursor VGF has potent antidepressant effects and has been report-
edly associatedwith bipolar disorder. Here we show that DISC1 knockdown leads to a reduction of VGF, in neu-
rons. VGF is also downregulated in the cortices from sporadic cases with major mental disease. A positive
correlation of VGF single-nucleotide polymorphisms (SNPs) with social anhedonia was also observed.
We now propose that VGF participates in a common pathophysiology of major mental disease.
INTRODUCTION
A neuropeptide precursor VGF is a neuroprotective protein that
is known to regulate neuronal energy metabolism has an
important role in neural processes such as adult neurogenesis,
synaptic plasticity and also harbors an antidepressant-like activ-
ity (1–5). Expression of VGF has been found to be decreased in
leukocytes of patients from major depression and in brains of
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patients affected with bipolar disorder (6,7). With regard to
schizophrenia, data are conflicting: increased concentration of a
VGF-derived peptide has been reported in the cerebrospinal
fluid (CSF) of patients with schizophrenia (8); however, results
from the Stanley Medical Research Institute (SMRI) Genomics
Database showed decreased VGF in prefrontal cortices of schizo-
phrenic patients (6). More recently, reduced density of hypothal-
amic VGF-immunoreactive neurons was detected in brains from
patients with schizophrenia as compared with controls (9).
In a large Scottish pedigree, disruption of the gene coding for
DISC1 clearly segregates with major depression, schizophrenia
and related mental conditions (10). Hence, DISC1 might be used
as a ‘molecular Rosetta stone’ to explore the molecular mechan-
isms underlying mental disease (11), just as rare mutations in the
amyloid precursor protein (APP) and presenilin genes were used
to decipher the molecular underpinnings of Alzheimer’s disease
(12). DISC1 is an intracellular scaffold protein and mediates
multiple roles in neurodevelopment and neurosignaling by
interacting with many molecules, such as Glycogen synthase
kinase-3b (GSK3b), nuclear distribution protein nudE-like
1 (NDEL1), TRAF2 and NCK-interacting protein kinase
(TNIK), Kalirin and cAMP-specific 3′,5′-cyclic phosphodiester-
ase 4B (PDE4B) (11,13). In the Scottish pedigree, loss of
DISC1 function (e.g. dominant-negative and/or haploinsuffi-
ciency) is likely to underlie the pathophysiology of the mental
conditions (14,15). Likewise, many preclinical studies have sup-
ported the views that loss of DISC1 function leads to biological
and circuitry changes relevant to major mental illness (11).
Therefore, in the present study, we initially explored molecu-
lar changes elicited by loss of DISC1 function by utilizing a
proteomic approach: loss of DISC1 leads to a reduction in the
expression of VGF. We also report that VGF is downregulated
in the brains from patients with major mental illness and is
genetically associated with social anhedonia.
RESULTS
Proteomic screening in cells with DISC1 knockdown:
a marked reduction of VGF
We performed an unbiased proteomic study aimed at identifying
proteins directly affected by loss of DISC1 function. SH-SY5Y
cells were initially chosen as a convenient neuronal model.
DISC1 was knocked down by using lentiviral particles carrying
five different shRNAs (Supplementary Material, Fig. S1 and
Table S1). The five shRNA sequences used exhibited different
efficacies: silenced 1 exhibited the highest efficacy, with only
4.3% of DISC1 residual expression, as calculated by real
time-PCR (Supplementary Material, Fig. S1B and Table S2).
Proteomic analysis of control and DISC1-knocked down
SH-SY5Y cells was carried out by using four gels for each con-
dition, analyzed with Redfin Ludesi 3 software (16). Several
spots with fold intensity change ≥2 and P , 0.05 were detected
(to be reported elsewhere), and were excised and subjected to
MALDI analysis after in-gel tryptic digestion. Among these,
14 different spots, most of them located in two different
groups with molecular weights (MWs) 90 and 80 kDa, were
found to correspond to VGF, and were all downregulated with
a fold change between 2 and 11.5 (Fig. 1, Supplementary Mater-
ial, Fig. S2 and Table S3). Considering their similar MW but
different isoelectric points, they might result from different post-
translational modifications, including limited cleavage. To date,
VGF has been detected by western blot analysis as a doublet of
80–90 kDa, even though its predicted molecular weight is
68 kDa and no post-translational modifications have yet been
identified (17). Since recombinant VGF also migrates at this un-
expectedly high position, the behavior has been attributed to the
high content of proline residues in VGF (17). Several short pep-
tides derived from VGF, such as AQEE30, TLQP-21, TLQP-62,
Neuroendocrine Regulatory Peptide-1 (NERP-1) or Neuroendo-
crine Regulatory Peptide-2 (NERP-2) have been described (18).
To our knowledge, however, this is the first time that VGF var-
iants with apparent MWs close to that of full-length VGF are
reported. We are currently investigating whether these corres-
pond to post-translational modifications and/or limited proteo-
lytic trimming of full-length VGF.
DISC1 knockdown leads to a reduction of VGF
expression in primary neurons
Encouraged by the results obtained with SH-SY5Y cells, we pre-
pared murine primary neurons (combined cortical and hippo-
campal neurons). DISC1 was knocked down by using three
different shRNAs, introduced through lentiviral particles
(Fig. 2A). The DISC1 RNAi #1 construct was chosen for these
experiments because it has been used previously (19), resulting
in 85% DISC1 downregulation (Fig. 2B and C). Non-specific
effects of the infection on DISC1 expression were ruled out by
lack of differences between untreated cells and cells treated
with viral particles carrying control sequences (Supplementary
Material, Fig. S3).
Knockdown of DISC1 led to a 75% drop in the levels of
VGF (Fig. 2B and D), a result that was reproducibly obtained
with all three constructs used to silence DISC1 (Fig. 2A), in
agreement with results obtained with SH-SY5Y cells. The
very substantial downregulation of VGF produced in all the
DISC1 silencing conditions suggests that these results are not
due to a specific effect produced in a particular cell line.
To validate further the specificity of DISC1-induced regula-
tion of VGF expression, a conditional stable cell line where full-
length non-mutant human DISC1 was inducibly overexpressed
(by addition of 1 mg/ml doxycycline) was generated. VGF was
upregulated in this line with respect to control cells (Supplemen-
tary Material, Fig. S4).
We also examined changes of molecules associated with
DISC1signaling,when VGFdownregulationoccurred in response
to DISC1 knockdown (Supplementary Material, Fig. S5). We
observed downregulation of the expression of phosphorylated
AKT and CREB, while the expression of phosphoERK and
Brain derived neurotrophic factor (BDNF) remained unchanged
in the DISC1 knocked down cells.
Reduction of VGF in brains from patients with major
mental illnesses
Decreased levels of VGF mRNA have been previously described
in hippocampus and prefrontal cortex regions of human bipolar
postmortem brains (6). Given that loss of DISC1 function is asso-
ciated with a wide range of major mental illness, including
schizophrenia, major depression and bipolar disorder (14), we
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measured and compared levels of VGF in cortical tissue of a
group of patients with these disorders compared with those
from normal controls (20). Lower expression of VGF was
found in the group of psychiatric patients (Fig. 3). These lower
levels of VGF expression did not correlate with occurrence of
psychosis, substance abuse, duration of disease, medication or
tissue variables such as pH or postmortem interval (Supplemen-
tary Material, Table S4). Only a gender correlation was observed
and females showed significantly decreased VGF levels, inde-
pendent of illness or diagnosis (Supplementary Material,
Table S4 and Fig. S6).
In the same set of samples, we did not detect differences
in DISC1 expression between patient and control groups
(Supplementary Material, Fig. S7). In these samples we failed to
find correlation between VGF levels and the previously reported
aggregation of DISC1 in a subset of cases with mental disease
(21) (Supplementary Material, Fig. S8). These results indicated
that DISC1 does not contribute as a major driver to the changes
in VGF levels in the sporadic cases in the brain set.
Genetic association of the VGF gene with social anhedonia
Through mining of the existing genetic data we were able to test
for the presence of genetic variation at the VGF genomic locus
that associates with chronic mental illness-related endopheno-
types. To control for the effective number of tests performed
Figure 1.VGF expression in SH-SY5Y cells. (A) 2D gel areas containing most spots corresponding to VGF in representative DISC1 silenced (right) and control (left)
2D-PAGE gels. (B) Volumetric quantification of two representative spots, spot 3382, with a fold-negative change of 11.52, P , 0.0001, and spot 281, with a fold
change of 2.09, P , 0.001. (C) VGF western blot analysis of control and silenced cells. (D) Quantification of data presented in C (n ¼ 6 independent experiments).
Total protein was normalized to tubulin. Error bars represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. ∗∗∗P , 0.001,
∗∗∗∗P , 0.001.
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(n ¼ 15) through this data mining an experiment-wide threshold
of P ¼ 0.0033 was set. Two SNPs, out of the four in the region,
were thus observed to associate significantly with the social anhe-
donia scale (rs1048303 P ¼ 0.0025, beta¼ 20.385; rs734688
P ¼ 0.0019, beta ¼ 20.408) (Fig. 4). Analysis of linkage dis-
equilibrium (LD) over the VGF region demonstrates that both
SNPs could be indicative of the same haplotypic background
(Supplementary Material, Fig. S9); however, the two significant
SNPs arenot within strong LD witheachother, r2 ¼ 0.59 (Supple-
mentary Material, Table S5). No significant association was
observed for either physical anhedonia (PHAS) or golden and
meehl schizodia scale (GM).
In the model including DISC1 as a covariate the observed signi-
ficance increased with social anhedonia (SAS) (Supplementary
Material, Table S6), with the breakdown of individuals depending
on their DISC1 status establishing that VGF plays a significant
role in the variability of these traits when in combination with
risk-modifying factors at the DISC1 locus, this role was further
echoed through the observation of significant association be-
tween PHAS and rs1048303 only in those individuals carrying
DISC1 risk increasing alleles (Supplementary Material, Fig. S10
and Table S6). No interaction effect between VGF and DISC1
was found, demonstrating an additive, rather than epistatic, effect
between these variants (Supplementary Material, Table S7).
DISCUSSION
The main finding of this study is that the neuroprotective VGF
protein is downregulated in the brains from sporadic cases of
Figure2.DISC1and VGF expression in primary neuron cell cultures. (A) DISC1 and VGF expression in neuron cells infectedwith three different shRNAconstructs to
knock-down DISC1. A non-target shRNA was used as control. (B) Expression of DISC1and VGF in cells infected with lentiviral particles containing the construct
‘DISC1 RNAi #1’. (C) Quantification of DISC1 knockdown shown in (B). (D) Quantification of VGF expression shown in B. (C, D): n ¼ 8 independent experiments.
Error bars represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. Data were normalized to tubulin. ∗∗P , 0.01, ∗∗∗∗P , 0.0001.
Figure 3. Expression of VGF in brains of patients with mental disease. (A) Western blot analysis of the SMRI samples [normal controls (N), patients with bipolar
disorder (B), major depression (D) and schizophrenia (S)] (B) Densitometric analysis of the normalized VGF signal of SMRI collection brains. VGF signal intensity
is decreased in patients with psychiatric illnesses (n ¼ 44) compared with normal controls (n ¼ 15); error bars represent SEM. Statistical analysis was carried out by
using unpaired one-tailed Mann–Whitney U-test; P ¼ 0.031) (B: bipolar disorder/D: major depression/ S: schizophrenic patients)
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major mental illness. Reduction of VGF was also observed upon
DISC1 knockdown. We also observed that VGF is genetically
associated with social anhedonia, an endophenotype that under-
lies a wide range of major mental illness.
Diagnostic and Statistical Manual of Mental Disorders or
International Statistical Classification of Diseases (ICD)-based
diagnostic classification is based on good reliability and clinical
utility, whereas biological validity is not fully considered by def-
inition. As a result, it is reasonable that no clear-cut correlation of
one molecular trait with one single diagnosis is seen. Likewise,
in the Scottish pedigree, the same mutation (disruption ofDISC1
gene) leads to mental conditions labeled with different diagnoses
(such as schizophrenia, bipolar disorder and major depression) in
the family members. This perspective matches the efforts in
the Research Domain Criteria from the NIH, which focuses on
specific domains (e.g. cognition and motivation) associated
with specific neural circuitry (e.g. that involving the prefrontal
cortex) and molecular markers, instead of focusing on a specific
disease diagnosis. In the present study, reduction of VGF may be
associated with social anhedonia, which underlies a wide range
of major mental illness, including schizophrenia, bipolar dis-
order and major depression.
We used DISC1 as an entry point or an initial lead or driver for
research to elucidate an important cascade that might be relevant
to the pathophysiology of mental conditions. As a result of
DISC1 knockdown we found a reduction of VGF expression.
The reduction of VGF was also observed in the brains of ‘spor-
adic’ cases with major mental illness. Thus, it is reasonable to
conceive that multiple types of etiologies may contribute to
‘common’ downstream pathophysiology (that is, in this case, a
reduction of VGF). Very mild or even negligible contribution
of DISC1 to the VGF change in the brain samples is consistent
with this notion. There is precedence that depicts a similar
relationship of multiple etiologies and common downstream
pathophysiology in mental condition (22): a mouse model repre-
senting a condition of human 22q11 deletion frequently asso-
ciated with major mental illness displays disturbance of
CXCR4/CXCL12 signaling and interneuron deficits. In olfac-
tory neuronal cells from ‘sporadic’ cases with schizophrenia, a
reduction of CXCL12 is observed without any change in the
key driver in the 22q11 locus. Therefore, the present study sup-
ports the working hypothesis, also defended in other studies, that
although the etiologies of mental disease are diverse, they may
converge in some common pathophysiologies.
MATERIALS ANDMETHODS
Cell culture
SH-SY5Y (European Collection of Cell Cultures, Salisbury,
UK) were maintained in 1:1 Earle’s balanced salt solution-
F12HAM (Sigma-Aldrich, Germany) with 15% fetal bovine
serum (FBS) (Gibco, Life Technologies, Gaithersburg, MD,
USA), 1% Glutamine (Gln) (Sigma-Aldrich), 1% non-essential
amino acids (NEAA) (Sigma-Aldrich), 1% Penicillin–Strepto-
mycin (P/S) (Invitrogen, Carlsbad, CA, USA). 293FT cells
(Invitrogen) were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Sigma-Aldrich) with 10% FBS, 1%
sodium pyruvate (Invitrogen), 1% NEAA, 1% Gln and 1% P/S.
An inducible human full length DISC1 SH-SY5Y cell line
was generated by expression of non-mutant DISC1 in the
tet-on retroTIGHT (Invitrogen) retroviral expression system.
DISC1 expression was induced by adding doxycycline to the
medium at a final concentration of 1 mg/ml.
Control and DISC1 knocked down SH-SY5Y stable cell lines
were generated by expression of PLK0.1-Puro-CMV shRNA
plasmids (Sigma-Aldrich) through lentiviral expression system
(Sigma-Aldrich). The cells that expressed the constructs were
selected after puromycin (Sigma-Aldrich) treatment (3 mg/ml)
Murine cortex and hippocampal primary neurons were pre-
pared from 14 to 15 day embryos. Pregnant dams were eutha-
nized by cervical dislocation in accordance with institutional
guidelines for care and use of animals. The embryos were dis-
sected in PBS Ca/Mg (Invitrogen) supplemented with 33 mM
glucose. Pooled tissue was mechanically triturated, treated with
trypsin (Invitrogen) and DNaseI (Roche Applied Science, Mann-
heim, Germany), and resuspended in Neurobasal medium (Invi-
trogen) supplemented with 50× B27 (Invitrogen), 0.55 g/
100 ml glucose (Sigma-Aldrich), 42 mg/100 ml sodium bicar-
bonate (Sigma-Aldrich), 1% P/S and 1% glutamine. The cells
were plated on poly-D-lysine-coated Petri dishes. Cultures were
maintained in serum-free medium at 378C in 95% air/5% CO2.
DISC1 knockdown
DISC1 was silenced in SH-SY5Y cells using Missionw shRNA
lentiviral transduction particles (Sigma-Aldrich, reference
NM_018662) containing five alternative PLK0.1-Puro-CMV
shRNA plasmids (Supplementary Material, Fig. S1 and Table S1).
Missionw pLKO.1-puro non-mammalian shRNA particles (ref-
erence: SHC002V) were used as control. For DISC1 knock-
down in primary neurons, lentiviruses were produced by
calcium phosphate co-transfection of the shRNA constructs
(DISC1 RNAi #1, Silenced N2, Silenced N3) (see Supplemen-
tary Material, Table S8) and the helper constructs VSVG and
DR8.9 into 293FT packaging cells; virus-containing medium
was collected 48 h after transfection, and added (10 ml of lenti-
viral solution/3 × 106 neurons) to the medium of primary
neurons at 7 DIV. The medium was changed 24 h after infection,
and incubation was continued for 72 h.
Protein extraction and western blot analysis
Cells were solubilized in lysis buffer (20 mM 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM
ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol
Figure4.Average performance on the social anhedonia scale for: (A) each geno-
type of SNP rs1048303; (B) each genotype of SNP rs734688. Graphs show
the mean scores for the logarithmically transformed scales of the Revised
Social Anhedonia Scale. 95% Confidence intervals are shown.
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(DTT), 1 mM sodium orthovanadate, 1% Triton X-100, 10% gly-
cerol, 2 mM leupeptine, 400 mM phenylmethanesulfonylfluor-
ide (PMSF), 50 mM b-glycerophosphate, 100 mg/ml trasylol).
Protein content was determined by using the BCA protein
assay kit (Pierce Chemical, Rockford, IL, USA). Samples were
subjected to SDS-PAGE and western blotting as described in
Supplementary Methods. Antibodies used are described in Sup-
plementary Material, Table S9. Protein band intensities were
evaluated with Image J 10.2 software (National Institutes of
Health, USA). All blots shown are representative of multiple
independent experiments.
Proteomic studies
Proteomic analysis of cell lysates was performed by using high-
resolution two-dimensional gel electrophoresis (2-DE) and
Matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS) analysis of selected protein spots. A detailed de-
scription is available in the Supplementary Material.
Expression of VGF in brains from patients affected by
schizophrenia, bipolar disorder, and major depression
Frozen BA6 cortical tissues from the Consortium Collection
were obtained from the SMRI (Baltimore, MD) by C. K. (20).
Tissue was homogenized in ice-cold 10% VRL buffer consisting
of 50 mM HEPES pH 7.5, 250 mM sucrose, 100 mM KAc, 5 mM
MgCl2 and protease inhibitor (Roche Applied Science). Homo-
genates (2.5%) were subjected to SDS-PAGE, blotted on 0.2 mm
nitrocellulose membrane (Whatman, Schleicher & Schuell,
Germany), and probed with a VGF antibody sc-10383 (Santa
Cruz Biotechnology Inc., CA, USA). Samples were randomized
and run blind in several blots (15 samples in the same blot) and
for normalization, blots were incubated with a GAPDH anti-
body. Densitometric analysis was performed with ImageJ 10.2
software. Band intensities of VGF signal were normalized to
GAPDH signal.
Statistical analysis
Statistical analysis was performed with the IBM SPSS Statistic
20 package. For analysis of VGF in the SMRI samples, control
brains were compared with brains of psychiatric patients by
using a one-tailed unpaired Mann–Whitney U-test.
Genetic association of VGF with endophenotypes
of the schizophrenia continuum
The genetic methods used here are described in detail in Supple-
mentary methods. Briefly, we mined pre-existing genome-wide
association data from studies of the Northern Finland Birth
Cohort from 1966 (NFBC66) relating to scales derived from a
psychometric questionnaire (23). To study the VGF gene
region, 4 SNPs genotyped as part of the GWAS study were iden-
tified from a region 10 kb upstream to 10 kb downstream
of VGF. Their SNP P-values for the three endophenotypes
were extracted from the data from previous studies, includ-
ing results from the analyses of (SAS) and (PHAS) condi-
tioned on previously identified DISC1 risk-modulating
variants. Association analysis had been performed by using
PLINK (version 1.05) (24), and its additive linear regression
model.
In order to distinguish between significant association and
false discovery at the candidate gene level, multiple test correc-
tion was performed. The SNP spectral decomposition method
was used, for multiple test correction, (25) with modifications
by Li and Ji (26) to determine the effective number of independ-
ent marker loci (Meff) (n ¼ 3). In addition to the number of
markers, three variables were studied, and two of these measures
were further analyzed in conjunction with DISC1. Although
these measures and models are not completely independent of
each other, we have included them in our multiple test correction
in order to provide a conservative threshold for significance.
Thus, the experiment-wide significance threshold required to
keep type I error rate at 5% is P ¼ 0.05/15 ¼ 0.0033. To study
how the pattern of associations related to each other and the
VGF gene, haplotype blocks of LD were determined by using
the HapMap CEU data according to the solid spine of LD criteria
in the haploview program (27,28).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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Title: Proteomic studies reveal Disrupted in Schizophrenia 1 as a key regulator unifying 
neurodevelopment and synaptic function 
 
ABSTRACT 
A balanced chromosomal translocation of the Disrupted in Schizophrenia 1 (DISC1) gene in a 
large Scottish pedigree is linked to major depression, bipolar disorder and schizophrenia, cutting 
through classic diagnostic categories. Even though many DISC1-interacting molecules are 
known, suggesting its role as a scaffold protein, consequences of DISC1 knockdown on the 
cellular proteome of primary neurons, which might indicate the most relevant pathways 
regulated by DISC1, are lacking. Using an unbiased proteomic approach, we show that 
expression of 31 proteins related to neurodevelopment (e.g. CRMP-2, stathmin) and synaptic 
function (e.g. MUNC-18, NCS-1) is regulated by DISC1 in primary mouse neurons. Hence, this 
study reinforces the idea that DISC1 is a unifying regulator of both neurodevelopment and adult 
synaptic function, thereby providing a link between these two key anatomical and cellular 
circuitries. To date schizophrenia is known to be a neurodevelopmental disease in which the 
most critical lesions occur during early development. The present study emphasizes the 
importance of synaptic changes, a notion that is also supported by other recent reports. These 
data also lend support to a multifactorial origin of these illnesses in which several processes, 
both during neurodevelopment but also during adulthood, are deregulated. 
 
INTRODUCTION 
Disrupted in Schizophrenia 1 (DISC1) is a susceptibility gene for major mental illness. DISC1 
was found mutated when studying a chromosomal translocation t(1;11)(q42.1;q14.3) in a 
Scottish family in which it correlates with cases of schizophrenia, bipolar disorder and major 
depression (St Clair et al. 1990). Truncation of this gene was also described in an American 
family that presented cases of schizophrenia (Sachs et al. 2005).  
A number of yeast two hybrid experiments demonstrated that DISC1 interacts with many 
proteins (Camargo et al. 2007). Moreover, other studies revealed that DISC1 has several 
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important interaction partners, including GSK3β (Mao et al. 2009), PDE4B (Millar et al. 2005), 
Rac1 (Hayashi-Takagi et al. 2010), Girdin (Enomoto et al. 2009) and TNIK (Wang et al. 2011), 
among others. Thus, DISC1 might act as a scaffold in different pathways. To date, DISC1 has 
been shown to take part in many processes, including neurogenesis (Mao et al. 2009; Kim et al. 
2012), synapse regulation (Hayashi-Takagi et al. 2010; Wang et al. 2011; Lepagnol-Bestel et al. 
2013; Zhou et al. 2013), neurite outgrowth (Lepagnol-Bestel et al. 2013; Wen et al. 2014), 
neural migration (Namba et al. 2011; Kamiya et al. 2005), and proliferation and differentiation 
in adult and developing brains. This suggests that DISC1 is an important regulator in neurons.  
So far, functional consequences of DISC1 knockdown in primary cells that would highlight 
specific DISC1-regulated proteins in the wide range of DISC1 interactors are lacking. In order 
to acquire a deeper understanding of the mechanisms of action of DISC1, we carried out an 
unbiased global proteomic analysis of DISC1-silenced neurons, in order to identify proteins 
regulated by DISC1. 
We report that DISC1 regulates the expression of many relevant proteins related to 
neurodevelopment and synaptic function, suggesting that DISC1 is a molecular link bridging 
neurodevelopmental functions with the regulation of synaptic formation and neurosignaling 
processes. 
 
MATERIALS AND METHODS 
Antibodies 
Commercial antibodies specific for the following proteins were used: CRMP-2, 
p(Thr514)CRMP-2, Stathmin, p(Ser38)Stathmin (1: 1000; Cell Signaling Technology, Danvers, 
MA, USA); tubulin, GAPDH (1:5000; Sigma-Aldrich, St. Louis, MO, USA); the human 
DISC1-specific antibody 14F2 has been previously described(Ottis et al. 2011); the mouse 
DISC1-specific antibody D27 was a kind gift from Merck (New Jersey, USA). Goat anti-rabbit 
(1:2000; DakoCytomation, Glosstrup, Denmark), sheep anti-mouse (1:5000; GE Healthcare 
Amersham Bioscience, Uppsala, Sweden) and donkey anti-goat (1:2000; Santa Cruz 
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Biotechnologies, CA, USA) were used as secondary antibodies. Dilutions are indicated in Table 
S1 in Supplement 1. 
 
Cell culture 
SH-SY5Y neuroblastoma cells (European Collection of Cell Cultures, Salisbury, UK) were 
maintained in 1:1 Earle’s Balanced Salt Solution (EBSS)- F12HAM  (Sigma Aldrich) with 15% 
fetal bovine serum (FBS) (Gibco, Life Technologies, Gaithesburg, MD), 1% Glutamine (Gln) 
(Sigma Aldrich), 1% non-essential amino acids (NEAA) (Sigma Aldrich), and 1% Penicilin-
Streptomycin (P/S) (Invitrogen). 293FT cells (Invitrogen) were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma Aldrich) with 10% FBS, 1% sodium pyruvate 
(Sigma Aldrich), 1% NEAA, 1% Gln, and 1% P/S.  
Murine cortex and hippocampal primary neurons were prepared from 14-15 day embryos. 
Pregnant dams were killed by cervical dislocation in accordance with institutional guidelines for 
care and use of animals. The embryos were maintained and dissected in PBS Ca/Mg 
(Invitrogen) supplemented with 33 mM glucose. Pooled tissue was mechanically triturated, 
treated with trypsin (Invitrogen) and DNaseI (Roche Applied Science, Mannheim, Germany) 
and resuspended in Neurobasal medium (Invitrogen) supplemented with 50X B27 (Invitrogen), 
0.55g/100ml glucose (Sigma Aldrich), 42 mg/100 ml sodium bicarbonate (Sigma Aldrich), 1% 
P/S and 1% glutamine. The cells were plated on poly-D-lysine (Sigma Aldrich) coated Petri 
dishes. Cultures were maintained in serum free medium at 37ºC in 95% air/5% CO2. 
 
DISC1 silencing 
DISC1 was silenced in SH-SY5Y cells using commercial Mission® shRNAlentiviral 
transduction particles (Sigma Aldrich, reference NM_018662) containing two alternative 
PLK0.1-Puro-CMV shRNA plasmids (Figure S1 and Table S1 in Supporting Information). 
Mission® pLKO.1-puro non-mammalian shRNA particles (reference: SHC002V) were used as 
control. For DISC1 knock-down in primary neurons, lentiviruses were produced by calcium 
phosphate co-transfection of the shRNA construct DISC1 RNAi #1 (see Table S2 and Figure S2 
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in Supporting Information) and the helper constructs VSVG and ΔR8.9 into 293FT packaging 
cells; virus-containing medium was collected 48h after transfection, and added (10 ml of 
lentiviral solution/ 3x10
6
 neurons) to the medium of primary neurons at 7 DIV. The medium 
was changed 24 h after infection, and incubation continued for 72 h. 
 
Sample preparation for proteomic studies 
Cells (confluent 100 mm plates) were washed twice with cold PBS and solubilized in lysis 
buffer (20 mM HEPES, 2mM EGTA, 1mM DTT, 1mM sodium orthovanadate, 1% Triton X-
100, 10% Glycerol, 2 M leupeptin, 400 M PMSF, 50 M β-glycerophosphate, 100 µg/ml 
trasylol). The cells were scraped on ice for 10 minutes, incubated on ice for 30 minutes with 
periodic vortexing every 5 minutes and centrifuged for 20 minutes at 14000 g, 4ºC. The 
supernatant was saved and the pellet discarded. The protein content was determined using the 
BCA protein assay kit (Pierce Chemical). Proteins were precipitated with 60% trichloroacetic 
acid (TCA) in acetone. Following  a couple of acetone washes, proteins were dissolved in 500 
μl of 2D sample buffer (5 M urea, 2 M thiourea, 2 mM tributyl-phosphine, 65 mM DTT, 65 mM 
CHAPS, 0.15 M NDSB-256, 1 mM sodium vanadate, 0.1 mM sodium fluoride, and 1 mM 
benzamidine). Ampholytes (Servalyte 4-7) were added to the sample to a final concentration of 
1.6 % (v/v).  
 
Proteomic studies  
Primary neuron cell lysates were subjected to two-dimensional gel electrophoresis (2-DE). 
Protein quantitation was performed with the Coomassie plus protein reagent (Thermo Scientific, 
Asheville, NC). Five hundred micrograms of protein were loaded onto each gel to allow 
detection of low abundant proteins. Four gels per study group (DISC1 knock-down and control) 
were compared. Immobilized pH gradient (IPG) strips (4-7, 24 cm, GE Healthcare,Uppsala, 
Sweden) were rehydrated in the sample, and isoelectric focusing (IEF) was performed in a 
Multiphor (GE Healthcare) for 85 kVh at 17ºC. Following focusing, the IPG strips were 
immediately equilibrated for 15 min in 4 M urea, 2 M thiourea, 130 mM DTT, 50 mMTris pH 
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6.8, 2% w/v SDS, 30% v/v glycerol. Later, the strips were placed during 15 minutes in the same 
buffer, in which DTT was replaced by 4.5% iodoacetamide (Sigma Aldrich). The IPG strips 
were placed on top of the second dimension gels and embedded with 0.5% melted agarose. 
Proteins were separated in the second dimension by SDS-polyacrylamide gel electrophoresis 
(PAGE) on 10% gels at run conditions of 10ºC, 20 mA per gel for 1 h, followed by 40 mA per 
gel for 4 h by using an EttanDalt 6 system (GE Healthcare). Following electrophoresis, gels 
were fixed in 10% methanol/7% acetic acid for 1 hour, and stained overnight with Sypro Ruby 
fluorescent dye (Lonza, Switzerland). After staining, gels were washed for 1 hour in 10% 
methanol/7% acetic acid, and scanned in a Typhoon 9410 (GE Healthcare). 
 
Differential image analysis 
Image analysis was performed with the Ludesi REDFIN 3 Solo software (Ludesi, Malmö, 
Sweden). The integrated intensity of each of the spots was measured, and the background 
corrected and normalized. Differential expression of proteins was defined on the basis of ≥2-
fold change between group averages and p<0.05. 
 
Mass Spectrometric Analysis 
Spots of interest were carefully excised and subjected to in-gel digestion with trypsin 
(Shevchenko et al. 1996). Tryptic digests were analyzed using a 4800 MALDI-TOF/TOF 
analyzer (Applied Biosystems). Dried peptides were dissolved in 4 µL of 0.5% formic acid.  
Equal volumes (0.5 µL) of peptide and matrix solution, consisting of 3 mg alpha-cyano-4-
hydroxycinnamic acid (α-CHCA) dissolved in 1 mL of 50% acetonitrile in 0.1% trifluoroacetic 
acid, were deposited using the thin layer method, onto a 384 Opti-TOF MALDI plate (Applied 
Biosystems). MS spectra were acquired in reflectron positive-ion mode with a Nd:YAG, 355 
nm wavelength laser, averaging 1000 laser shots and using at least three trypsin autolysis peaks 
as internal calibration.  All MS/MS spectra were performed by selecting the precursors with a 
relative resolution of 300 (FWHM) and metastable suppression.  Automated analysis of mass 
data was achieved by using the 4000 Series Explorer Software V3.5.  MS and MS/MS spectra 
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data were combined through the GPS Explorer Software v3.6. Database search was performed 
with the Mascot v2.1 search tool (Matrix Science, London, UK) screening SwissProt (release 
56.0). Searches were restricted to mouse taxonomy allowing carbamidomethyl cysteine as a 
fixed modification and oxidized methionine as potential variable modification. Both the 
precursor mass tolerance and the MS/MS tolerance were set at 30 ppm and 0.35 Da, 
respectively, allowing 1 missed tryptic cleavage site. All spectra and database results were 
manually inspected in detail using the above software.  Protein scores greater than 56 were 
accepted as statistically significant (P< 0.05), considering positive the identification when 
protein score CI (confidence interval) was above 98%. In case of MS/MS spectra, total ion score 
CI was above 95%. 
 
SDS-PAGE and Western Blotting 
50 µg of protein was mixed with the Laemmli sample buffer (BioRad), heated at 100ºC for 10 
minutes, spun, and the supernatant loaded on a 7.5% SDS-PAGE gel. Samples were subjected 
electrophoresis and transferred to polyvinyllidenedifluoride (PVDF) membranes (Millipore, 
Bedford, MA). The conditions of the electrophoresis were 200V, 1h. Electrophoresis was 
performed using a Mini-PROTEAN 3 cell electrophoresis system (BioRad). The transfer was 
performed in a Trans-blot SD semi-dry transfer cell (BioRad) using the following conditions: 
0.8mA/cm
2
, 90 minutes. The PVDF membranes were blocked in 5% non-fat milk in PBS-0.1% 
Tween solution overnight at 4°C, then 4 washes of 5 minutes with PBS-0.1%Tween20 were 
performed, and the membrane was incubated with the primary antiserum (in 5% BSA in PBS-
0.1%Tween20) for 1 hour at room temperature, washed again and incubated with the 
peroxidase-conjugated secondary antibody (in PBS-0.1%Tween20), and subjected to 4 washes 
of 5 minutes each with PBS-0.1%Tween20. Finally the membrane was incubated with the 
chemiluminescence solution Luminata Forte Western HRP substrate (Merck Millipore). To 
develop the membranes Hypercassette (GE Healthcare) and Amersham Hyperfilm ECL (GE 
Healthcare) were used.  
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2D Wetern blotting 
The protocol used is the same that was used for the proteomic studies with minor differences: 
7cm pH 4-7 IPG strips were used and 50 µg of protein were loaded. 8x8 cm commercial 4-12% 
Bis-TrisNuPAGEgels (Life Technologies) were used for the second dimension with MOPS 
running buffer (0.25 M Tris BASE, 1.92 M Glycine, 1% (w/v) SDS) were used. Second 
dimension was performed with constant voltage of 120V for 1h and 45 min. Following, 2-DE 
proteins were transferred to a PVDF membrane. Immunodetections were performed as indicated 
above. 
 
Ingenuity pathway  
Ingenuity Pathway Analysis software (Ingenuity Systems, CA) was used to investigate 
interactions between all the identified proteins. Interactive pathways were generated to observe 
potential direct and indirect relations among the differentially expressed proteins.  
 
Neurite outgrowth assays 
Stable SH-SY5Y cell lines generated using TRCN0000118997 (Silenced 1), TRCN0000119000 
(Silenced 4) and non-target shRNAs were cultured for 7 and 14 days in medium containing 10 
µM retinoic acid (RA) (Sigma Aldrich). To analyse neurite outgrowth, images of live cells were 
taken under a microscope and processed using ImageJ software (http://rsb.info.nih.gov/ij). Cells 
with and without neurites longer than two cell bodies were counted in photomicrographs of the 
differentiated control and DISC1-silenced cells. 
 
Immunocytochemistry of SH-SY5Y cells 
Retinoic acid-differentiated cells were fixed in paraformaldehyde and immunostained for β3-
tubulin and nuclei were visualized using DAPI, as previously described (Castaño et al. 2010). 
 
 
 
Ramos et al. 
 
10 
 
Statistical analysis  
In the proteomic analysis, to determine statistically significant differences between groups of 
samples One-way ANOVA (“Analysis of Variance”) was employed. For each spot ID, ANOVA 
p-value was calculated using the quantified and normalized spots volumes for the matched spot 
in each of the images. Differential expression of proteins was defined on the basis of ≥2-fold 
change between group averages and p<0.05 
In the neurite outgrowth assay, three fields of up to 100 cells were analyzed for each condition 
and the experiment was performed twice. Statistical analysis was performed using a non-
parametric unpaired Mann-Whitney U-test (two-tailed); results were considered significant with 
p < 0.05. 
 
RESULTS 
Proteomic analysis  
Cell extracts from control and DISC1 knockdown murine primary neurons were subjected to 
proteomic analysis. Four gels for the silenced condition versus four gels of the control condition 
were analyzed. The software detected 3474 spots per gel. One representative gel is shown in 
Figure S3 in Supporting Information, where the spots that were analyzed are highlighted. 
68 differentially-expressed spots with a fold change ≥2 and p value <0.05 that correspond to 48 
unique proteins were identified using mass spectrometry. The identities of these selected 
proteins are presented in Table S5 and Figure S4 in the supporting information. The majority of 
them are related to neurodevelopmental processes or synaptic function. Remarkably, some have 
been shown in other studies to be DISC1 binding partners. That is the case of the 14-3-3 
proteins (Ozeki et al. 2003) and LIS1 (Taya et al. 2007), while CRMP-2 has been identified as a 
possible DISC1 interactor (Camargo et al. 2007). However, to the best of our knowledge this is 
the first time that DISC1 has been found to also regulate their expression. 
Nineteen unique proteins related to neurodevelopmental processes (Table 1) and nineteen 
unique proteins related to synaptic function (Table 2) were identified. Seven of these proteins 
have shared functions (Figure S4 in the Supporting information).  Some of the more relevant 
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proteins identified are shown in Figures 1 and 2. These results suggest that DISC1 plays an 
important role in these two processes. 
Of note, some of the proteins found are known substrates of GSK3β, as is the case of stathmin, 
CRMP-2, and MAP1B. Furthermore, some proteins identified as being regulated by DISC1 
have important roles in neurosignaling, including 14-3-3 proteins, LIS-1, MUNC18, NCS-1 and 
Rab proteins, among others. 
Some of the proteins identified were validated by 1D-SDS-PAGE (Figure 3) and 2-DE (Figure 
4) Western blot analysis to confirm the proteomic results. In some cases this approach allowed 
the identification of post-translational modifications.  
 
DISC1 regulates the expression of neurodevelopment related proteins 
One of the essential requirements for normal neurodevelopment is adequate regulation of 
microtubule assembly and disassembly, a process in which many proteins, besides tubulin, 
participate. We found tubulin to be downregulated by DISC1 knockdown (Table 1). Among the 
proteins that regulate microtubule dynamics are microtubule associated proteins (MAPs), which 
stabilize assembled microtubules by suppressing depolymerization or facilitating their 
reassembly. MAP1B was found to be upregulated in silenced cells (Table 1). Specifically, 
MAP1B promotes microtubule assembly and is involved in axonal outgrowth, playing an 
essential role in neuronal polarity. MAP1B interacts with LIS1, interfering with its binding to 
dynein in a GSK3β-regulated manner (Jiménez-Mateos et al. 2005). Strikingly the expression of 
LIS-1, another DISC1 interactor, was found to be downregulated in DISC1-silenced cells (Table 
1). 
14-3-3 proteins are known to interact with more than 100 partners; their ubiquitous interactions 
allow these proteins to play many roles. DISC1, LIS-1, NUDEL, dynein and 14-3-3ε form a 
complex that positively regulates axon elongation (Taya et al. 2007; Shinoda et al. 2007). In our 
study, two spots corresponding to 14-3-3ε, eight spots corresponding to 14-3-3θ/Δ, and two 
corresponding to 14-3-3γ were found to be differentially expressed in silenced vs. control cells 
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(Table 1).This, together with increased expression of MAP1B, is expected to lead to decreased 
association of LIS1 to dynein and would result in impaired axon elongation. 
Collapsin response mediator proteins (CRMPs) constitute a family of five homologous cytosolic 
proteins (CRMP-1-5) involved in microtubule regulation.  All of them are phosphorylated and 
highly expressed in the developing and adult nervous system where they play important roles in 
neuronal development and maturation (Yamashita & Goshima 2012).  Six spots corresponding 
to CRMP-5, CRMP-3, CRMP-2 and CRMP-1 were seen to be differentially expressed in 
silenced vs. control cells (Table 1); in all cases the proteins were found to be upregulated in 
silenced cells.  
CRMP-2 is a candidate gene for susceptibility to schizophrenia (Nakata et al. 2003) and was 
found to be upregulated in a proteomic study performed with brain samples from patients with 
bipolar disorder, schizophrenia and major depression (Johnston-wilson et al. 2000). CRMP-1, 
closely related to CRMP-2, has also been linked to schizophrenia, by means of genetic and 
biochemical studies (Bader et al. 2012).1D Western blotting also showed increased expression 
of CRMP-2 in silenced cells, and conspicuous differences in band patterns were seen using 
CRMP-2 and Thr-514 p-CRMP-2 antibodies (Figure 3), which showed phosphorylated forms to 
be downregulated and unphosphorylated forms to be upregulated in DISC1 silenced cells 
(Figure 3). Phosphorylation of CRMP-2 at Thr-514 is effected by GSK3β, which agrees with 
data showing that GSK3β activity is also altered in DISC1 silenced cells (Mao et al. 2009). 
A decreased expression of Septin-5, a protein that directly interacts with CRMP-2, was also 
found in the DISC1 silenced cells (Table 1).  
The stathmin family of proteins is also involved in the control of microtubule dynamics. 
Stathmins interact with tubulin, inhibiting its polymerization capacity and thus disrupting 
microtubule assembly, which regulates axonal and neurite outgrowth (Grenningloh et al. 
2004).Stathmin expression was found to be downregulated in DISC1 silenced cells in the 
proteomic study (Table 1, Figure 1) and a 2-DE Western blot confirmed this result (Figure 4). 
Stathmin phosphorylation at Ser-60, Ser-31 and Ser-38 have been proposed to be carried out by 
GSK3β (Moreno & Avila 1998). No differences were found with the pSer-38-Stathmin antibody 
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(Figure 4a).  It is possible that Ser-38 is not the relevant phosphorylation site affected under the 
study conditions. Still, a different pattern of expression of different stathmin forms in control vs. 
silenced cells was detected by 2D WB (Figure 4b). 
Other important proteins related with the maintenance of the cell shape and growth, such as 
actin, one of the major components of the cytoskeleton, and tropomyosin, a regulator of actin 
function, were also found to be differentially expressed (Table1).   
 
DISC1 regulates the expression of synaptic function related proteins 
The process of neurotransmission requires fusion of synaptic vesicles with the presynaptic 
plasma membrane. This process involves two families of SNARE proteins, that form the 
SNARE complex, and SM proteins (Sec1/Munc18-like proteins). Syntaxin-7 (member of the 
SNARE complex present on plasma membrane) and syntaxin binding protein (STXBP, also 
known as MUNC18) were found to be upregulated in DISC1-silenced cells (Table 2, Figure 2). 
These proteins are known to be related to the exocytosis (Dulubova et al. 2007) and 
endocytosis(Xu et al. 2013)processes that take place in the synapse. This is the first time that 
these proteins have been reported to be under the control of DISC1.  
Other proteins that regulate the exocytosis process responsible for neuronal communication are 
Rab proteins (Fischer von Mollard et al. 1994), which catalyze SNARE complex assembly 
(Søgaard et al. 1994). In this study four different Rab proteins were found to be differentially 
regulated in DISC1-silenced cells. Two of them were upregulated, while two others identified 
were downregulated (Table 2). 
Two proteins related to clathrin mediated synaptic endocytosis (Jung & Haucke 2007) were also 
found altered in DISC1 silenced cells: dynamin 1 and NECAP-1 (Table 2, Figure 2). 
Another family of proteins that is regulated by DISC1 and is directly implicated in the 
formation of the synapses is the cadherin family. N-cadherin was found to be downregulated in 
DISC1 silenced cells (Table 2).  When synapses are formed, N-cadherins cluster on the pre- and 
postsynaptic sides of the nascent synapse and at the same time bind to the actin cytoskeleton via 
catenins. 
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Neuronal Calcium Sensor-1 (NCS-1) is linked to psychiatric illness(Koh et al. 2003)and 
regulates intracellular levels of Ca
2+
 in neurons. Calcium and calcium sensor proteins are 
thought to play an essential role in regulating synaptic plasticity signaling pathways (Amici et 
al. 2009).  In the present study, NCS-1 was found to be upregulated in DISC1silenced cells 
(Table 1, Figure 2a).  
Finally, another protein that was found differentially expressed in DISC1 silenced vs. control 
cells is Rho-GDP dissociation inhibitor; this protein is known to form a heterodimer with Rac1 
and participates in Rac1 activation/inhibition.  Activation of Rac1 has been previously shown to 
be regulated by DISC1 (Hayashi-Takagi et al. 2010) and this event was shown to regulate the 
number of dendritic spines. 
 
Ingenuity Pathway 
The program Ingenuity Pathways Analysis (IPA) was used to analyze possible interactions 
among the proteins identified in the proteomic analysis. The IPA functional analysis related 
many of the proteins of our study to the following functional categories: “nervous system 
development and function” (Table S3 in Supporting information) and “cellular assembly and 
organization” (Table S4 in Supporting information). 
 
DISC1 silenced SH-SY5Y cells show impaired neurite outgrowth  
Supporting the fact that silencing of DISC1 results in disruption of neural development, DISC1 
knockdown in SH-SY5Y cells resulted in morphological changes (Figure 5). Thus, upon 
retinoic acid-induced differentiation, DISC1-silenced cells exhibited fewer and shorter neurites 
(Figure 5).  
 
DISCUSSION 
Our results highlight the importance of DISC1 both in neurodevelopment and synaptic 
regulation. Both functions have been already ascribed to DISC1; however, this study describes 
for the first time that DISC1 regulates the expression of many proteins involved in these two 
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processes, including several DISC1 binding partners. This is a powerful mechanism by which 
DISC1 participates in these processes and should therefore be taken into account when 
considering the role(s) of DISC1 in mental disease. 
Key proteins involved in normal neurodevelopment were reported to be altered by DISC1 
knockdown. Furthermore, DISC1 knockdown resulted in a neurite outgrowth deficit in RA-
treated SH-SY5Y cells. Previous studies have reported an impaired neurite outgrowth in cell 
models that overexpress mutant isoforms of DISC1 (Wen et al. 2014; Pletnikov et al. 2008)and 
an increase of neurite outgrowth was seen in PC12 cells that overexpress DISC1 (Miyoshi et al. 
2003). Therefore our study reinforces the idea that DISC1 is critical for proper regulation of 
these neurodevelopmental processes.  
At the same time, we have found that several proteins that participate in synaptic membrane 
trafficking and synapse formation are altered in DISC1 silenced neurons: syntaxin 7, MUNC-
18, cadherin-13 and Rab proteins (Table2). We cannot conclude whether the trafficking is up- or 
downregulated, although previous studies have shown that DISC1 enhances synaptic vesicle 
transport: knocking down DISC1 expression produced an attenuated vesicle transport in primary 
cortical neurons (Flores et al. 2011).  
Our study shows that DISC1 is an important regulator of proteins that are directly involved both 
in neurodevelopment and in adult synaptic regulation and therefore represents a unifier factor of 
both seemingly different categories. 
 
CONCLUSIONS 
This study shows for the first time that DISC1 regulates the expression of a number of proteins 
involved in neurodevelopment and synaptic function.  Thus, DISC1 acts as a key regulator of 
two mechanisms that have been critically implicated in the development of mental disease. 
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FIGURE LEGENDS 
Figure 1: Proteins involved in neurodevelopment showing altered expression in DISC1-
silenced neurons. a) Microtubule associated protein. b) 14-3-3 epsilon. c) Dihydropyriminidase 
related protein 2. d) Stathmin. e) LIS-1 (Control samples are represented in red, DISC1 silenced 
samples are represented in green). 
Figure 2: Proteins involved in synaptic function that show altered expression in DISC1-
silenced neurons. a) Neuronal Calcium Sensor 1. b) Syntaxin. c) MUNC-18. d) NECAP-1. e) 
Dynamin-1. f) Rab-2A g) Rab-11B (Control samples are represented in red, DISC1 silenced 
samples are represented in green). 
Figure 3: Confirmation of proteomic results. a) Western blot of CRMP-2 and pCRMP-2 
proteins. 
Figure 4: Corroboration of proteomic results employing bidimensional western blots. 50 µg of 
protein were used in all the cases a) Stathmin b) pStathmin. 
Figure 5: DISC1-silenced cells show morphological impairment in neurite outgrowth assays. 
Cells were treated with retinoic acid (RA) for 7 and 14 days and neurite length was measured 
using ImageJ. a) Fluorescence images of SH-SY5Y cells expressing control and DISC1 
shRNAs treated with RA for 7 days and immunostained for βIII-tubulin (red); nuclei were 
stained using DAPI (blue). (b, c) Average neurite length -/+ SD; * significantly different 
Ramos et al. 
 
23 
 
between control and DISC1-silenced cells (n > 200 for each cell line). (d, e) Frequency 
(percentile) of cells according to neurite length at 7 days (d) and 14 days (e) for each cell 
population; p<0.0001 control vs silenced 1 at 7 and 14 days, p<0.0001 control vs silenced 4 at 7 
days, p<0.001 control vs silenced 4 at 14 days (Mann–Whitney U test). 
 
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1: Western blot analysis showing DISC1 knock down using lentiviral 
vectors in the SH-SY5Y cell line. 
Supplementary Figure 2: DISC1 knockdown expression in neuron primary cell culture using 
three different constructs. 
Supplementary Figure 3: Representative gel obtained during the proteomic analysis. Identified 
spots with a fold-change >2 appear highlighted with their mass spectrometry identification 
number. a) Bidimensional gel image b) Zoom of the lower left corner of the gel.  
Supplementary Figure 4: Classification of the proteins identified in the proteomic study 
according to their functions.
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TABLE.1 Proteins involved in neurodevelopment identified through proteomic analysis of 
primary neurons. All the proteins had a fold change >2 and p value <0.05. Fold change in red 
indicates that the protein is overexpressed in DISC1 silenced cells, while fold change in black 
indicates a downregulation in DISC1 silenced cells 
Protein Spot Function Binding 
partner DISC1 
Fold 
change 
P value 
Dihydropyrimidinase-
related protein 5 
(CRMP-5) 
(DPYL5_MOUSE) 
58 Neuronal differentiation 
Neurite outgrowth 
Not 
described 
2.59 3.066x10-5 
Dihydropyrimidinase-
related protein 3 
(CRMP-3) 
(DPYL3_MOUSE) 
734,  
1168 
Neurite outgrowth 
Neural migration 
Not 
described 
3.12, 
2.23 
1.469x10-4 
2.894x10-4 
Dihydropyrimidinase-
relatedprotein 2 
(CRMP-2) 
(DPYL2_MOUSE) 
80, 
175 
Neurite outgrowth 
Neural migration 
 
Not 
described 
2.21, 
2.03 
2.457x10-4 
0.059 
Dihydropyrimidinase-
related protein 1 
(CRMP-1) 
(DPYL1_MOUSE) 
376 Neurite outgrowth 
Neural migration 
Not 
described 
2.10 9.180x10-5 
Tubulin alpha-1A chain 
(TBA1A_MOUSE) 
 
336, 
563, 
853 
Neurite outgrowth 
Neural migration 
 
Not 
described 
2.01, 
2.99, 
2.13 
0.0043 
1.326x10-4 
4.067x10-4 
Tubulin beta-2B chain 
(TBB2B_MOUSE) 
1291, 
1669 
Neurite outgrowth 
Neural migration 
Not 
described 
Inf, 
2.42 
0.0065 
0.0156 
Microtubule-associated 
protein 
(MAP1B_MOUSE) 
453, 
1213, 
1596 
Neurite outgrowth 
 
Yes 2.04,  
2.20,  
3.03 
3.661x10-7 
2.894x10-4 
2.717x10-5 
14-3-3 protein épsilon 
(14-3-3ε) 
676, 
972 
Neurite outgrowth Yes 2.67,  
3.19 
6.713x10-5 
1.854x10-4 
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(1433E_MOUSE) 
14-3-3 protein zeta/delta 
(14-3-3θ/Δ) 
(1433Z_MOUSE) 
169,  
239, 
599, 
933,  
943, 
1388, 
1404,  
601 
Neurite outgrowth Not 
described 
8.42, 
2.63, 
3.26, 
3.88, 
3.89, 
6.81, 
3.82, 
6.20 
3.028x10-6 
2.334x10-4 
1.579x10-4 
9.307x10-4 
0.021 
2.080x10-5 
0.0022 
2.572x10-6 
14-3-3 protein gamma 
(14-3-3γ) 
(1433G_MOUSE) 
286,  
2490 
 
Neurite outgrowth Yes 3.24,  
2.30 
6.104x10-5 
0.0084 
Platelet-activating factor 
acetylhydrolase IB subunit 
β Lis-1 
(PA1B2_MOUSE) 
686 Neurite outgrowth Yes 2.48 0.0049 
Stathmin 
(STMN1_MOUSE) 
829, 
828 
Neurite outgrowth Not 
described 
2.12,  
4.64 
8.206x10-4 
1.021x10-4 
Tropomyosin alpha-3 chain 
(TPM3_MOUSE) 
470 Neurite outgrowth 
Neural migration 
Not 
described 
2.88 0.0115 
Actin, cytoplasmic 2 
(ACTG_MOUSE) 
485,  
1312 
Neurite outgrowth 
Neural migration 
Not 
described 
4.94,  
2.95 
4.398x10-5 
1.081x10-5 
Cadherin-13 
(CAD13_MOUSE) 
804 Neurite outgrowth 
Neuronal migration 
Not described 2.31 0.0108 
Calreticulin 
(CALR_MOUSE) 
1342 Neurite outgrowth 
 
Not described 2.60 0.0088 
Septin-5 
(SEPT5_MOUSE) 
2750 Interacts with CRMPs  
Neurite outgrowth 
Neural migration 
Not described 2.15 0.0034 
Apolipoprotein A-I 
(APOA1_MOUSE) 
407 
 
Neurite outgrowth Not described 2.41 9.215x10-5 
Dynamin 1 
(DYN1_MOUSE) 
2230 Neurite outgrowth 
Neural migration 
Not described 4.33 1.440x10-4 
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TABLE.2 Proteins involved in synaptic function identified through proteomic analysis of 
primary neurons. All the proteins had a fold change >2 and p value <0.05. Fold change in red 
indicates that the protein is overexpressed in DISC1 silenced cells, while fold change in black 
indicates a downregulation in DISC1 silenced cells. 
Protein Spot Function Binding 
partner DISC1 
Fold 
change 
pValue 
Dihydropyrimidinase-
related protein 5 
(CRMP-5) 
(DPYL5_MOUSE) 
58 Regulates synaptic 
plasticity. 
 
Not 
described 
2.59, 3.066x10-5 
Dihydropyrimidinase-
relatedprotein 2 
(CRMP-2) 
(DPYL2_MOUSE) 
80, 
175 
Involved in synaptic 
vesicle transport. 
 
Not 
described 
2.21, 
2.03 
2.457x10-4 
0.059 
Microtubule-associated 
protein 
(MAP1B_MOUSE) 
453, 
1213, 
1596 
Synaptic maturation 
Autophagy 
 
Yes 2.04,  
2.20, 
3.03 
3.661x10-7 
2.894x10-4 
2.717x10-5 
Transitional endoplasmic 
Reticulum ATPase 
(TERA_MOUSE) 
240 Synaptic regulation 
Associates with clathrin 
Autophagy 
Not 
described 
2.21 5.537x10-4 
Stathmin 
(STMN1_MOUSE) 
829, 
828 
Involved in synapse 
formation 
Not 
described 
2.12,  
4.64 
8.206x10-4 
1.021x10-4 
Syntaxin-binding protein 1 
(STXB1_MOUSE) 
460 Regulates synaptic vesicle 
transport 
Neurotransmission 
Not described 3.43 0.0010 
Syntaxin-7 
(STX7_MOUSE) 
812 Forms part of the SNARE 
complex 
Synaptic transport/ 
function 
Not described 2.13 0.0022 
Ras-related protein (Rab-
1A) 
(RAB1A_MOUSE) 
585 Transport from ER to AG 
Synaptic function 
Not described 2.01 0.0023 
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Ras-related protein (Rab-
2A) 
(RAB2A_MOUSE) 
823 Transport from ER to AG 
Synaptic function 
Not described 2.43 4.164x10-4 
Ras-related protein (Rab-
11B) 
(RB11B_MOUSE) 
988 Endosomal trafficking 
Synaptic function 
Not described 3.25 0.0305 
Ras-related protein (Rab-
18) 
(RAB18_MOUSE) 
2079 Endocytosis/recycling 
Synaptic function 
Not described 3.23 5.527x10-4 
Cadherin-13 
(CAD13_MOUSE) 
804 Synapse formation. 
 
Not described 2.31 0.0108 
Rho GDP-dissociation 
inhibitor 2 
(GDIR2_MOUSE) 
841 Forms a heterodimer with 
Rac1. 
Synapse function 
Not described 2.28 1.061x10-4 
Phosphatidylethanolamine-
binding protein 1 
(HCNP) 
(PEBP1_MOUSE) 
1267, 
1495 
Synaptic function 
Inhibits neuropsin and 
RAF1 
 
Not described 3.84, 
 6.49 
4.081x10-
42.377x10-4 
Calreticulin 
(CALR_MOUSE) 
1342 Interacts with 
GABARAP. 
Synaptic function 
Not described 2.60 0.0088 
Adaptin ear-binding coat-
associated protein 1 
(NECAP1) 
(NECP1_MOUSE) 
1689 Clatrhin mediated 
endocytosis 
Synaptic function 
Not described 2.51 6.028x10-5 
Neuronal calcium sensor 1 
(NCS1_MOUSE) 
2005 Synaptic function 
 
Not described 2.24 9.215x10-5 
Dynamin 1 
(DYN1_MOUSE) 
2230 Synaptic function 
It is regulated by Ndel1 
Not described 4.33 1.440x10-4 
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Title: DISC1 regulates expression of the neurotrophin VGF through 
the PI3K/AKT/CREB pathway 
 
Abstract     
 
Disrupted in schizophrenia (DISC1) is a risk factor for chronic mental disease. In a 
previous proteomic study, we reported that knocking-down DISC1 results in a sharp 
decrease in the levels of the neuropeptide precursor VGF (non-acronymic) and leads to 
reduced activation of cAMP response element-binding protein (CREB) and protein 
kinase B (AKT) in neurons.  
 
The main objective of this study is to complete the characterization of the route or 
routes involving AKT and CREB through which DISC1 modulates the expression of 
VGF. For that we explored known players upstream of AKT and the DISC1 binding 
partners Glycogen synthase kinase-3 beta (GSK3β) and Phosphodiesterase-4 (PDE4), 
whom in turn might reach out to CREB, in murine neuron primary culture.  
 
We found that DISC1 modulates the activation of Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K). Further, pharmacological inhibition of PI3K resulted in 
decreased expression of VGF. All this strongly suggests that the PI3K/AKT pathway 
mediates the effects of DISC1 silencing on VGF expression.  
 
Given the important roles of VGF in mental disease, and its drugability, the DISC1-
VGF connection might prove to be important for efforts to develop new therapies for 
these diseases.  
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Introduction  
 
Disrupted in schizophrenia (DISC1) was discovered in a large Scottish family with a 
high load of major mental illness in which a translocation affecting this gene was causal 
for schizophrenia, bipolar disorder and major depression (St Clair et al. 1990; Millar et 
al. 2000). The protein DISC1 is involved in different processes in the brain such as 
neurogenesis, synapse regulation, neurite outgrowth, neural migration, proliferation and 
differentiation (Thomson et al. 2013; Brandon and Sawa 2011). 
 
VGF (non-acronymic) is a neuroprotective peptide precursor that regulates neuronal 
energy metabolism and has an important role in adult neurogenesis and synaptic 
plasticity (Thakker-Varia and Alder 2009). VGF-derived peptide levels were found to 
be decreased in leukocytes of depressed and brain of bipolar disorder patients (Cattaneo 
et al. 2010; Thakker-Varia et al. 2010). VGF administration has been reported to act as 
an antidepressant-like agent in depression paradigms (Thakker-Varia et al. 2007) and its 
expression is restored by effective antidepressant treatment, lithium and voluntary 
exercise (Cattaneo et al. 2010; Thakker-Varia et al. 2010; Hunsberger et al. 2007). The 
vgf gene contains a cAMP-response element in its promotor and a CREB binding site 
critical for Brain Derived Neurotrophic Factor (BDNF) induced VGF expression. 
 
In a recent study, our group described that VGF is downregulated in the brain of major 
mental illness patients. A similar decrease in VGF levels was found in mouse cortical 
and hippocampal neurons when DISC1 expression was silenced (Ramos et al. 2014). 
Additionally, phosphorylation at the activating CREB-Ser133 site, which induces VGF 
expression, was also decreased and the same result was obtained for the activating 
phosphorylation of AKT at Ser473. BDNF has been reported to stimulate CREB 
mediated VGF expression (Alder et al. 2003), however, no differences in BDNF levels 
were observed in the DISC1 silenced neurons. Our results therefore suggested that 
DISC1 regulates VGF levels via AKT/CREB in a BDNF-independent pathway.  
 
The objective of this study was to complete the elucidation of the route or routes 
encompassing AKT and CREB through which DISC1 modulates the expression of 
VGF. For that, we worked in two directions: on the one hand, we explored the 
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activation status of PI3K, upstream of AKT; on the other, we studied some DISC1 
binding partners which in turn might reach out to AKT and/or CREB. With this double-
pronged approach, we hoped to bridge the signaling route connecting DISC1 and VGF. 
 
We studied the phosphorylation of PI3K, an obvious possible player upstream of AKT: 
activation of PI3K canonically results in an increase in the phosphorylation of AKT at 
Ser473 and consequently, in its activation. Therefore, the observed decrease in AKT 
phosphorylation observed in DISC1 silenced neurons might be a consequence of a 
DISC1-regulated decrease in PI3K activation. 
  
On the other hand, among DISC1 partners studied, GSK3β has been shown to be 
inhibited by DISC1 by direct binding (Mao et al. 2009) and at the same time its activity 
was found to be regulated by VGF (Thakker-Varia et al. 2010). Besides, active AKT is 
capable of phosphorylating GSK3β at Ser9, which results in its inactivation (Cross et 
al.).  Furthermore, GSK3β has been also found to phosphorylate CREB taking part in 
the control of CREB activity (Fiols et al. 1994).These data led us to think that GSK3β 
could be part of the regulatory pathway between DISC1 and VGF.  
 
Finally, a different level at which DISC1 might be acting is through PDE4. DISC1 
binds members of each of the four PDE4 subfamilies (PDE4A-D) and this interaction 
has been shown to be disrupted in response to high le els of cAMP. In this situation, the 
release of PDE4 leads to the hydrolysis of cAMP which is a key inducer of CREB 
activation (Millar et al. 2005; Murdoch et al. 2007). A number of studies have 
demonstrated that the inhibition of  PDE4 by the drug rolipram has neuroprotective 
effects in neurons and exerts an antidepressant activity (Zhu et al. 2001; Schaal et al. 
2012).  
 
We report here the results of our studies. 
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Materials and Methods  
 
Ethical statement 
All animal studies were carried out according to institutional ethical guidelines that 
comply with the European Directive 2010/63/UE. Protocols were approved by the 
University of Santiago Ethics Commission. 
 
Cell culture  
Murine cortex and hippocampal primary neurons were prepared from 14-15 day 
embryos. Pregnant female mice were killed by cervical dislocation in accordance with 
institutional guidelines for care and use of animals. The embryos were maintained and 
dissected in PBS Ca/Mg (Invitrogen) supplemented with 33 mM glucose. Pooled tissue 
was mechanically triturated, treated with trypsin (Invitrogen) and DNaseI (Roche 
Applied Science, Mannheim, Germany) and resuspended in Neurobasal medium 
(Invitrogen) supplemented with 2% B27 (Invitrogen), 0.55g/100ml glucose (Sigma-
Aldrich), 42 mg/100 ml sodium bicarbonate (Sigma-Aldrich), 1% P/S and 1% L-
glutamine. The cells were plated on poly-D-lysine (Sigma Aldrich) coated Petri dishes. 
Cultures were maintained in serum free medium at 37ºC in 95% air/5% CO2. LY294002 
(Sigma-Aldrich) (Seshadri et al. 2010), Rolipram (Sigma-Aldrich) (Bradshaw et al. 
2011), CHIR-99021 (Selleck chemicals) (Zhang et al. 2012) were added to the neuronal 
media at 7DIV during one hour at final concentration of 10µM in DMSO before lysis.  
 
DISC1 silencing 
For DISC1 knock-down in primary neurons, lentiviruses were produced by calcium 
phosphate co-transfection of a shRNA construct previously used for this purpose 
targeting the sequence 5’-GGCAAACACTGTGAAGTGC-3’(named RNAi #1 in the 
bibliography) (Ramos et al. 2014; Hayashi-Takagi et al. 2010) and the helper constructs 
VSVG and ∆R8.9 into 293FT packaging cells. A non-target shRNA (SHC002 Sigma-
Aldrich) was used as a control; virus-containing medium was collected 48h after 
transfection, and added (10 ml of lentiviral solution/ 3x10
6
 neurons) to the medium of 
primary neurons at 7 DIV. The medium was changed 24 h after infection, and 
incubation continued for 72 h. 
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Sample preparation 
Cells (confluent 100 mm plates) were washed twice with cold PBS and solubilized in 
lysis buffer (20mM HEPES, 2mM EGTA, 1mM DTT, 1mM sodium orthovanadate, 1% 
Triton X-100, 10% Glycerol, 2µM leupeptin, 400µM PMSF, 50µM β-
glycerophosphate, 100µg/ml trasylol). The cells were scraped on ice for 10 minutes, 
incubated on ice for 30 minutes with periodic vortexing every 5 minutes and centrifuged 
for 20 minutes at 14000 g, 4ºC. The supernatant was saved and the pellet discarded. 
Protein supernatant content was determined using the Bradford protein assay kit 
(BioRad). 
 
SDS-PAGE, transfer and inmunodetection 
50 µg of protein was mixed with Laemmli sample buffer (BioRad) with 5% β-
mercaptoethanol, heated at 100ºC for 10 minutes, spun, and the supernatant loaded on a 
10% SDS-PAGE gel. Samples were subjected electrophoresis and transferred to 
polyvinyllidenedifluoride (PVDF) membranes (Millipore, Bedford, MA). The 
conditions of the electrophoresis wer  200V, 1h. Electrophoresis was performed using a 
Mini-PROTEAN 3 cell electrophoresis system (BioRad). The transfer was performed in 
a Trans-blot SD semi-dry transfer cell (BioRad) using the following conditions: 
0.8mA/cm
2
, 90 minutes. The PVDF membranes were blocked in 5% non-fat milk in 
PBS-0.1% Tween solution overnight at 4°C, then 4 washes of 5 minutes with PBS-
0.1%Tween20 were performed, and the membrane was incubated with the primary 
antiserum (in 5% BSA in PBS-0.1%Tween20) for 1 hour at room temperature, washed 
again and incubated with the peroxidase-conjugated secondary antibody (in PBS-
0.1%Tween20) during 1hour at room temperature, and subjected to 4 washes of 5 
minutes each with PBS-0.1%Tween20.  Finally the membrane was incubated with the 
chemiluminescent solution Luminata Forte Western HRP substrate (Merck Millipore). 
To develop the membranes Hypercassette (GE Healthcare) and Amersham Hyperfilm 
ECL (GE Healthcare) were used. Densitometric analysis was performed using ImageJ 
software. 
 
Antibodies 
Commercial antibodies specific for the following proteins were used: GSK3β Rabbit 
monoclonal antidoby (mAb) #9315 (1: 1000; Cell Signaling Technology, Danvers, MA, 
USA), Phospho-GSK3β (Ser9) Rabbit mAb #9323 (1: 1000; Cell Signaling 
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Technology, Danvers, MA, USA); Phospho-GSK3β (Tyr216) Rabbit polyclonal 
antibody (pAb) #44604G (1:1000; Invitrogen, Camarillo, CA, USA); Phospho-AKT 
(Ser473) Rabbit mAb #4058 (1: 1000; Cell Signaling Technology, Danvers, MA, USA); 
Phospho-CREB (Ser133) Rabbit mAb # 9198 (1:500; Cell Signaling Technology, 
Danvers, MA, USA); PI3 Kinase p85 Rabbit pAb #4292 (1:1000; Cell Signaling 
Technology, Danvers, MA, USA); Phospho-PI3 Kinase p85 (Tyr458)/ p55 (Tyr199) 
pAb #4228 (1:1000; Cell Signaling Technology, Danvers, MA, USA); VGF (R-15) 
Goat pAb #sc-10383 (1:200; Santa Cruz Biotechnologies, CA, USA); GAPDH Rabbit 
pAb #G9545 (1:5000; Sigma-Aldrich, St. Louis, MO, USA); the Mouse DISC1-specific 
pAb D27(1:200) (Brandon et al. 2004) was a kind gift from Merck (New Jersey, USA). 
Goat anti-rabbit (1:2000; DakoCytomation, Glosstrup, Denmark), sheep anti-mouse 
(1:5000; GE Healthcare Amersham Bioscience, Uppsala, Sweden) and donkey anti-goat 
(1:2000; Santa Cruz Biotechnologies, CA, USA) were used as secondary antibodies.  
 
Statistical analysis 
Student’s t test was used for statistical comparisons between groups with a minimum of 
3 independent experiments as indicated for each case in figure legends. Results are 
expressed as mean ± SD.  
 
 
Results  
 
DISC1 regulation of PI3K 
DISC1 was knocked-down in primary cultures of murine cortical and hippocampal 
neurons by means of lentiviral-based interference RNA. Treatment with DISC1 RNAi 
#1 resulted in a downregulation of DISC1 to 12.6 ± 3.8% of the levels of the protein in 
control cells infected with non-target shRNA (Fig. 1A, B). As expected, knock-down of 
DISC1 led to a significant decline in VGF expression (Fig. 1A) as recently published by 
our group (Ramos et al. 2014). Thereafter, the activation status of PI3K was assessed by 
western blot in these cells. Levels of phosphorylation of PI3K at Tyr458 were found to 
be decreased in DISC1 knock-down primary neurons indicating a drop in the activation 
status of the kinase (control: 139.6 ± 17.8; DISC1 RNAi #1: 56 ± 11.7) (Fig. 2A, B). 
This result agrees with the previously observed reduction of the phosphorylation of 
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AKT at Ser473 in these neurons. The data strongly suggest that the regulation of VGF 
by DISC1 occurs through the PI3K/AKT/CREB signaling route. 
 
The role of PI3K in the regulation of the levels of VGF was further confirmed by its in 
vitro inhibition in murine neurons with the selective inhibitor LY294002. A decrease in 
the phosphorylation of AKT at Ser473 (Fig. 3A) was observed confirming the 
effectiveness of the treatment. A significant decrease in VGF expression was also found 
(DMSO: 95.2 ± 6.7; LY294002: 43.9 ± 11) (Fig. 3A, B), the same effect seen with 
DISC1 knock-down, confirming that PI3K activity is involved in the regulation of VGF 
expression by DISC1.   
 
 
DISC1 regulation of GSK3β 
Phosphorylation of GSK3β upon DISC1 knock-down was assessed in these cells by 
western blot (Fig. 4A). The level of the inhibitory phosphorylation of GSK3β at Ser9 
was found to be significantly decreased in DISC1 silenced cells (control: 120.9 ± 2.1; 
DISC1 RNAi #1: 64.6 ± 9.5) (Fig. 4A, C).  The activating autophosphorylation at 
Tyr216 did not change significantly (control: 96.3 ± 11.5; DISC1 RNAi #1: 112.4 ± 
15.7) (Fig. 4A, D). Surprisingly, in DISC1-silenced cells there was also a decline of the 
total amount of GSK3β to 55.4 ± 8.5% of levels in the control (Fig. 4A, B). These 
results suggest that the absence of DISC1 produces a miss-regulation in the quantity and 
phosphorylation of GSK3β in cortical and hippocampal cultured neurons; however, they 
do not allow to conclude whether such miss-regulation might or might not contribute to 
decreased phosphorylation of CREB as seen in our experimental model, given that the 
decrease in total GSK3β might compensate the decrease in the inhibitory 
phosphorylation at Ser9. 
 
To further assess this point, murine neurons were treated in vitro with CHIR-99021, a 
selective GSK3β inhibitor. CHIR-99021 produced a decrease in phosphorylation of 
GSK3β-Tyr216 (Fig. 3A) confirming the effectiveness of the treatment. However, 
GSK3β phosphorylation inhibition did not lead to any change in VGF protein levels 
(DMSO: 186.9 ± 63.9; CHIR-99021: 176.8 ± 39.4) (Fig. 3A, C). This result indicates 
that, despite the effects of DISC1 on GSK3β, this kinase is not likely to contribute to 
DISC1 regulation of VGF expression. 
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Effect of PDE4 on VGF regulation 
Due to the fact that DISC1 modulates the activity of PDE4 and consequently cAMP 
levels, which in turn plays a key role in CREB activation, murine cortical and 
hippocampal neurons were treated in vitro with rolipram to asses a possible role of 
PDE4 in the regulation of VGF by DISC1. Rolipram administration to the cells 
produced an increase in the levels of CREB phosphorylation at Ser133 in the neurons 
(DMSO: 91.3 ± 15.5%; rolipram: 115.6 ± 19.9%) confirming the effectiveness of the 
treatment (Fig. 5A, B). However, no significant changes in means of VGF expression 
were found (DMSO: 84.5 ± 29%; rolipram: 113.5 ± 13.6%)  (Fig. 5A, C). 
 
 
Discussion 
In a previous unbiased proteomic study (Ramos et al. 2014), we reported that knocking 
down DISC1 results in a sharp decrease in the levels of the neuropeptide precursor VGF 
in primary neuronal cells from mouse cortex. We also found that DISC1 exerts an effect 
on the phosphorylation status of CREB and AKT.  
 
Given the neuroprotective and antidepressant properties of VGF (Thakker-Varia et al. 
2007; Hunsberger et al. 2007; Alder et al. 2003; Shimazawa et al. 2010) as well as its 
implication in depression (Cattaneo et al. 2010) , bipolar disorder (Thakker-Varia et al. 
2010) and schizophrenia (Busse et al. 2012), it seems important to elucidate the 
signalling pathways that link it to DISC1, and therefore we explored known players 
upstream of AKT (PI3K) and downstream of DISC1, namely, its known interactors: 
GSK3β (Mao et al. 2009; Ming and Song 2009), PDE4B (Murdoch et al. 2007; Millar 
et al. 2005; Bradshaw et al. 2008) , and Gr2b (Shinoda et al. 2007). 
 
Active PI3K promotes the phosphorylation of AKT at Ser473 leading to its activation. 
In the present study, we observed a marked decrease in the phosphorylation of PI3K at 
position Tyr548 in DISC1 knock-down primary neurons indicating a clear reduction of 
the activation status of this kinase. This result explains the drop in the phosphorylation 
levels of AKT and CREB previously observed in DISC1 silenced neurons that leads to a 
fall in the levels of VGF. In addition, inhibition of PI3K, led to a pronounced decrease 
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of VGF levels in neurons of mouse embryos, further confirming that PI3K is as a key 
link in the DISC1 regulation of VGF expression upstream of AKT.  
 
How could DISC1 regulate the phosphorylation status of PI3K? DISC1 interacts with 
Growth factor receptor-bound protein 2 (Grb2) (Shinoda et al. 2007). Grb2 links 
activated Tyrosine kinase (Trk) receptors to intracellular signaling cascades in neurons 
(MacDonald et al. 2000) and one of these molecular routes is the PI3K/AKT pathway. 
Grb2 is responsible for the recruitment of Gab2, which binding to PI3K, is necessary for 
the activation of the kinase and, consequently AKT (Gu et al. 2000; Holgado-Madruga 
et al. 1997). Shinoda and coworkers observed that DISC1 knock-down in rat 
hippocampal neurons leads to inhibition of Grb2 accumulation at the distal part of the 
axons and impairment of neurotropin-induced axon elongation indicating that proper 
DISC1-dependent Grb2 localization is necessary for this process (Shinoda et al. 2007). 
Considering all this, it is tempting to speculate that Grb2 might be the link connecting 
DISC1 with PI3K, thus "closing" the signaling route by which DISC1 regulates 
expression of VGF (Fig. 6). Lack or malfunction of DISC1 could lead to a change in the 
normal localization of Grb2 which in turn might result in defective activation of the 
PI3K cascade at localized sites. This would eventually cause a decrease of the 
neuropeptide VGF by downregulation of the PI3K/AKT/CREB pathway. Experiments 
to explore such possibility might be of interest. 
 
While the involvement of the PI3K/AKT/CREB signaling route is clear, two other 
DISC1 binding partners, GSK3β and PDE4, have possible connections with CREB, and 
therefore offer alternative entry points connecting DISC1 with VGF, therefore we 
explored these two possibilities. 
 
GSK3β activity has been found to be regulated by DISC1 direct binding (Mao et al. 
2009; Ishizuka et al. 2011). Furthermore, VGF was also shown to regulate the activity 
of GSK3β (Thakker-Varia et al. 2010). In the present study we demonstrated that 
DISC1 knock-down in cortical and hippocampal primary cultured neurons leads to 
changes in the quantity and phosphorylation of GSK3β. Given that GSK3β can 
phosphorylate CREB taking part in the control of its activity (Grimes and Jope 2001; 
Mai et al. 2002; Hur and Zhou 2010) we thought that the changes in GSK3β activity, 
elicited by DISC1 knock-down, might be involved in the defective phosphorylation of 
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CREB. However, we did not observe any change in VGF levels when GSK3β was 
inhibited with CHIR-99021 in primary neurons. This indicates that in our model the 
decrease in VGF expression caused by DISC1 knock-down is not likely to be an effect 
of changes in GSK3β activity. 
 
With regard to PDE4, although we observed consistently slightly increased levels of 
VGF when PDE4 was inhibited with rolipram (Fig. 4A, C), the differences did not reach 
statistical significance. Hence, we cannot exclude the possibility that under different 
experimental conditions, DISC1 might exert an additional regulatory effect on VGF 
expression through regulation of PDE4, leading to sustained levels of cAMP and CREB 
activation.  Rolipram has been shown to display antidepressant properties (Itoh et al. 
2004); however this is not the first time that the lack of effect of acute rolipram 
treatment on neurotrophin expression is described, contrary to what happens with other 
antidepressants (Kranz et al. 2014). 
 
In summary, our data show that DISC1 regulates expression of the neuropeptide 
precursor VGF in neurons through the PI3K/AKT/CREB signaling route.  Given the 
important roles of VGF in mental disease, and its drugability, the DISC1-VGF 
connection might prove to be important for efforts to develop new therapies for these 
devastating diseases. 
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Figure 1: DISC1 and VGF expression in murine neuron primary cell cultures. A) 
Western blot showing DISC1 and VGF levels in primary neuronal cells transfected both 
with Control-RNAi and DISC1-RNAi #1. B) Densitometric analysis of data presented 
in A (n=3 independent experiments),
 ***
p<0.001. Total protein was normalized to 
GAPDH. Error bars represent SD. Statistical analysis was carried out by the (paired) 
two-tailed Student’s t-test. 
 
Figure 2: PI3K expression and phosphorylation in murine neuron primary 
cultures.  A) Western blot showing PI3K, phospho-PI3K (Tyr 458) and GAPDH levels 
in primary neuronal cells transfected both with Control-RNAi and DISC1 RNAi #1. B) 
Densitometric analysis of data presented in A (n=4 independent experiments), 
**
p<0.01. 
Total protein was normalized to GAPDH. Error bars represent SD. Statistical analysis 
was carried out by the (paired) two-tailed Student’s t-test. 
 
Figure 3: Chemical inhibition of PI3K leads to a decrease in VGF expression. A) 
Western Blot showing VGF levels in murine neuron primary cells treated with 
LY294002 or CHIR-99021 to inhibit PI3K and GSK3β, respectively. Only the inhibitor 
of PI3K had an effect on VGF expression. The effectiveness of the treatments was 
assessed measuring phospho-AKT (Ser473) and phospho-GSK3β (Tyr216). B) 
Densitometric analysis of VGF on LY294002 treated cells (n=5 independent 
experiments),
 ***
p<0.001. C) Densitometric analysis of VGF on CHIR-99021 treated 
cells (n=5 independent experiments), n.s.: non-significant. Total protein was normalized 
to GAPDH. Error bars represent SD. Statistical analysis was carried out by the (paired) 
two-tailed Student’s t-test. 
 
Figure 4: GSK3β expression and phosphorylation in murine neuron primary cell 
cultures. A) Western blot showing GSK3β total levels, phospho-GSK3β (Ser9) and 
phospho-GSK3 β (Tyr216) and GAPDH in primary neuronal cells transfected both with 
Control RNAi and DISC1 RNAi #1. B) Densitometric analysis of GSK3β (n=3 
independent experiments),
 ***
p<0.001. C) Densitometric analysis of phospho-GSK3β 
(Ser9) (n=3 independent experiments),
 ***
p<0.001. D) Densitometric analysis of 
phospho-GSK3β (Tyr 216) (n=3 independent experiments), n.s.: non-significant.  Total 
protein was normalized to GAPDH. 
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Figure 5: Effect of rolipram on VGF expression. A) Western Blot showing VGF 
levels in murine neuron primary cells treated with rolipram. The effectiveness of the 
treatment was assessed measuring phospho-CREB (Ser133) levels. B) Densitometric 
analysis of phospho-CREB (Ser133) on rolipram treated cells (n=9 independent 
experiments),
 *
p<0.05. C) Densitometry of VGF on rolipram treated cells (n=6 
independent experiments), n.s.: non-significant. Total protein was normalized to 
GAPDH. Error bars represent SD. Statistical analysis was carried out by the (paired) 
two-tailed Student’s t-test. 
 
Figure 6: DISC1 regulation of VGF. DISC1 controls VGF expression through the 
PI3K/AKT/CREB signaling pathway. Neurotrophins bind to and activate Trk receptors 
that lead to the activation of the PI3K/AKT/CREB signaling route. When Trk receptors 
are activated they recruit local Grb2 and Gab2 leading to the activation of PI3K. By 
direct binding DISC1 regulates the localization of Grb2 in the cell. We have observed a 
drop in the activation status of th  PI3K pathway that ends in a fall in the levels of VGF 
when DISC1 was silenced in primary neurons. DISC1 knock-down might cause a 
deficient accumulation of Grb2 at certain regions that would explain the drop observed 
drop in PI3K activation. Thus, Grb2 might be connecting DISC1 with the PI3K 
pathway. Arrows indicate activating (green) or inhibitory (red) effects; phosphorylation 
is indicated with a dot; inhibitors are indicated in star-shaped enclosures. DISC1 
binding to PDE4 and GSK3β inhibits their activities.   
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